SC TO-T

QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE TO

TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR SECTION 13(E)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934

MILLENNIUM PHARMACEUTICALS, INC.
(Name of Subject Company)

MAHOGANY ACQUISITION CORP.
a wholly-owned subsidiary of

TAKEDA AMERICA HOLDINGS, INC.
a wholly-owned subsidiary of

TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Names of Filing Persons (Offerors))

COMMON STOCK, PAR VALUE $0.001 PER SHARE
(Title of Class of Securities)

599902103
(CUSIP Number of Class of Securities)

Iwaaki Taniguchi
President
Takeda America Holdings, Inc.
767 Third Avenue, 8^th Floor
New York, NY 10017
Tel: (212) 421-6954
Fax: (212) 355-5243
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications on Behalf of Filing Persons)

Copies to:

Bruce W. Raphael, Esq.
Matthew J. Gardella, Esq.
Edwards Angell Palmer & Dodge LLP
111 Huntington Avenue
Boston, Massachusetts 02199
Tel: (617) 239-0100
Fax: (617) 227-4420

CALCULATION OF FILING FEE

Transaction Valuation*	Amount of Filing Fee**
$8,362,883,945	$328,662

*

Estimated solely for the purpose of calculating the filing fee. The transaction valuation was calculated based on the offer to purchase all of the outstanding shares of common stock, par value $0.001 per share, of Millennium Pharmaceuticals, Inc. at a purchase price of $25.00 per share, with 326,704,024 shares issued and outstanding and 21,718,903 shares issuable upon exercise of outstanding options (with a weighted average exercise price of $16.0086), in each case as of April 7, 2008, as represented by Millennium Pharmaceuticals, Inc.



**

The amount of the filing fee is calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, by multiplying the transaction valuation by 0.0000393.

o

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number or the Form or Schedule and the date of its filing.

Amount Previously Paid: None	Filing party: N/A
Form or Registration No.: N/A	Date Filed: N/A

o

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

ý

third-party tender offer subject to Rule 14d-1.



o

issuer tender offer subject to Rule 13e-4.



o

going-private transaction subject to Rule 13e-3.



o

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: o

        This Tender Offer Statement on Schedule TO (which, together with any amendments and supplements thereto, collectively constitute this "Schedule TO") is filed by Mahogany Acquisition Corp. ("Purchaser"), a Delaware corporation and wholly-owned subsidiary of Takeda America Holdings, Inc. ("Takeda America"), which is a New York corporation and wholly-owned subsidiary of Takeda Pharmaceutical Company Limited ("TPC"), a corporation organized under the laws of Japan, to purchase all of the outstanding shares of common stock, par value $0.001 per share, of Millennium Pharmaceuticals, Inc., a Delaware corporation ("Millennium") (collectively the "Shares" and each share thereof a "Share"), at a purchase price of $25.00 per Share, net to the seller in cash, without interest thereon and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated April 11, 2008 (the "Offer to Purchase") and the related Letter of Transmittal (the "Letter of Transmittal" which, together with the Offer to Purchase, as each may be amended and supplemented from time to time, constitute the "Offer"). This Schedule TO is being filed on behalf of Purchaser, Takeda America and TPC.

        The information set forth in the Offer to Purchase and the Letter of Transmittal, copies of which are filed with this Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B) hereto, respectively, is incorporated by reference in answers to Items 1 through 9 and Item 11 of this Schedule TO, and is supplemented by the information specifically provided in this Schedule TO.

ITEM 1.    SUMMARY TERM SHEET

        The information set forth in the section of the Offer to Purchase entitled "Summary Term Sheet" is incorporated herein by reference.

ITEM 2.    SUBJECT COMPANY INFORMATION

        (a) The name of the subject company and the issuer of securities to which this Schedule TO relates is Millennium Pharmaceuticals, Inc., a Delaware corporation. Millennium's principal executive offices are located at 40 Landsdowne Street, Cambridge, Massachusetts 02139, and its telephone number is (617) 679-7000.

        (b) This Schedule TO relates to the outstanding shares of common stock, par value $0.001 per share, of Millennium. Based on information provided by Millennium in its representation of capitalization, as of April 7, 2008 there were 326,704,024 shares of common stock, par value $0.001 per share, of Millennium issued and outstanding. The information set forth in the "Introduction" section of the Offer to Purchase is incorporated herein by reference.

        (c) The Shares are traded on the Nasdaq Global Select Market under the symbol "MLNM." The information set forth in Section 6 "Price Range of Shares; Dividends" of the Offer to Purchase is incorporated herein by reference.

ITEM 3.    IDENTITY AND BACKGROUND OF FILING PERSON

        (a), (b), (c) The information set forth in Section 8 "Certain Information Concerning TPC, Takeda America and Purchaser" and Schedule I "Directors and Executive Officers of TPC, Takeda America and Purchaser" of the Offer to Purchase is incorporated herein by reference.

ITEM 4.    TERMS OF THE TRANSACTION

        The information set forth in the Summary Term Sheet, Section 1 "Terms of the Tender Offer," Section 2 "Acceptance for Payment and Payment for Shares," Section 3 "Procedures for Accepting the Offer and Tendering Shares," Section 4 "Withdrawal Rights," Section 5 "Certain United States Federal Income Tax Consequences," Section 10 "Background of the Offer; Past Contacts or Negotiations with Millennium," Section 11 "The Transaction Documents," Section 12 "Purpose of the Offer; Plans for Millennium," Section 13 "Certain Effects of the Offer" and Section 15 "Certain Conditions of the Offer" of the Offer to Purchase is incorporated herein by reference.

ITEM 5.    PAST CONTACTS, TRANSACTIONS, NEGOTIATIONS AND AGREEMENTS

        (a)(1) Other than the transactions described in Item 5(b) below, during the past two years none of TPC, Takeda America or Purchaser nor, to the best knowledge of TPC, Takeda America and Purchaser, any of the persons listed in Schedule I "Directors and Executive Officers of TPC, Takeda America and Purchaser" of the Offer to Purchase has entered into any transaction with Millennium or any of Millennium's affiliates that are not natural persons.

        (a)(2) Other than the transactions described in Item 5(b) below, during the past two years none of TPC, Takeda America or Purchaser nor, to the best knowledge of TPC, Takeda America and Purchaser, any of the persons listed in Schedule I "Directors and Executive Officers of TPC, Takeda America and Purchaser" of the Offer to Purchase has entered into any transaction or series of similar transactions with any executive officer, director or affiliate of Millennium that is a natural person with an aggregate value that exceeds $60,000.

        (b) The information set forth in Section 8 "Certain Information Concerning TPC, Takeda America and Purchaser," Section 10 "Background of the Offer; Past Contacts or Negotiations with Millennium," Section 11 "The Transaction Documents" and Section 12 "Purpose of the Offer; Plans for Millennium" of the Offer to Purchase is incorporated herein by reference.

ITEM 6.    PURPOSES OF THE TRANSACTION AND PLANS OR PROPOSALS

        (a),(c)(1)-(7) The information set forth in Section 10 "Background of the Offer; Past Contacts or Negotiations with Millennium," Section 12 "Purpose of the Offer; Plans for Millennium" and Section 13 "Certain Effects of the Offer" of the Offer to Purchase is incorporated herein by reference.

ITEM 7.    SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

        (a), (b), (d) The information set forth in Section 9 "Source and Amount of Funds" of the Offer to Purchase is incorporated herein by reference.

ITEM 8.    INTEREST IN SECURITIES OF THE SUBJECT COMPANY

        (a), (b) The information set forth in the "Introduction," Section 8 "Certain Information Concerning TPC, Takeda America and Purchaser," Section 10 "Background of the Offer; Past Contacts or Negotiations with Millennium," Section 11 "The Transaction Documents," Section 12 "Purpose of the Offer; Plans for Millennium" and Schedule I of the Offer to Purchase is incorporated herein by reference.

ITEM 9.    PERSONS/ASSETS, RETAINED, EMPLOYED, COMPENSATED OR USED

        (a) The information set forth in Section 18 "Fees and Expenses" of the Offer to Purchase is incorporated herein by reference.

ITEM 10.    FINANCIAL STATEMENTS

        Not applicable.

ITEM 11.    ADDITIONAL INFORMATION

        (a)(1) Except as disclosed in Items 1 through 10 above, there are no present or proposed material agreements, arrangements, understandings or relationships between (i) TPC, Takeda America, Purchaser or any of their respective executive officers, directors, controlling persons or subsidiaries and (ii) Millennium or any of its executive officers, directors, controlling persons or subsidiaries.

        (a)(2)-(4) The information set forth in Section 13 "Certain Effects of the Offer," Section 15 "Certain Conditions of the Offer," and Section 16 "Certain Legal Matters; Regulatory Approvals" of the Offer to Purchase is incorporated herein by reference.

        (b) The information set forth in the Offer to Purchase and the Letter of Transmittal, copies of which are attached hereto as Exhibits (a)(1)(A) and (a)(1)(B), respectively, to the extent not otherwise incorporated herein by reference, is incorporated herein by reference.

ITEM 12.    EXHIBITS

        See Exhibit Index following the Signature Page.

ITEM 13.    INFORMATION REQUIRED BY SCHEDULE 13E-3

        Not applicable.

SIGNATURES

        After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 11, 2008	MAHOGANY ACQUISITION CORP.
	By:	/s/  IWAAKI TANIGUCHI
		Name:	Iwaaki Taniguchi
		Title:	President
Dated: April 11, 2008	TAKEDA AMERICA HOLDINGS, INC.
	By:	/s/  IWAAKI TANIGUCHI
		Name:	Iwaaki Taniguchi
		Title:	President
Dated: April 11, 2008	TAKEDA PHARMACEUTICAL COMPANY LIMITED
	By:	/s/  YASUCHIKA HASEGAWA
		Name:	Yasuchika Hasegawa
		Title:	President

EXHIBIT INDEX

Exhibit Number	Document
(a)(1)(A)	Offer to Purchase dated April 11, 2008.
(a)(1)(B)	Form of Letter of Transmittal.
(a)(1)(C)	Form of Notice of Guaranteed Delivery.
(a)(1)(D)	Form of Letter to Brokers, Dealers, Banks, Trust Companies and other Nominees.
(a)(1)(E)	Form of Letter to Clients for Use by Brokers, Dealers, Banks, Trust Companies and other Nominees.
(a)(1)(F)	Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9.
(a)(1)(G)	Form of Summary Advertisement as published in The Wall Street Journal on April 11, 2008.
(a)(1)(H)	Joint Press Release, dated April 10, 2008, issued by TPC and Millennium, incorporated by reference to the Schedule TO-C filed by Purchaser with the SEC on April 10, 2008.
(a)(5)	Press Release, dated April 11, 2008.
(d)(1)	Agreement and Plan of Merger, dated as of April 10, 2008, among Millennium, Purchaser, Takeda America and (for certain purposes) TPC, incorporated by reference to Exhibit (e)(1) to the Schedule 14D-9 filed by Millennium with the SEC on April 11, 2008 (the "14D-9").
(d)(2)	Tender and Support Agreement, dated April 10, 2008, between Takeda America and certain stockholders of Millennium named therein.
(d)(3)	Confidentiality Agreement, dated February 20, 2008, between Millennium and TPC.
(d)(4)(A)	Amendment to Letter Agreement, dated April 10, 2008 between Millennium and Christophe Bianchi, incorporated by reference to Exhibit (e)(17) to the 14D-9.
(d)(4)(B)	Amendment to Letter Agreement, dated April 10, 2008 between Millennium and Joseph B. Bolen, incorporated by reference to Exhibit (e)(20) to the 14D-9.
(d)(4)(C)	Amendment to Letter Agreement, dated April 10, 2008 between Millennium and Deborah Dunsire, incorporated by reference to Exhibit (e)(16) to the 14D-9.
(d)(4)(D)	Amendment to Letter Agreement, dated April 10, 2008 between Millennium and Marsha H. Fanucci, incorporated by reference to Exhibit (e)(14) to the 14D-9.
(d)(4)(E)	Amendment to Letter Agreement, dated April 10, 2008 between Millennium and Stephen M. Gansler, incorporated by reference to Exhibit (e)(18) to the 14D-9.
(d)(4)(F)	Amendment to Letter Agreement, dated April 10, 2008 between Millennium and Laurie B. Keating, incorporated by reference to Exhibit (e)(15) to the 14D-9.
(d)(4)(G)	Amendment to Letter Agreement, dated April 10, 2008 between Millennium and Anna Protopapas, incorporated by reference to Exhibit (e)(19) to the 14D-9.
(d)(4)(H)	Amendment to Letter Agreement, dated April 10, 2008 between Millennium and Nancy Simonian, incorporated by reference to Exhibit (e)(21) to the 14D-9.
(d)(4)(I)	Amendment to Letter Agreement, dated April 10, 2008 between Millennium and Peter F. Smith, incorporated by reference to Exhibit (e)(22) to the 14D-9.

QuickLinks

SCHEDULE TO
SIGNATURES
EXHIBIT INDEX

EX-99.(A)(1)(A)

Exhibit (a)(1)(A)

Offer To Purchase For Cash
All Outstanding Shares of Common Stock
of
MILLENNIUM PHARMACEUTICALS, INC.
at
$25.00 NET PER SHARE
by
MAHOGANY ACQUISITION CORP.
a wholly-owned subsidiary of
TAKEDA AMERICA HOLDINGS, INC.
a wholly-owned subsidiary of
TAKEDA PHARMACEUTICAL COMPANY LIMITED

THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME,
AT THE END OF THURSDAY, MAY 8, 2008, UNLESS THE OFFER IS EXTENDED.

        Mahogany Acquisition Corp. ("Purchaser"), a Delaware corporation and wholly-owned subsidiary of Takeda America Holdings, Inc. ("Takeda America"), which is a New York corporation and wholly-owned subsidiary of Takeda Pharmaceutical Company Limited ("TPC"), a corporation organized under the laws of Japan, is offering to purchase all of the outstanding shares of common stock, par value $0.001 per share (the "Shares" and each a "Share"), of Millennium Pharmaceuticals, Inc., a Delaware corporation ("Millennium"), at a purchase price of $25.00 per Share, net to the seller in cash (the "Offer Price"), without interest thereon and less any required withholding taxes, upon the terms and subject to the conditions set forth in this Offer to Purchase and in the related Letter of Transmittal (which, together with the Offer to Purchase, as each may be amended or supplemented from time to time, collectively constitute the "Offer").

        The Offer is being made pursuant to an Agreement and Plan of Merger, dated as of April 10, 2008 (as it may be amended from time to time, the "Merger Agreement"), by and among Takeda America, Purchaser and Millennium. TPC is also a party to the Merger Agreement for certain purposes. The Merger Agreement provides, among other things, for the making of the Offer and, following the consummation of the Offer and subject to certain conditions, for Purchaser to be merged with and into Millennium (the "Merger") with Millennium continuing as the surviving corporation and a wholly-owned subsidiary of Takeda America. Each share outstanding immediately prior to the effective time of the Merger (the "Effective Time") (other than shares held by Millennium, TPC, Purchaser, Takeda America or any wholly-owned subsidiary of Takeda America, all of which will be cancelled and shall cease to exist, or by stockholders who properly exercise appraisal rights under Delaware law) will be cancelled and converted in the Merger into the right to receive $25.00 per Share (or any higher price paid in the Offer), net to the seller in cash, without interest thereon and less any required withholding taxes. Under no circumstances will interest be paid on the purchase price for the Shares, regardless of any extension of the Offer or any delay in making payment for the Shares.

        The Offer is conditioned upon, among other things, (i) the satisfaction of the Minimum Tender Condition (as described below) and (ii) the expiration or termination of any applicable waiting periods (and any extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), and certain applicable foreign antitrust laws (the "Regulatory Condition"). The Minimum Tender Condition requires that the number of Shares that are validly tendered and not properly withdrawn prior to the expiration of the Offer, together with any Shares beneficially owned by TPC, Takeda America or any subsidiary thereof, equals at least a majority of the outstanding Shares on a fully diluted basis (including for these purposes the number of Shares issuable upon exercise of vested options and the number of Shares into which Millennium's outstanding convertible notes may be

converted). The Offer also is subject to the other conditions set forth in this Offer to Purchase. See Section 15—"Certain Conditions of the Offer."

The Millennium Board of Directors has represented to us, among other things, that it has unanimously adopted resolutions (i) declaring that the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are fair to and in the best interests of Millennium and its stockholders, (ii) approving and declaring advisable the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, and (iii) recommending that Millennium's stockholders accept the Offer and tender their Shares to Purchaser pursuant to the Offer and adopt the Merger Agreement.

        A summary of the principal terms of the Offer appears on pages S-i through S-vii. You should read this entire document carefully before deciding whether to tender your Shares in the Offer.

	The Dealer Manager for the Offer is:	The Information Agent for the Offer is:

April 11, 2008

IMPORTANT

        If you wish to tender all or a portion of your Shares in the Offer, you should either (i) complete and sign the letter of transmittal (or a facsimile thereof) that accompanies this Offer to Purchase (the "Letter of Transmittal") in accordance with the instructions in the Letter of Transmittal and mail or deliver the Letter of Transmittal and all other required documents to the Depositary (as defined herein) together with certificates representing the Shares tendered or follow the procedure for book-entry transfer set forth in Section 3—"Procedures for Accepting the Offer and Tendering Shares" or (ii) request your broker, dealer, commercial bank, trust company or other nominee to effect the transaction for you. If you hold Shares in the name of a broker, dealer, commercial bank, trust company or other nominee, you must contact that institution in order to tender your Shares.

        If you wish to tender Shares and cannot deliver certificates representing such Shares and all other required documents to the Depositary on or prior to the Expiration Date (as defined herein) or you cannot comply with the procedures for book-entry transfer on a timely basis, you may tender your Shares by following the guaranteed delivery procedures described in Section 3—"Procedures for Accepting the Offer and Tendering Shares."

        Questions and requests for assistance should be directed to the Information Agent (as defined herein) at its address and telephone number set forth on the back cover of this Offer to Purchase. Additional copies of this Offer to Purchase, the related Letter of Transmittal, the related Notice of Guaranteed Delivery and other materials related to the Offer may also be obtained at our expense from the Information Agent. Additionally, copies of this Offer to Purchase, the related Letter of Transmittal, the related Notice of Guaranteed Delivery and other material related to the Offer may be found at www.sec.gov. If you own your Shares through a broker, commercial bank, trust company or nominee, you may contact such broker, commercial bank, trust company or nominee for assistance with the Offer.

TABLE OF CONTENTS

SUMMARY TERM SHEET		S-i
INTRODUCTION		1
THE TENDER OFFER		2
1.	Terms of the Tender Offer	2
2.	Acceptance for Payment and Payment for Shares	5
3.	Procedures for Accepting the Offer and Tendering Shares	6
4.	Withdrawal Rights	9
5.	Certain United States Federal Income Tax Consequences	10
6.	Price Range of Shares; Dividends	10
7.	Certain Information Concerning Millennium	11
8.	Certain Information Concerning TPC, Takeda America and Purchaser	14
9.	Source and Amount of Funds	15
10.	Background of the Offer; Past Contacts or Negotiations with Millennium	15
11.	The Transaction Documents	20
12.	Purpose of the Offer; Plans for Millennium	35
13.	Certain Effects of the Offer	37
14.	Dividends and Distributions	38
15.	Certain Conditions of the Offer	38
16.	Certain Legal Matters; Regulatory Approvals	41
17.	Appraisal Rights	44
18.	Fees and Expenses	44
19.	Miscellaneous	45
SCHEDULE I—DIRECTORS AND EXECUTIVE OFFICERS OF TPC, TAKEDA AMERICA AND PURCHASER		I-1

SUMMARY TERM SHEET

The information contained in this summary term sheet is a summary only and is not meant to be a substitute for the more detailed description and information contained in this Offer to Purchase, the Letter of Transmittal and the Notice of Guaranteed Delivery. You are urged to read carefully this Offer to Purchase, the Letter of Transmittal and the Notice of Guaranteed Delivery in their entireties. We have included cross-references in this summary term sheet to other sections of this Offer to Purchase where you will find more complete descriptions of the topics mentioned below.

Securities Sought	All issued and outstanding shares of common stock, par value $0.001 per share, of Millennium Pharmaceuticals, Inc.
Price Offered Per Share	$25.00 in cash, without interest thereon and less any required withholding taxes.
Scheduled Expiration of Offer	12:00 midnight, New York City time, at the end of Thursday, May 8, 2008, unless the Offer is otherwise extended. See Section 1—"Terms of the Tender Offer."
Purchaser	Mahogany Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of Takeda America Holdings, Inc., which is a New York corporation and wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan.

Who is offering to buy my securities?

        We are Mahogany Acquisition Corp., a Delaware corporation, formed for the purpose of making this Offer. We are a wholly-owned subsidiary of Takeda America Holdings, Inc., which we refer to as "Takeda America." Takeda America is a direct, wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a research-based, global pharmaceutical company organized under the laws of Japan, which we refer to as "TPC."

        Unless the context indicates otherwise, in this Offer to Purchase, we use the terms "us," "we" and "our" to refer to Mahogany Acquisition Corp. and, where appropriate, Takeda America. We use the term "Takeda America" to refer to Takeda America Holdings, Inc. alone, the term "Purchaser" to refer to Mahogany Acquisition Corp. alone and the terms "Millennium" or the "Company" to refer to Millennium Pharmaceuticals, Inc.

        See the "Introduction" to this Offer to Purchase and Section 8—"Certain Information Concerning TPC, Takeda America and Purchaser."

What are the classes and amounts of securities sought in the Offer?

        We are offering to purchase all of the outstanding shares of common stock, par value $0.001 per share, of Millennium on the terms and subject to the conditions set forth in this Offer to Purchase. Unless the context otherwise requires, in this Offer to Purchase we use the term "Offer" to refer to this offer and the term "Shares" to refer to shares of Millennium common stock that are the subject of the Offer.

        See the "Introduction" to this Offer to Purchase and Section 1—"Terms of the Tender Offer."

S-i

How much are you offering to pay? What is the form of payment? Will I have to pay any fees or commissions?

        We are offering to pay $25.00 per Share net to you, in cash, without interest thereon and less any required withholding taxes. We refer to this $25.00 per Share amount as the "Offer Price." If you are the record owner of your Shares and you directly tender your Shares to us in the Offer, you will not have to pay brokerage fees or similar expenses. If you own your Shares through a broker, commercial bank or other nominee, and your nominee tenders your Shares on your behalf, your broker, commercial bank or other nominee may charge you a fee for doing so. You should consult your broker, commercial bank or other nominee to determine whether any charges will apply.

        See the "Introduction" to this Offer to Purchase.

Is there an agreement governing the Offer?

        Yes. Purchaser, Takeda America and Millennium have entered into an Agreement and Plan of Merger dated as of April 10, 2008 (as may be amended from time to time, the "Merger Agreement"). TPC is also a party to the Merger Agreement for certain purposes. The Merger Agreement provides, among other things, for the terms and conditions of the Offer and the subsequent merger of Purchaser with and into Millennium (the "Merger").

        See Section 11—"The Transaction Documents" and Section 15—"Certain Conditions of the Offer."

Do you have the financial resources to make payment?

        Yes. We estimate that we will need approximately $8.8 billion to purchase all of the Shares pursuant to the Offer, to cash out certain employee options, restricted stock and restricted stock units, to fund amounts that may become payable under Millennium's outstanding convertible notes, and to consummate the Merger, plus related fees and expenses. To the extent necessary, TPC, our parent company, will provide us with sufficient funds through cash on hand to purchase all Shares properly tendered in the Offer and will provide funding for the Merger, which is expected to follow the successful completion of the Offer in accordance with the terms and conditions of the Merger Agreement. The Offer is not conditioned upon our or TPC's ability to finance the purchase of Shares pursuant to the Offer. Pursuant to the Merger Agreement, TPC has unconditionally guaranteed the full and complete performance by Takeda America and Purchaser of their respective obligations under the Merger Agreement.

        See Section 9—"Source and Amount of Funds."

Is your financial condition relevant to my decision to tender my Shares in the Offer?

        No. We do not think our financial condition is relevant to your decision whether or not to tender Shares and accept the Offer because:

•

the Offer is being made for all outstanding Shares solely for cash;



•

through TPC, which has unconditionally guaranteed our obligations under the Merger Agreement, and Takeda America, we will have sufficient funds available through cash on hand to purchase all Shares validly tendered and not properly withdrawn in the Offer;



•

the Offer is not subject to any financing condition; and



•

if we consummate the Offer, we expect to acquire any remaining Shares for the same cash price pursuant to the Merger.

        See Section 9—"Source and Amount of Funds."

S-ii

How long do I have to decide whether to tender my Shares in the Offer?

        You will have until 12:00 midnight, New York City time, at the end of Thursday, May 8, 2008 to tender your Shares in the Offer, unless we extend the Offer. In addition, if we decide or if we are obligated under the Merger Agreement to provide a subsequent offering period for the Offer as described below, you will have an additional opportunity to tender your Shares. We do not currently intend to provide a subsequent offering period unless obligated to do so pursuant to the Merger Agreement, although we reserve the right to do so.

        See Section 11—"The Transaction Documents" for more details on our ability to, and in some cases, obligation to, provide for a subsequent offering period.

        If you cannot deliver everything required to make a valid tender by that time, you may still participate in the Offer by using the guaranteed delivery procedure that is described later in this Offer to Purchase prior to that time.

        See Section 1—"Terms of the Tender Offer" and Section 3—"Procedures for Accepting the Offer and Tendering Shares."

Can the Offer be extended and under what circumstances?

        Yes. We have agreed in the Merger Agreement that, if at the scheduled initial expiration date of the Offer, all of the conditions to the Offer, including the Minimum Tender Condition and the Regulatory Condition (each as described below), are not satisfied and we have not waived those conditions (other than the Minimum Tender Condition, which cannot be waived without Millennium's consent), we will, subject to our rights to terminate the Merger Agreement in accordance with its terms, extend the Offer for a period of up to ten business days and will thereafter re-extend the Offer for periods between three and ten business days, if necessary, until such time as such conditions are satisfied or waived, but in no event beyond October 31, 2008 (the "Walk Away Date"). See Section 15—"Certain Conditions of the Offer." We will also extend the Offer for any period required by applicable rule, regulation or interpretation of the U.S. Securities and Exchange Commission (the "SEC") or by any other law.

        See Section 1—"Terms of the Tender Offer" of this Offer to Purchase for more details on our obligation and ability to extend the Offer.

How will I be notified if the Offer is extended?

        If we extend the Offer, we will inform Computershare Trust Company, N.A., which is the depositary for the Offer (the "Depositary"), of the extension and will issue a press release announcing the extension not later than 9:00 a.m., New York City time, on the next business day after the day on which the Offer was scheduled to expire.

        See Section 1—"Terms of the Tender Offer."

Will there be a subsequent offering period?

        We may, without the consent of Millennium, provide for a subsequent offering period (and one or more extensions thereof) in accordance with Rule 14d-11 under the Securities Exchange Act of 1934, as amended (the "Exchange Act") (each, a "Subsequent Offering Period"), following the acceptance for payment of and payment for Shares pursuant to the Offer (the "Acceptance Time") if at the commencement of any Subsequent Offering Period (or extension thereof) the number of Shares owned by TPC, Takeda America, Purchaser and their respective subsidiaries (including any Shares beneficially owned by any of the foregoing) represent less than 90% of the then outstanding number of Shares. If immediately following the Acceptance Time, TPC, Takeda America, Purchaser and their respective

S-iii

subsidiaries own more than 80% but less than 90% of the Shares outstanding at that time (which shall include (i) Shares beneficially owned by TPC, Takeda America, Purchaser and their respective subsidiaries and (ii) Shares validly tendered in the Offer and not properly withdrawn), to the extent requested by Millennium, we will provide for a Subsequent Offering Period of at least ten business days; provided, however, that we will not be required to provide for such Subsequent Offering Period if the number of Shares issuable upon exercise of the Top-Up Option (described in Section 1—"Terms of the Tender Offer") would, after giving effect to such exercise when added to the number of Shares owned by TPC, Takeda America and Purchaser and their respective subsidiaries, represent not less than 90% of the then outstanding number of Shares.

        If we elect or are required to provide or extend any Subsequent Offering Period, a public announcement of such election or extension will be made no later than 9:00 a.m., New York City time, on the next business day following the Expiration Date or date of termination of any prior Subsequent Offering Period.

        See Section 1—"Terms of the Tender Offer."

What are the most significant conditions to the Offer?

        The Offer is conditioned upon, among other things:

•

the satisfaction of the Minimum Tender Condition. The Minimum Tender Condition requires that the number of Shares that have been validly tendered (including by guaranteed delivery) in accordance with the terms of the Offer and not properly withdrawn, together with any Shares beneficially owned by TPC, Takeda America or any subsidiary of TPC or Takeda America, equals at least a majority of the Shares outstanding on a fully diluted basis on the date of purchase (where "on a fully diluted basis" means the number of Shares outstanding, plus (i) the number of Shares issuable upon the exercise of all then outstanding vested options and (ii) the number of Shares into which Millennium's then outstanding convertible notes may be converted); and



•

the satisfaction of the Regulatory Condition. The Regulatory Condition provides that immediately prior to the expiration of the Offer, any waiting period (and any extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act") and any approvals or clearances applicable to the Offer or the consummation of the Merger under the antitrust laws of the Federal Republic of Germany and the Republic of Austria must have expired, terminated or been obtained, as applicable.

        The Offer also is subject to a number of other conditions set forth in this Offer to Purchase. We expressly reserve the right to waive any such conditions, but, without Millennium's consent, we cannot, among other things, waive the Minimum Tender Condition, impose any additional conditions to the Offer or modify the conditions to the Offer in any manner adverse to the holders of the Shares. There is no financing condition to the Offer.

        See Section 15—"Certain Conditions of the Offer."

How do I tender my Shares?

        If you hold your Shares directly as the registered owner, you can tender your Shares in the Offer by delivering the certificates representing your Shares, together with a completed and signed Letter of Transmittal and any other documents required by the Letter of Transmittal, to the Depositary, not later than the date and time the Offer expires. The Letter of Transmittal is enclosed with this Offer to Purchase.

S-iv

        If you hold your Shares in street name through a broker, dealer, commercial bank, trust company or other nominee, the institution that holds your Shares can tender your Shares on your behalf, and may be able to tender your Shares through the Depositary. You should contact the institution that holds your Shares for more details.

        If you are unable to deliver everything that is required to tender your Shares to the Depositary by the expiration of the Offer, you may obtain a limited amount of additional time by having a broker, a commercial bank or another fiduciary that is an eligible institution guarantee that the missing items will be received by the Depositary using the enclosed Notice of Guaranteed Delivery. To validly tender Shares in this manner, however, the Depositary must receive the missing items within the time period specified in the Notice of Guaranteed Delivery.

        See Section 3—"Procedures for Accepting the Offer and Tendering Shares."

Until what time may I withdraw previously tendered Shares?

        You may withdraw your previously tendered Shares at any time until the Offer has expired. In addition, if we have not accepted your Shares for payment by June 9, 2008, you may withdraw them at any time after that date until we accept Shares for payment. This right to withdraw will not, however, apply to Shares tendered in any Subsequent Offering Period, if one is provided. See Section 4—"Withdrawal Rights."

How do I withdraw previously tendered Shares?

        To withdraw previously tendered Shares, you must deliver a written notice of withdrawal, or a facsimile of one, with the required information to the Depositary while you still have the right to withdraw Shares. If you tendered Shares by giving instructions to a broker, dealer, commercial bank, trust company or other nominee, you must instruct the broker, dealer, commercial bank, trust company or other nominee to arrange for the withdrawal of your Shares.

        See Section 4—"Withdrawal Rights."

What does the Millennium Board think of the Offer?

        The Millennium Board of Directors has represented to us, among other things, that it has unanimously adopted resolutions (i) declaring that the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are fair to and in the best interests of Millennium and its stockholders, (ii) approving and declaring advisable the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, and (iii) recommending that Millennium's stockholders accept the Offer and tender their Shares to Purchaser pursuant to the Offer and adopt the Merger Agreement.

        A more complete description of the reasons for the Millennium Board's approval of the Offer and the Merger will be set forth in the Solicitation/Recommendation Statement on Schedule 14D-9 that is being mailed to you at the same time as or shortly after this Offer to Purchase.

If a majority of the Shares are tendered and accepted for payment, will Millennium continue as a public company?

        No. Following the purchase of Shares in the Offer, we expect to consummate the Merger. If the Merger takes place, Millennium will no longer be publicly owned. Even if for some reason the Merger does not take place, if we purchase all of the tendered Shares, there may be so few remaining stockholders and publicly held Shares that Millennium's common stock will no longer be eligible to be traded through the NASDAQ Global Select Market ("Nasdaq") or other securities exchanges, there may not be an active public trading market for Millennium common stock, and Millennium may no

S-v

longer be required to make filings with the SEC or otherwise comply with the SEC rules relating to publicly held companies.

        See Section 13—"Certain Effects of the Offer."

If I decide not to tender, how will the Offer affect my Shares?

        If the Offer is consummated and certain other conditions are satisfied, Purchaser will merge with and into Millennium and all then outstanding Shares (other than those held by Millennium, TPC, Takeda America or any wholly-owned subsidiary of Takeda America or Millennium or by stockholders who exercise appraisal rights under Delaware law) will be cancelled and converted in the Merger into the right to receive an amount in cash equal to the highest price per Share paid pursuant to the Offer, without interest thereon and less any required withholding taxes. If we purchase Shares in the Offer, we will have sufficient voting power to adopt the Merger Agreement without the affirmative vote of any other stockholder of Millennium. Furthermore, if pursuant to the Offer or otherwise we own in excess of 90% of the outstanding Shares, we may effect the Merger without any further action by the stockholders of Millennium.

        See Section 11—"The Transaction Documents," including the subsection entitled "The Merger Agreement."

        If the Merger is consummated, Millennium's stockholders who do not tender their Shares in the Offer will, unless they validly exercise appraisal rights (as described below), be entitled to receive the same amount of cash per Share that they would have received had they tendered their Shares in the Offer. Therefore, if the Offer and the Merger are consummated, the only differences to you between tendering your Shares and not tendering your Shares in the Offer are that (i) you will be paid earlier if you tender your Shares in the Offer and (ii) appraisal rights will not be available to you if you tender Shares in the Offer but will be available to you in the Merger. See Section 17—"Appraisal Rights." If the Offer is consummated but the Merger is not consummated, however, the number of Millennium's stockholders and the number of Shares that are still in the hands of the public may be so small that there will no longer be an active public trading market (or, possibly, there may not be any public trading market) for the Shares. Also, as described below, Millennium may cease making filings with the SEC or otherwise may not be required to comply with the rules relating to publicly held companies.

        See the "Introduction" to this Offer to Purchase and Section 13—"Certain Effects of the Offer."

What is the market value of my Shares as of a recent date?

        On April 9, 2008, the last full day of trading before the public announcement of the terms of the Offer and the Merger, the reported closing sales price of the Shares on Nasdaq was $16.35 per Share.

        We encourage you to obtain a recent quotation for the Shares in deciding whether to tender your Shares.

        See Section 6—"Price Range of Shares; Dividends."

What is the "Top-Up Option" and when will it be exercised?

        Under the Merger Agreement, if we do not acquire at least 90% of the outstanding Shares in the Offer after our acceptance of and payment for Shares pursuant to the Offer, we have the option, subject to certain limitations, to purchase from Millennium at a price per Share equal to the Offer Price up to the number of additional shares sufficient to cause us to own one share more than 90% of the Shares then outstanding to enable us to effect a short-form merger under Delaware law. We refer to this option as the "Top-Up Option." The number of additional Shares that we can purchase under the Top-Up Option is limited to the number of authorized but unissued shares of Millennium common

S-vi

stock (including as authorized but unissued any Shares held by Millennium but excluding shares reserved for issuance under outstanding convertible notes, options and restricted stock units). We have agreed to exercise the Top-Up Option if doing so would allow us to consummate the Merger without a vote of Millennium's stockholders pursuant to Section 253 of the General Corporation Law of the State of Delaware (the "DGCL").

Will I have appraisal rights in connection with the Offer?

        No appraisal rights will be available to you in connection with the Offer. However, stockholders will be entitled to appraisal rights in connection with the Merger if they do not tender their Shares in the Offer and do not vote in favor of the adoption of the Merger Agreement, subject to and in accordance with Delaware law. Stockholders must properly perfect their right to seek appraisal under Delaware law in connection with the Merger in order to exercise appraisal rights.

        See Section 17—"Appraisal Rights."

What will happen to my employee stock options in the Offer?

        The Offer is made only for Shares and is not made for any employee stock options to purchase Shares that were granted under any Millennium stock plan ("Options"). Pursuant to the Merger Agreement, each Option that is outstanding immediately prior to the effective time of the Merger (the "Effective Time") will become fully vested and be cancelled immediately following the Effective Time in exchange for the right to receive an amount in cash, without interest and less any required withholding taxes, equal to the excess of the Offer Price over the per Share exercise price for each Share subject to the Option. If the exercise price of an Option is equal to or greater than the Offer Price, the Option will be cancelled, without any consideration being payable in respect thereof, and have no further force or effect.

What will happen to my restricted stock or restricted stock units in the Offer?

        Pursuant to the Merger Agreement, each outstanding share of restricted stock and each outstanding restricted stock unit will be converted immediately prior to the Effective Time into the right to a restricted cash payment equal to the Offer Price (net of applicable taxes). Such restrictions will lapse immediately following the Effective Time, at which time the payment shall be made.

What are the consequences of the Merger for Millennium employees who participate in the Employee Stock Purchase Plan (ESPP)?

        The current offering period under Millennium's 1996 Employee Stock Purchase Plan, or ESPP, will close in its ordinary course and ESPP options from the current period will be exercised as scheduled at the end of April. Upon the closing of the Merger, any future contributions under new offering periods will be returned and the ESPP will be terminated.

What are the material United States federal income tax consequences of tendering Shares?

        The receipt of cash in exchange for your Shares pursuant to the Offer or the Merger will be a taxable transaction for U.S. federal income tax purposes. In general, you will recognize capital gain or loss in an amount equal to the difference between the amount of cash you receive and your adjusted tax basis in the Shares sold pursuant to the Offer or exchanged for cash pursuant to the Merger. This capital gain or loss will be long-term capital gain or loss if you have held the Shares for more than one year as of the date of your sale or exchange of the Shares pursuant to the Offer or the Merger. See Section 5—"Certain United States Federal Income Tax Consequences" for a more detailed discussion of the tax treatment of the Offer.

S-vii

We urge you to consult with your own tax advisor as to the particular tax consequences to you of the Offer and the Merger.

Who should I call if I have questions about the Offer?

        You may call Altman Group, the information agent for the Offer (the "Information Agent"), at (212) 681-9600. See the back cover of this Offer to Purchase for additional contact information. If you own your Shares through a broker, commercial bank, trust company or nominee, you may contact such broker, commerical bank, trust company or nominee for assistance with the Offer.

S-viii

To the Holders of Shares of
Common Stock of Millennium Pharmaceuticals, Inc.:

INTRODUCTION

        We, Mahogany Acquisition Corp., a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of Takeda America Holdings, Inc., a New York corporation ("Takeda America"), which is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan ("TPC"), are offering to purchase for cash all outstanding shares of common stock, par value $0.001 per share (the "Shares" and each, a "Share"), of Millennium Pharmaceuticals, Inc., a Delaware corporation ("Millennium" or the "Company"), at a price of $25.00 per Share (the "Offer Price"), net to the seller in cash, without interest thereon and less any required withholding taxes, upon the terms and subject to the conditions set forth in this Offer to Purchase and in the related Letter of Transmittal (which collectively, as each may be amended or supplemented from time to time, constitute the "Offer").

        We are making the Offer pursuant to an Agreement and Plan of Merger, dated as of April 10, 2008 (as it may be amended from time to time, the "Merger Agreement"), by and among Takeda America, Purchaser, TPC (for certain provisions) and Millennium. The Merger Agreement provides, among other things, for the making of the Offer and also provides that following the consummation of the Offer and subject to certain conditions, Purchaser will be merged with and into Millennium (the "Merger"), with Millennium continuing as the surviving corporation, wholly-owned by Takeda America. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each Share outstanding immediately prior to the Effective Time (other than Shares held by Millennium, TPC, Takeda America or Purchaser, or their wholly-owned subsidiaries, all of which will be cancelled and shall cease to exist, and any Shares held by stockholders who properly exercise their appraisal rights under Delaware law in connection with the Merger as described in Section 17—"Appraisal Rights") will be converted into the right to receive an amount in cash equal to the highest price per Share paid in the Offer, without interest thereon and less any required withholding taxes. The Merger Agreement is more fully described in Section 11—"The Transaction Documents," which also contains a discussion of the treatment of employee stock options ("Options"), restricted stock and restricted stock units.

        Tendering stockholders who are record owners of their Shares and who tender directly to the Depositary (as defined below) will not be obligated to pay brokerage fees or commissions or, except as otherwise provided in Instruction 6 of the Letter of Transmittal, stock transfer taxes with respect to the purchase of Shares by Purchaser pursuant to the Offer. Stockholders who hold their Shares through a broker, commercial bank or other nominee should consult such institution as to whether it charges any service fees or commissions.

The Millennium Board of Directors has represented to us, among other things, that it has unanimously adopted resolutions (i) declaring that the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are fair to and in the best interests of Millennium and its stockholders, (ii) approving and declaring advisable the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, and (iii) recommending that Millennium's stockholders accept the Offer and tender their Shares to Purchaser pursuant to the Offer and adopt the Merger Agreement.

        A more complete description of the reasons for the Millennium Board's approval of the Offer and the Merger will be set forth in the Solicitation/Recommendation Statement on Schedule 14D-9 that is being mailed to you at the same time as or shortly after this Offer to Purchase.

        The Offer is conditioned upon, among other things, (i) the satisfaction of the Minimum Tender Condition (as described below) and (ii) the expiration or termination of all statutory waiting periods

1

(and any extensions thereof) applicable to the Offer under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), and the antitrust laws of the Federal Republic of Germany and the Republic of Austria (the "Regulatory Condition"). The Minimum Tender Condition requires that the number of Shares that have been validly tendered and not properly withdrawn prior to the expiration of the Offer, together with any Shares beneficially owned by TPC, Takeda America or any subsidiary thereof, equals at least a majority of the Shares outstanding on a fully diluted basis on the date of purchase ("fully diluted basis" meaning the number of Shares outstanding, plus (i) the number of Shares issuable upon the exercise of all then outstanding vested Options and (ii) the number of Shares into which Millennium's then outstanding convertible notes may be converted). The Offer also is subject to other conditions set forth in this Offer to Purchase. See Section 15—"Certain Conditions of the Offer."

        Consummation of the Merger is conditioned upon, among other things, the adoption of the Merger Agreement by the requisite vote of stockholders of Millennium, if required by Delaware law. Under Section 251 of the DGCL, the affirmative vote of a majority of the outstanding Shares is the only vote of any class or series of Millennium's capital stock that would be necessary to adopt the Merger Agreement at any required meeting of Millennium's stockholders. If we purchase Shares in the Offer, we will have sufficient voting power to adopt the Merger Agreement without the affirmative vote of any other stockholder of Millennium. In addition, Delaware law provides that if a corporation owns at least 90% of the outstanding shares of each class of stock of a subsidiary corporation otherwise entitled to vote on the merger, the corporation holding such stock may merge such subsidiary into itself, or itself into such subsidiary, without any action or vote on the part of the Board of Directors or the stockholders of such other corporation. Under the Merger Agreement, if, after the expiration of the Offer or the expiration of any subsequent offering period, TPC, Purchaser and Takeda America, taken together, own at least 90% of the outstanding Shares (including shares issued pursuant to the Top-Up Option), Takeda America and Purchaser are required to take all necessary and appropriate action to cause the Merger to become effective, without a meeting of the holders of Shares. If a vote of Millennium's stockholders is required to adopt the Merger Agreement, we have agreed to cause all Shares purchased pursuant to the Offer and all other Shares beneficially owned by TPC, Takeda America, Purchaser or any subsidiary of TPC or Takeda America to be voted in favor of the adoption of the Merger Agreement.

        This Offer to Purchase and the related Letter of Transmittal contain important information that should be read carefully before any decision is made with respect to the Offer.

THE TENDER OFFER

1.     Terms of the Tender Offer

        Purchaser is offering to purchase all of the outstanding Shares of Millennium. According to Millennium, as of April 7, 2008, there were 326,704,024 Shares issued and outstanding, options to purchase 21,718,903 Shares issued and outstanding, 41,853,826 Shares reserved and available for issuance upon or otherwise deliverable in connection with the grant of awards under Millennium's stock plans or the exercise of Options and 17,045,032 Shares reserved and available for issuance upon conversion of Millennium's convertible notes. As of April 7, 2008, outstanding options to purchase 16,472,555 Shares were vested and exercisable and outstanding options to purchase 13,661,517 Shares had exercise prices per share lower than the Offer Price.

        Upon the terms and subject to the conditions of the Offer (including, if the Offer is extended or amended, the terms and conditions of such extension or amendment), we will accept for payment and pay for all Shares validly tendered prior to the Expiration Date and not properly withdrawn as permitted under Section 4—"Withdrawal Rights." The term "Expiration Date" means 12:00 midnight, New York City time, at the end of Thursday, May 8, 2008, unless we, in accordance with the Merger

2

Agreement, extend the period during which the Offer is open, in which event the term "Expiration Date" means the latest time and date at which the Offer, as so extended, expires.

        The Offer is conditioned upon, among other things, the satisfaction of the Minimum Tender Condition, the Regulatory Condition and the other conditions described in Section 15—"Certain Conditions of the Offer."

        We have agreed in the Merger Agreement that if at the scheduled Expiration Date any of the conditions to our obligation to purchase the Shares have not been satisfied or waived, we shall extend (and re-extend) the Offer for one or more periods of not more than 10 business days each until the earlier to occur of (i) a date as of which all of the Offer Conditions have been satisfied or waived and (ii) October 31, 2008 (the "Walk Away Date"). We shall also extend the Offer for any period required by any rule, regulation, interpretation or position of the SEC or the staff thereof applicable to the Offer or any period required by any other law.

        We have further agreed in the Merger Agreement that, without the consent of Millennium, we will not (i) reduce the number of Shares subject to the Offer; (ii) reduce the Offer Price; (iii) change or waive the Minimum Tender Condition; (iv) extend the Offer, except (A) as required by law, (B) to comply with SEC rules and regulations in connection with an increase in the Offer Price of at least $0.25 per Share, or (C) as otherwise set forth in the immediately preceding paragraph; (v) change the form of the consideration payable in the Offer; (vi) amend, modify or supplement any of the Offer Conditions in any manner adverse to the holders of Shares or that would, individually or in the aggregate, reasonably be expected to prevent or materially delay the consummation of the Offer or prevent or materially delay or impair the ability of Takeda America or Purchaser to consummate the Offer or the Merger or the other transactions contemplated by the Merger Agreement; or (vii) impose any condition to the Offer other than the Offer Conditions.

        If we extend the Offer, are delayed in our acceptance for payment of or payment (whether before or after our acceptance for payment for Shares) for Shares or are unable to accept Shares for payment pursuant to the Offer for any reason, then, without prejudice to our rights under the Offer, the Depositary may retain tendered Shares on our behalf, and such Shares may not be withdrawn except to the extent that tendering stockholders are entitled to withdrawal rights as described herein under Section 4—"Withdrawal Rights." However, our ability to delay the payment for Shares that we have accepted for payment is limited by Rule 14e-1(c) under the Exchange Act, which requires us to pay the consideration offered or return the securities deposited by or on behalf of stockholders promptly after the termination or withdrawal of the Offer.

        Except as set forth above, and subject to the applicable rules and regulations of the SEC, we expressly reserve the right to waive any condition to the Offer (other than the Minimum Tender Condition, which may not be waived without Millennium's prior consent), increase the Offer Price and/or modify the other terms of the Offer. Any extension, delay, termination or amendment of the Offer will be followed as promptly as practicable by public announcement thereof, and such announcement in the case of an extension will be made no later than 9:00 a.m., New York City time, on the next business day after the previously scheduled Expiration Date. Without limiting the manner in which we may choose to make any public announcement, we currently intend to make announcements regarding the Offer by issuing a press release and making any appropriate filing with the SEC.

        If we make a material change in the terms of the Offer or the information concerning the Offer or if we waive a material condition of the Offer, we will disseminate additional tender offer materials and extend the Offer if and to the extent required by Rules 14d-4(d), 14d-6(c) and 14e-1 under the Exchange Act. The minimum period during which an offer must remain open following material changes in the terms of the offer or information concerning the offer, other than a change in price or a change in percentage of securities sought, will depend upon the facts and circumstances, including the

3

relative materiality of the terms or information changes. In the SEC's view, an offer should remain open for a minimum of five business days from the date the material change is first published, sent or given to stockholders and, with respect to a change in price or a change in percentage of securities sought, a minimum of ten business days generally is required to allow for adequate dissemination to stockholders and investor response.

        If, on or before the Expiration Date, we increase the consideration being paid for Shares accepted for payment in the Offer, such increased consideration will be paid to all stockholders whose Shares are purchased in the Offer, whether or not such Shares were tendered before the announcement of the increase in consideration.

        We expressly reserve the right, in our sole discretion, subject to the terms and conditions of the Merger Agreement and the applicable rules and regulations of the SEC, not to accept for payment any Shares if, at the expiration of the Offer and any extensions thereof, any of the conditions to the Offer have not been satisfied or upon the occurrence of any of the events set forth in Section 15—"Certain Conditions of the Offer." Under certain circumstances, we may terminate the Merger Agreement and the Offer.

        Following our acceptance of and payment for Shares tendered in the Offer (the "Acceptance Time"), we may, without the consent of Millennium, elect to provide for a subsequent offering period (a "Subsequent Offering Period") in accordance with Rule 14d-11 of the Exchange Act for up to 20 business days if at the commencement of the Subsequent Offering Period, the number of Shares owned by us and our affiliates represents less than 90% of the outstanding number of Shares. The Merger Agreement obligates us to provide for a Subsequent Offering Period of at least 10 business days, if requested by Millennium, in the event that, at the Acceptance Time, TPC, Takeda America, Purchaser and their respective subsidiaries own more than 80% but less than 90% of the Shares outstanding at that time, unless the exercise of the Top-Up Option described below would result in such entities owning not less than 90% of the outstanding Shares. We are required pursuant to the Merger Agreement to as promptly as practicable accept and pay for Shares validly tendered during the Subsequent Offering Period.

        Except to the extent required by the Merger Agreement, we do not currently intend to provide a Subsequent Offering Period for the Offer, although we reserve the right to do so. If we elect to provide or extend any Subsequent Offering Period, a public announcement of such inclusion or extension will be made no later than 9:00 a.m., New York City time, on the next business day following the Expiration Date.

        Under the Merger Agreement, if we do not acquire at least 90% of the outstanding Shares in the Offer after our acceptance of, and payment for Shares pursuant to the Offer, we have the option, subject to certain limitations, to purchase from Millennium at a price per Share equal to the Offer Price up to the number of additional Shares sufficient to cause us to own one Share more than 90% of the Shares then outstanding, in order to enable us to effect a short-form merger under Delaware law. We refer to this option as the "Top-Up Option." The number of additional Shares that we can purchase under the Top-Up Option is limited to the number of authorized but unissued shares of Millennium common stock (including as authorized but unissued any Shares held by Millennium but excluding the number of shares reserved for issuance under its outstanding convertible notes, options and restricted stock units). We agreed in the Merger Agreement to exercise the Top-Up Option if doing so would allow us to consummate the Merger without a vote of Millennium's stockholders pursuant to Section 253 of the DGCL.

        Millennium has provided us with Millennium's stockholder list and security position listings for the purpose of disseminating the Offer to holders of Shares. This Offer to Purchase and the related Letter of Transmittal will be mailed (along with the Schedule 14D-9, which will be mailed together with or shortly following the Offer to Purchase and Letter of Transmittal) to record holders of Shares whose

4

names appear on Millennium's stockholder list and will be furnished, for subsequent transmittal to beneficial owners of Shares, to brokers, dealers, commercial banks, trust companies and similar persons whose names, or the names of whose nominees, appear on the stockholder list or, if applicable, who are listed as participants in a clearing agency's security position listing.

2.     Acceptance for Payment and Payment for Shares

        Upon the terms and subject to the conditions of the Offer (including, if the Offer is extended or amended, the terms and conditions of any extension or amendment), we will accept for payment and pay for all Shares validly tendered and not properly withdrawn pursuant to the Offer as promptly as practicable following the later of (i) the earliest date as of which we are permitted under applicable law to accept such Shares for payment and (ii) the earliest date as of which each of the conditions of the Offer set forth in Section 15—"Certain Conditions of the Offer" shall have been satisfied or waived. If we elect to provide a Subsequent Offering Period (or are required to do so upon Millennium's request), we will accept for payment and pay for all Shares validly tendered and not withdrawn during such Subsequent Offering Period as promptly as practicable after any such Shares are tendered during any Subsequent Offering Period and in any event in compliance with Rule 14d-11 under the Exchange Act.

        For information with respect to approvals that we are required to obtain prior to completion of the Offer, including under the HSR Act and the laws and regulations of the Federal Republic of Germany and the Republic of Austria, see Section 16—"Certain Legal Matters; Regulatory Approvals."

        If we extend the Offer, are delayed in our acceptance for payment of or payment for Shares or are unable to accept for payment or pay for Shares pursuant to the Offer for any reason, then, without prejudice to our rights under the Offer (but subject to compliance with Rule 14e-1(c) under the Exchange Act), the Depositary may, nevertheless, on our behalf, retain tendered Shares, and such Shares may not be withdrawn except to the extent tendering stockholders are entitled to do so as described in Section 4—"Withdrawal Rights."

        In all cases, we will pay for Shares tendered and accepted for payment pursuant to the Offer only after timely receipt by the Depositary of (i) the certificates evidencing such Shares (the "Share Certificates") or confirmation of a book-entry transfer of such Shares (a "Book-Entry Confirmation") into the Depositary's account at The Depository Trust Company (the "Book-Entry Transfer Facility") or an affidavit of loss relating to such Share Certificates, (ii) the Letter of Transmittal (or a manually signed facsimile thereof), properly completed and duly executed, with any required signature guarantees or, in the case of a book-entry transfer, an Agent's Message (as defined below) in lieu of the Letter of Transmittal and (iii) any other documents required by the Letter of Transmittal. Accordingly, tendering stockholders may be paid at different times depending upon when Share Certificates or Book-Entry Confirmations with respect to Shares are actually received by the Depositary.

        The term "Agent's Message" means a message, transmitted by a Book-Entry Transfer Facility to, and received by, the Depositary and forming a part of a Book-Entry Confirmation, that states that the Book-Entry Transfer Facility has received an express acknowledgment from the participant in the Book-Entry Transfer Facility tendering the Shares that are the subject of such Book-Entry Confirmation, that such participant has received and agrees to be bound by the terms of the Letter of Transmittal and that Purchaser may enforce such agreement against such participant.

        For purposes of the Offer (including during a Subsequent Offering Period), we will be deemed to have accepted for payment Shares validly tendered and not properly withdrawn as, if and when we give oral or written notice to the Depositary of our acceptance for payment of such Shares pursuant to the Offer. Upon the terms and subject to the conditions of the Offer, payment for Shares accepted for payment pursuant to the Offer will be made by deposit of the Offer Price for such Shares with the Depositary, which will act as agent for tendering stockholders for the purpose of receiving payments

5

from us and transmitting such payments to tendering stockholders whose Shares have been accepted for payment. If we extend the Offer, are delayed in our acceptance for payment of Shares or are unable to accept Shares for payment pursuant to the Offer for any reason, then, without prejudice to our rights under the Offer, the Depositary may retain tendered Shares on our behalf, and such Shares may not be withdrawn except to the extent that tendering stockholders are entitled to withdrawal rights as described herein under Section 4—"Withdrawal Rights" and as otherwise required by Rule 14e-1(c) under the Exchange Act. Under no circumstances will we pay interest on the purchase price for Shares by reason of any extension of the Offer or any delay in making such payment.

        If any tendered Shares are not accepted for payment for any reason pursuant to the terms and conditions of the Offer, or if Share Certificates are submitted evidencing more Shares than are tendered, Share Certificates evidencing such unpurchased Shares will be returned, without expense to the tendering stockholder (or, in the case of Shares tendered by book-entry transfer into the Depositary's account at the Book-Entry Transfer Facility pursuant to the procedure set forth in Section 3—"Procedures for Accepting the Offer and Tendering Shares," such Shares will be credited to an account maintained at the Book-Entry Transfer Facility), as promptly as practicable following the expiration or termination of the Offer.

3.     Procedures for Accepting the Offer and Tendering Shares

        Valid Tenders.    In order for a stockholder validly to tender Shares pursuant to the Offer, either (i) the Letter of Transmittal (or a manually signed facsimile thereof), properly completed and duly executed, together with any required signature guarantees (or, in the case of a book-entry transfer, an Agent's Message in lieu of the Letter of Transmittal) and any other documents required by the Letter of Transmittal must be received by the Depositary at one of its addresses set forth on the back cover of this Offer to Purchase and either (A) the Share Certificates evidencing tendered Shares must be received by the Depositary at such address or (B) such Shares must be tendered pursuant to the procedure for book-entry transfer described below and a Book-Entry Confirmation must be received by the Depositary, in each case prior to the Expiration Date, or (ii) the tendering stockholder must comply with the guaranteed delivery procedures described below under "Guaranteed Delivery."

        Book-Entry Transfer.    The Depositary will establish an account with respect to the Shares at the Book-Entry Transfer Facility for purposes of the Offer within two business days after the date of this Offer to Purchase. Any financial institution that is a participant in the system of the Book-Entry Transfer Facility may make a book-entry delivery of Shares by causing the Book-Entry Transfer Facility to transfer such Shares into the Depositary's account at the Book-Entry Transfer Facility in accordance with the Book-Entry Transfer Facility's procedures for such transfer. However, although delivery of Shares may be effected through book-entry transfer at the Book-Entry Transfer Facility, either the Letter of Transmittal (or a manually signed facsimile thereof), properly completed and duly executed, together with any required signature guarantees, or an Agent's Message in lieu of the Letter of Transmittal, and any other required documents, must, in any case, be received by the Depositary at one of its addresses set forth on the back cover of this Offer to Purchase prior to the Expiration Date, or the tendering stockholder must comply with the guaranteed delivery procedure described below. Delivery of documents to the Book-Entry Transfer Facility does not constitute delivery to the Depositary.

        Signature Guarantees.    No signature guarantee is required on the Letter of Transmittal (i) if the Letter of Transmittal is signed by the registered holder(s) (which term, for purposes of this Section 3, includes any participant in the Book-Entry Transfer Facility's systems whose name appears on a security position listing as the owner of the Shares) of the Shares tendered therewith, unless such holder has completed either the box entitled "Special Delivery Instructions" or the box entitled "Special Payment Instructions" on the Letter of Transmittal or (ii) if the Shares are tendered for the account of a financial institution (including most commercial banks, savings and loan associations and brokerage

6

houses) that is a participant in the Security Transfer Agents Medallion Program or any other "eligible guarantor institution," as such term is defined in Rule 17Ad-15 of the Exchange Act (each an "Eligible Institution" and collectively "Eligible Institutions"). In all other cases, all signatures on a Letter of Transmittal must be guaranteed by an Eligible Institution. See Instruction 1 of the Letter of Transmittal. If a Share Certificate is registered in the name of a person or persons other than the signer of the Letter of Transmittal, or if payment is to be made or delivered to, or a Share Certificate not accepted for payment or not tendered is to be issued in, the name(s) of a person other than the registered holder(s), then the Share Certificate must be endorsed or accompanied by appropriate duly executed stock powers, in either case signed exactly as the name(s) of the registered holder(s) appear on the Share Certificate, with the signature(s) on such Share Certificate or stock powers guaranteed by an Eligible Institution as provided in the Letter of Transmittal. See Instructions 1 and 5 of the Letter of Transmittal.

        Guaranteed Delivery.    If a stockholder desires to tender Shares pursuant to the Offer and the Share Certificates evidencing such stockholder's Shares are not immediately available or such stockholder cannot deliver the Share Certificates and all other required documents to the Depositary prior to the Expiration Date, or such stockholder cannot complete the procedure for delivery by book-entry transfer on a timely basis, such Shares may nevertheless be tendered, provided that all of the following conditions are satisfied:

•

such tender is made by or through an Eligible Institution;



•

a properly completed and duly executed Notice of Guaranteed Delivery, substantially in the form made available by us, is received prior to the Expiration Date by the Depositary as provided below; and



•

the Share Certificates (or a Book-Entry Confirmation) evidencing all tendered Shares, in proper form for transfer, in each case together with the Letter of Transmittal (or a manually signed facsimile thereof), properly completed and duly executed, with any required signature guarantees (or, in the case of a book-entry transfer, an Agent's Message), and any other documents required by the Letter of Transmittal are received by the Depositary within three trading days after the date of execution of such Notice of Guaranteed Delivery. A "trading day" is any day on which quotations are available for shares listed on Nasdaq.

        The Notice of Guaranteed Delivery may be delivered by hand or transmitted by manually signed facsimile transmission or mailed to the Depositary and must include a guarantee by an Eligible Institution in the form set forth in the form of Notice of Guaranteed Delivery made available by Purchaser.

        Notwithstanding any other provision of this Offer, payment for Shares tendered and accepted for payment pursuant to the Offer will in all cases only be made after timely receipt by the Depositary of (i) certificates evidencing such Shares or a Book-Entry Confirmation of a book-entry transfer of such Shares into the Depositary's account at the Book-Entry Transfer Facility pursuant to the procedures set forth in this Section 3, (ii) the Letter of Transmittal (or a manually signed facsimile thereof), properly completed and duly executed, with any required signature guarantees or, in the case of a book-entry transfer, an Agent's Message in lieu of the Letter of Transmittal and (iii) any other documents required by the Letter of Transmittal. Accordingly, tendering stockholders may be paid at different times depending upon when Share Certificates or Book-Entry Confirmations with respect to Shares are actually received by the Depositary.

        The method of delivery of Share Certificates, the Letter of Transmittal and all other required documents, including delivery through the Book-Entry Transfer Facility, is at the option and risk of the tendering stockholder, and the delivery will be deemed made only when actually received by the Depositary (including, in the case of a book-entry transfer, receipt of a Book-Entry Confirmation). If

7

delivery is by mail, registered mail with return receipt requested, properly insured, is recommended. In all cases, sufficient time should be allowed to ensure timely delivery.

        No alternative, conditional or contingent tenders will be accepted, and no fractional Shares will be purchased. By executing the Letter of Transmittal (or facsimile thereof), the tendering stockholder waives any right to receive any notice of the acceptance for payment of the Shares.

        The tender of Shares pursuant to any one of the procedures described above will constitute the tendering stockholder's acceptance of the Offer, as well as the tendering stockholder's representation and warranty that such stockholder has the full power and authority to tender and assign the Shares tendered, as specified in the Letter of Transmittal. Our acceptance for payment of Shares tendered pursuant to the Offer will constitute a binding agreement between the tendering stockholder and us upon the terms and subject to the conditions of the Offer.

        Determination of Validity.    All questions as to the validity, form, eligibility (including time of receipt) and acceptance for payment of any tender of Shares will be determined by us, in our sole discretion, which determination shall be final and binding on all parties. We reserve the absolute right to reject any and all tenders determined by us not to be in proper form or the acceptance for payment of which may, in the opinion of our counsel, be unlawful. We also reserve the absolute right to waive any defect or irregularity in the tender of any Shares of any particular stockholder, whether or not similar defects or irregularities are waived in the case of other stockholders. No tender of Shares will be deemed to have been validly made until all defects and irregularities have been cured or waived to our satisfaction. None of Purchaser, the Depositary, the Dealer Manager, the Information Agent or any other person will be under any duty to give notification of any defects or irregularities in tenders or incur any liability for failure to give any such notification. Our interpretation of the terms and conditions of the Offer (including the Letter of Transmittal and the instructions thereto) will be final and binding.

        Appointment.    By executing the Letter of Transmittal as set forth above, the tendering stockholder will irrevocably appoint Purchaser or designees of Purchaser as such stockholder's attorneys-in-fact and proxies in the manner set forth in the Letter of Transmittal, each with full power of substitution, to the full extent of such stockholder's rights with respect to the Shares tendered by such stockholder and accepted for payment by Purchaser and with respect to any and all other Shares or other securities or rights issued or issuable in respect of such Shares. All such powers of attorney and proxies will be considered irrevocable and coupled with an interest in the tendered Shares. Such appointment will be effective when, and only to the extent that, we accept for payment and pay for Shares tendered by such stockholder as provided herein and deposit the purchase price therefor with the Depositary. Upon such appointment, all prior powers of attorney, proxies and consents given by such stockholder with respect to such Shares or other securities or rights will, without further action, be revoked and no subsequent powers of attorney, proxies, consents or revocations may be given by such stockholder (and, if given, will not be deemed effective). The designees of Purchaser will thereby be empowered to exercise all voting and other rights with respect to such Shares and other securities or rights, including, without limitation, in respect of any annual, special or adjourned meeting of Millennium's stockholders, or otherwise, as they in their sole discretion deem proper. We reserve the right to require that, in order for Shares to be deemed validly tendered, immediately upon our acceptance for payment of such Shares, Purchaser must be able to exercise full voting, consent and other rights with respect to such Shares and other related securities or rights, including voting at any meeting of stockholders.

        Backup Withholding.    Under the "backup withholding" provisions of United States federal income tax law, the Depositary may be required to withhold and pay over to the Internal Revenue Service 28% of the amount of any payments pursuant to the Offer. In order to prevent backup federal income tax withholding with respect to payments to certain stockholders of the Offer Price for Shares purchased pursuant to the Offer, each such stockholder must provide the Depositary with such stockholder's

8

correct taxpayer identification number ("TIN") and certify that such stockholder is not subject to backup withholding by completing the Substitute Form W-9 in the Letter of Transmittal. Certain stockholders (including, among others, all corporations and certain foreign individuals and entities) may not be subject to backup withholding. If a stockholder does not provide its correct TIN or fails to provide the certifications described above, the Internal Revenue Service may impose a penalty on the stockholder and payment to the stockholder pursuant to the Offer may be subject to backup withholding. All stockholders surrendering Shares pursuant to the Offer who are U.S. persons (as defined for U.S. federal income tax purposes) should complete and sign the Substitute Form W-9 included in the Letter of Transmittal to provide the information necessary to avoid backup withholding. Foreign stockholders should complete and sign the appropriate Form W-8 (a copy of which may be obtained from the Depositary) in order to avoid backup withholding. Such stockholders should consult a tax advisor to determine which Form W-8 is appropriate. See Instruction 8 of the Letter of Transmittal.

4.     Withdrawal Rights

        Except as otherwise provided in this Section 4, tenders of Shares made pursuant to the Offer are irrevocable.

        Shares tendered pursuant to the Offer may be withdrawn at any time prior to the Expiration Date and, unless theretofore accepted for payment by Purchaser pursuant to the Offer, may also be withdrawn at any time after June 9, 2008.

        For a withdrawal to be effective, a written or facsimile transmission notice of withdrawal must be timely received by the Depositary at one of its addresses set forth on the back cover page of this Offer to Purchase. Any such notice of withdrawal must specify the name of the person who tendered the Shares to be withdrawn, the number of Shares to be withdrawn and the name of the registered holder of such Shares, if different from that of the person who tendered such Shares. If Share Certificates evidencing Shares to be withdrawn have been delivered or otherwise identified to the Depositary, then, prior to the physical release of such Share Certificates, the serial numbers shown on such Share Certificates must be submitted to the Depositary and the signature(s) on the notice of withdrawal must be guaranteed by an Eligible Institution, unless such Shares have been tendered for the account of an Eligible Institution. If Shares have been tendered pursuant to the procedure for book-entry transfer as set forth in Section 3—"Procedures for Accepting the Offer and Tendering Shares," any notice of withdrawal must also specify the name and number of the account at the Book-Entry Transfer Facility to be credited with the withdrawn Shares.

        Withdrawals of Shares may not be rescinded. Any Shares properly withdrawn will thereafter be deemed not to have been validly tendered for purposes of the Offer. However, withdrawn Shares may be re-tendered by again following one of the procedures described in Section 3—"Procedures for Accepting the Offer and Tendering Shares" at any time prior to the Expiration Date.

        No withdrawal rights will apply to Shares tendered during a Subsequent Offering Period and no withdrawal rights apply during the Subsequent Offering Period with respect to Shares tendered in the Offer and accepted for payment. See Section 1—"Terms of the Tender Offer."

        We will determine, in our sole discretion, all questions as to the form and validity (including time of receipt) of any notice of withdrawal and our determination will be final and binding. None of Purchaser, the Depositary, the Dealer Manager, the Information Agent or any other person will be under any duty to give notification of any defects or irregularities in any notice of withdrawal or incur any liability for failure to give any such notification.

9

5.     Certain United States Federal Income Tax Consequences

        The following is a summary of certain United States federal income tax consequences of the Offer and the Merger to stockholders of Millennium whose Shares are tendered and accepted for payment pursuant to the Offer or whose Shares are converted into the right to receive cash in the Merger. The discussion is for general information only and does not purport to consider all aspects of United States federal income taxation that might be relevant to stockholders of Millennium. The discussion is based on current provisions of the Internal Revenue Code of 1986, as amended (the "Code"), existing, proposed and temporary regulations thereunder and administrative and judicial interpretations thereof, all of which are subject to change, possibly with a retroactive effect. The discussion applies only to stockholders of Millennium in whose hands Shares are capital assets within the meaning of Section 1221 of the Code. This discussion does not apply to Shares received pursuant to the exercise of employee stock options or otherwise as compensation, or to certain types of stockholders (such as insurance companies, tax-exempt organizations, financial institutions and broker-dealers) who may be subject to special rules. This discussion does not discuss the United States federal income tax consequences to any stockholder of Millennium who, for United States federal income tax purposes, is a nonresident alien individual, a foreign corporation, a foreign partnership or a foreign estate or trust, nor does it consider the effect of any foreign, state or local tax laws.

Because individual circumstances may differ, each stockholder should consult its, his or her own tax advisor to determine the applicability of the rules discussed below and the particular tax effects of the Offer and the Merger on a beneficial holder of Shares, including the application and effect of the alternative minimum tax and any state, local and foreign tax laws.

        The exchange of Shares for cash pursuant to the Offer or the Merger will be a taxable transaction for United States federal income tax purposes. In general, a stockholder who sells Shares pursuant to the Offer or receives cash in exchange for Shares pursuant to the Merger will recognize gain or loss for United States federal income tax purposes in an amount equal to the difference, if any, between the amount of cash received and the stockholder's adjusted tax basis in the Shares sold pursuant to the Offer or exchanged for cash pursuant to the Merger. Gain or loss will be determined separately for each block of Shares (that is, Shares acquired at the same cost in a single transaction) tendered pursuant to the Offer or exchanged for cash pursuant to the Merger. Such gain or loss will be long-term capital gain or loss provided that a stockholder's holding period for such Shares is more than one year at the time of consummation of the Offer or the Merger, as the case may be. Capital gains recognized by an individual upon a disposition of a Share that has been held for more than one year generally will be subject to a maximum United States federal income tax rate of 15%. In the case of a Share that has been held for one year or less, such capital gains generally will be subject to tax at ordinary income tax rates. Certain limitations apply to the use of a stockholder's capital losses.

        A stockholder whose Shares are purchased in the Offer or exchanged for cash pursuant to the Merger may be subject to backup withholding unless certain information is provided to the Depositary or an exemption applies. See Section 3—"Procedures for Accepting the Offer and Tendering Shares."

6.     Price Range of Shares; Dividends

        The Shares currently trade on Nasdaq under the symbol "MLNM." According to Millennium, as of the close of business on April 7, 2008: (A) 326,704,024 Shares were issued and outstanding, including in each case the associated preferred share purchase rights issued pursuant to Millennium's rights agreement; (B) no shares of Millennium preferred stock were issued or outstanding; (C) no Shares were held by Millennium in its treasury; (D) there were outstanding Options to purchase 21,718,903 Shares and 41,853,826 Shares were reserved for issuance under Millennium's equity incentive plans (including upon exercise of the Options); and (E) there was outstanding $250,000,000 in aggregate principal amount of Millennium's 2.25% Convertible Senior Notes due November 15, 2011 convertible

10

into 17,045,032 Shares (after giving effect to any adjustment relating to the Offer Price and assuming the Acceptance Time occurs on May 15, 2008).

        The following table sets forth, for the periods indicated, the high and low sale prices per Share for each quarterly period presented, as reported by Nasdaq based on published financial sources.

		High		Low
Year Ended December 31, 2006
	First Quarter	$	11.25	$	9.56
	Second Quarter	$	11.46	$	7.83
	Third Quarter	$	11.04	$	8.75
	Fourth Quarter	$	12.08	$	9.70
Year Ending December 31, 2007
	First Quarter	$	11.57	$	10.20
	Second Quarter	$	12.29	$	9.85
	Third Quarter	$	10.89	$	9.49
	Fourth Quarter	$	16.62	$	10.06
Year Ending December 31, 2008
	First Quarter	$	17.19	$	12.82
	Second Quarter (through April 10, 2008)	$	24.51	$	15.39

        On April 9, 2008, the last full day of trading before the public announcement of the terms of the Offer and the Merger, the reported closing sales price of the Shares on Nasdaq was $16.35 per Share. The Offer Price represents a premium of 52.9% over the closing price on the last full day of trading before the public announcement of the Offer and the Merger. Millennium has never paid any dividends on the Shares. Under the terms of the Merger Agreement, Millennium is not permitted to declare or pay dividends with respect to the Shares. Stockholders are urged to obtain a current market quotation for the Shares.

7.     Certain Information Concerning Millennium

        General.    Millennium is a Delaware corporation with its principal executive offices located at 40 Landsdowne Street, Cambridge, MA 02139 USA. The telephone number at that location is (617) 679-7000. Millennium is an innovation-driven biopharmaceutical company focused on discovering, developing and commercializing medicines to improve the lives of patients with cancer, inflammatory bowel diseases and other inflammatory diseases.

        Except as specifically described herein, the information concerning Millennium contained in this Offer to Purchase has been taken from or is based upon information furnished by Millennium or its representatives or upon publicly available documents and records on file with the SEC and other public sources. The summary information set forth below is qualified in its entirety by reference to Millennium's public filings with the SEC (which may be obtained and inspected as described below) and should be reviewed in conjunction with the more comprehensive financial and other information contained in such reports and other publicly available information. None of TPC, Takeda America, Purchaser or any of their affiliates has any knowledge that would indicate that any statements contained herein based on such documents and records are untrue. However, none of TPC, Takeda America, Purchaser or any of their affiliates assumes any responsibility for the accuracy or completeness of the information concerning Millennium, whether furnished by Millennium or contained in such documents or records, or for any failure by Millennium to disclose events that may have occurred or may affect the significance or accuracy of any such information but that are unknown to TPC, Takeda America, Purchaser or their affiliates.

11

        Available Information.    Millennium is subject to the information and reporting requirements of the Exchange Act and, in accordance therewith, is obligated to file annual, quarterly and current reports and other information with the SEC relating to its business, financial condition and other matters. Certain information, as of particular dates, concerning Millennium's directors and officers, their remuneration, stock options granted to them, the principal holders of Millennium's securities, any material interests of such persons in transactions with Millennium and other matters is required to be disclosed in proxy statements distributed to Millennium's stockholders and filed with the SEC. Such reports, proxy statements and other information are available for inspection at the public reference room at the SEC's offices at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Information regarding the public reference room may be obtained from the SEC by telephoning 1-800-SEC-0330. Copies may be obtained, by mail, upon payment of the SEC's customary charges, by writing to its principal office at 100 F Street, N.E., Room 1580, Washington, D.C. 20549 and can be obtained electronically on the SEC's website at http://www.sec.gov.

        Millennium made available to us certain non-public business and financial information about Millennium, including financial projections through the fiscal year ending December 31, 2013 ("fiscal 2013"). These projections included the following estimates of Millennium's future financial performance:

	Projected
	2008			2009			2010			2011			2012			2013
	(unaudited, amounts in millions)
Total revenues	$	548		$	710		$	873		$	1,063		$	1,293		$	1,520
Operating income		53			142			289			453			543			736
Non-GAAP net operating income		87			178			332			333			400			533
GAAP adjustments		(65	)		(68	)		(69	)		(70	)		(68	)		(68	)
GAAP income		22			110			263			263			332			464

        Projected non-GAAP net operating income in the table above excludes restructuring charges, amortization and stock-based compensation.

        These projections incorporated the likelihood of each of Millennium's pipeline products, other than MLN 0002, reaching the market was probability weighted based on management's views. These projections assumed that MLN 0002 would reach the market in 2012.

        Millennium's non-public business and financial information and projections through fiscal 2013 that Millennium provided to TPC and Takeda America during the course of their due diligence investigation of Millennium were provided solely in connection with such due diligence investigation and not expressly for inclusion or incorporation by reference in any Offer documents. There is no guarantee that any projections will be realized, or that the assumptions on which they are based will prove to be correct.

        Millennium has advised TPC and Takeda America that it does not as a matter of course make public any projections as to future performance or earnings, other than limited guidance for periods no longer than one year, and the projections set forth above are included in this Offer to Purchase only because this information was provided to TPC and Takeda America. The projections were not prepared with a view to public disclosure or compliance with the published guidelines of the SEC or the guidelines established by the American Institute of Certified Public Accountants regarding projections or forecasts. The projections do not purport to present operations in accordance with U.S. generally accepted accounting principles, and Millennium's independent registered public accounting firm has not examined, compiled or otherwise applied procedures to the projections and accordingly assumes no responsibility for them. Millennium has advised TPC and Takeda America that its internal financial forecasts, upon which the projections were based in part, are, in general, prepared solely for internal use, such as budgeting and other management decisions, and are subjective in many respects. As a

12

result, these internal financial forecasts are susceptible to interpretations and periodic revision based on actual experience and business developments. The projections reflect numerous assumptions made by the management of Millennium and general business, economic, market and financial conditions and other matters, all of which are difficult to predict and many of which are beyond Millennium's, TPC's or Takeda America's control. Accordingly, there can be no assurance that the assumptions made in preparing the projections will prove accurate or that any of the projections will be realized.

        Millennium has advised that it expects, and TPC and Takeda America also expect, that there will be differences between actual and projected results, and actual results may be materially greater or less than those contained in the projections due to numerous risks and uncertainties, including but not limited to the important factors listed under "Item 1A. Risk Factors" in Millennium's Annual Report on Form 10-K for the year ended December 31, 2007. All projections are forward-looking statements, and these and other forward-looking statements are expressly qualified in their entirety by the risks and uncertainties identified in Millennium's Form 10-K.

        The inclusion of the projections herein should not be regarded as an indication that any of Millennium, TPC, Takeda America or their respective affiliates or representatives considered or consider the projections to be a prediction of actual future events, and the projections should not be relied upon as such. None of Millennium, TPC, Takeda America or any of their respective affiliates or representatives intends to update or otherwise revise the projections to reflect circumstances existing or arising after the date such projections were generated or to reflect the occurrence of future events, even in the event that any or all of the assumptions underlying the projections are shown to be in error.

Holders of Shares are cautioned not to place undue reliance on the projections included in this Offer to Purchase.

13

        On March 25, 2008, TPC sent a draft exclusivity agreement to Ms. Protopapas. Representatives from Millennium and TPC and each company's counsel negotiated the terms of the exclusivity agreement throughout that day and into the following morning. 8.     Certain Information Concerning TPC, Takeda America and Purchaser

        TPC is a Japanese corporation. TPC's principal executive offices are located at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan. The telephone number of TPC's principal executive offices is +81 6 6204-2111. TPC is a research-based global pharmaceutical company. TPC is engaged in the discovery, development, manufacturing, marketing, importing and exporting of pharmaceutical drugs.

        Takeda America is a New York corporation. Takeda America's principal executive offices are located at 767 Third Avenue, 8^th Floor, New York, NY 10017, USA. The telephone number of Takeda America's principal executive offices is (212) 421-6954. As a wholly-owned subsidiary of TPC, Takeda America handles cash management and investment activities for TPC within the North America region.

        Purchaser is a Delaware corporation and a wholly-owned subsidiary of Takeda America. Purchaser was organized by TPC to acquire Millennium and has not conducted any unrelated activities since its organization. All outstanding shares of the capital stock of Purchaser are wholly-owned by Takeda America. Purchaser's principal executive offices are located at the same address as Takeda America's principal executive office listed above, and its telephone number at that address is the same telephone number as Takeda America's telephone number listed above.

        The name, citizenship, business address, present principal occupation or employment and five-year employment history of each of the directors and executive officers of TPC, Takeda America and Purchaser are listed in Schedule I to this Offer to Purchase.

        During the last five years, none of TPC, Takeda America, Purchaser or, to the best knowledge of TPC, Takeda America and Purchaser, any of the persons listed in Schedule I to this Offer to Purchase (i) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to any judicial or administrative proceeding (except for matters that were dismissed without sanction or settlement) that resulted in a judgment, decree or final order enjoining the person from future violations of, or prohibiting activities subject to, federal or state securities laws, or a finding of any violation of such laws.

        Except as described in this Offer to Purchase and in Schedule I hereto, (i) none of TPC, Takeda America, Purchaser or, to the best knowledge of TPC, Takeda America and Purchaser, any of the persons listed in Schedule I to this Offer to Purchase or any associate or majority-owned subsidiary of TPC, Takeda America and Purchaser or any of the persons so listed beneficially owns or has any right to acquire, directly or indirectly, any Shares and (ii) none of TPC, Takeda America, Purchaser or, to the best knowledge of TPC, Takeda America and Purchaser, any of the persons or entities referred to in Schedule I hereto nor any director, executive officer or subsidiary of any of the foregoing has effected any transaction in the Shares during the past 60 days.

        Except as provided in the Merger Agreement or as otherwise described in this Offer to Purchase, none of TPC, Takeda America, Purchaser or, to the best knowledge of TPC, Takeda America and Purchaser, any of the persons listed in Schedule I to this Offer to Purchase, has any contract, arrangement, understanding or relationship with any other person with respect to any securities of Millennium, including, but not limited to, any contract, arrangement, understanding or relationship concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of loans, guarantees against loss, guarantees of profits, division of profits or loss or the giving or withholding of proxies.

        Except as set forth in this Offer to Purchase, none of TPC, Takeda America, Purchaser or, to the best knowledge of TPC, Takeda America and Purchaser, any of the persons listed on Schedule I hereto,

14

has had any business relationship or transaction with Millennium or any of its executive officers, directors or affiliates that is required to be reported under the rules and regulations of the SEC applicable to the Offer. Except as set forth in this Offer to Purchase, there have been no contacts, negotiations or transactions between TPC, Takeda America, Purchaser or any of its other subsidiaries or, to the best knowledge of TPC, Takeda America, Purchaser and any of the persons listed in Schedule I to this Offer to Purchase, on the one hand, and Millennium or its affiliates, on the other hand, concerning a merger, consolidation or acquisition, tender offer or other acquisition of securities, an election of directors or a sale or other transfer of a material amount of assets during the past two years.

9.     Source and Amount of Funds

        Purchaser estimates that it will need approximately $8.8 billion to purchase all of the Shares pursuant to the Offer, to cash out certain employee options, restricted stock and restricted stock units, to fund amounts that may become payable under Millennium's outstanding convertible notes, and to consummate the Merger, plus related fees and expenses. Takeda America or TPC will provide Purchaser with sufficient funds to purchase all Shares properly tendered in the Offer and to provide funding for our Merger with Millennium, which is expected to follow the successful completion of the Offer in accordance with the terms and conditions of the Merger Agreement. The Offer is not conditioned upon our ability to finance the purchase of Shares pursuant to the Offer. In addition, Takeda America expects to obtain the necessary funds from existing cash balances, cash equivalents and currently available sources of credit. Pursuant to the Merger Agreement, TPC has unconditionally guaranteed the full and complete performance by Takeda America and Purchaser of their respective obligations under the Merger Agreement.

        Purchaser does not think its financial condition is relevant to a decision by the holders of Shares whether or not to tender Shares and accept the Offer because:

•

the Offer is being made for all outstanding Shares solely for cash;



•

Purchaser, through TPC, which has unconditionally guaranteed Purchaser's obligations under the Merger Agreement, will have sufficient funds available to purchase all Shares validly tendered and not properly withdrawn in the Offer in light of TPC's and Takeda America's financial capacity in relation to the amount of consideration payable;



•

the Offer is not subject to any financing condition; and



•

if Purchaser consummates the Offer, it expects to acquire any remaining Shares for the same cash price in the Merger.

10.   Background of the Offer; Past Contacts or Negotiations with Millennium

        TPC continually evaluates its strategic opportunities to strengthen its business and deliver long-term value to its stockholders. As part of its long-term strategic planning, TPC has identified the continued expansion of its global oncology business and its U.S. operations as an important part of its long-term strategy, in addition to pursuing growth opportunities in its other drug businesses. In furtherance of this objective, in early 2007, TPC established a formal project team (the "Oncology Project Team"), consisting of executives and other key employees, to focus on oncology business strategies and the expansion of TPC's U.S. operations, including by seeking out and evaluating strategic acquisition candidates, as well as by establishing collaborative research and development efforts.

        These activities have resulted in a number of important strategic developments for TPC, including, most recently:

•

entering into an exclusive collaboration with Amgen, Inc. in Japan, including acquiring Amgen's wholly owned subsidiary in Japan and obtaining rights with respect to certain early to mid-stage

15

clinical-stage candidates across a range of therapeutic areas, including oncology, and entering into a global alliance with Amgen on the development and commercialization of another Amgen product candidate.

•

forming a global alliance with Cell Genesys, Inc. for the development and commercialization of Cell Genesys' lead product candidate for a prostate cancer vaccine.



•

consolidating its U.S. development and marketing functions pursuant to its agreement with Abbott Laboratories to conclude the TAP Pharmaceutical Products Inc. (TAP) joint venture, as a result of which Takeda Pharmaceuticals North America will absorb half of the TAP business, including most of its employees.

        As part of the above strategy, from time to time, TPC has had discussions with Millennium to explore potential collaborative ventures in oncology.

        In July 2007, Millennium's Chief Executive Officer, Deborah Dunsire, and its Senior Vice President, Corporate Development, Anna Protopapas, met with TPC's President, Yasuchika Hasegawa, and other members of TPC's senior management in Tokyo, Japan. The purpose of the meeting was to acquaint the senior management teams with one another and to discuss general areas of potential scientific collaboration between the companies.

        During the summer of 2007, business development personnel and scientists from TPC and Millennium continued to have further discussions about potential areas of collaboration, and the companies entered into a general confidentiality agreement to facilitate these discussions.

        In October and November 2007, senior scientists of Millennium and TPC met, respectively, at TPC's facilities in San Diego, California and at Millennium's headquarters in Cambridge, Massachusetts to discuss scientific capabilities and potential research collaborations.

        Based on these initial meetings, in the fall of 2007, the Oncology Project Team recommended that TPC formally evaluate Millennium as a potential strategic opportunity or relationship in furtherance of TPC's global oncology and U.S. business expansion plans.

        On December 3, 2007, TPC initiated the Project Millennium Evaluation team, an internal working group consisting of senior executives and scientists, to further focus TPC's strategic evaluation of Millennium. In addition, a Steering Committee (chaired by Dr. Kiyoshi Kitazawa, a Managing Director of TPC) was created consisting of both directors and certain senior executives. The purpose of the Steering Committee was to oversee this effort and to determine the optimal way to approach any strategic opportunities with Millennium, including evaluating the merits of an acquisition proposal involving Millennium.

        On December 5, 2007, Ms. Protopapas met with Hiroaki Ogata, TPC's then General Manager, Global Licensing and Business Development, in Boston, Massachusetts, to discuss the scope of a potential collaboration between Millennium and TPC.

        In mid-December 2007, senior executives and scientists at Millennium and TPC met in Japan to have further scientific discussions, followed by meetings between the respective business development personnel to discuss strategic opportunities, including forming a research collaboration relationship.

        On December 20, 2007, various members of TPC senior management and scientists met to review TPC's discussions with Millennium during the previous six months, including an assessment of the quality of the scientists at Millennium, the extensive drug discovery capabilities and infrastructure of Millennium, its commercialization and marketing expertise, the leading position of Millennium in oncology through its Velcade product and its pipeline of other drug candidates. Based on these attributes, senior management concluded that an acquisition of Millennium would significantly advance TPC's long-term strategic goals and that TPC should ascertain whether Millennium would be interested in discussing a potential acquisition proposal from TPC.

16

        On January 9, 2008, Mr. Hasegawa, Dr. Kitazawa and Ken Araki, a senior executive in TPC's business development department had a meeting with Dr. Dunsire and Ms. Protopapas during an industry conference. At that meeting, Mr. Hasegawa communicated TPC's interest in potentially acquiring Millennium as part of its global oncology expansion and discussed an overall strategic vision for TPC with Millennium.

        On January 21, 2008, the Steering Committee met with members of Project Millennium Evaluation team and other senior executives to discuss possible valuations of Millennium.

        On January 23, 2008, Mr. Hasegawa and Mr. Araki met with representatives from TPC's financial advisor, UBS Securities LLC ("UBS"), in Copenhagen, Denmark to discuss formulating an acquisition proposal for Millennium and potential valuation and other strategic matters regarding Millennium.

        On January 29, 2008, the Executive Committee of TPC, which consists of Kunio Takeda, the Chairman of the Board, and Mr. Hasegawa, discussed the potential terms of an acquisition proposal for Millennium.

        On January 31, 2008, based on TPC's internal valuation work, the board of directors of TPC approved the submission of a non-binding acquisition proposal to Millennium, as described below.

        On February 1, 2008, Mr. Hasegawa sent a letter to Dr. Dunsire setting forth a non-binding proposal to acquire 100% of Millennium's outstanding equity for a price of $23 per share in cash (with no financing condition), subject to due diligence and further valuation work. On January 31, 2008, the closing price of Millennium's common stock on the Nasdaq was $15.17 per share. This proposal requested a response by no later than February 22, 2008.

        On February 12, 2008, Dr. Dunsire telephoned Mr. Hasegawa to communicate that Millennium would give serious consideration to the letter and that she would be presenting the acquisition proposal to the Millennium board of directors at an upcoming meeting.

        On February 15, 2008, following a meeting of the Millennium Board, representatives of Millennium contacted representatives of Takeda to indicate that Millennium had determined to allow TPC to conduct limited due diligence on specific business, financial and legal matters.

        On February 20, 2008, TPC and Millennium entered into a confidentiality agreement to facilitate the exchange of information.

        On February 21, 2008, Millennium provided TPC limited access to an online secure data room containing due diligence information about Millennium. During the next six weeks, TPC and its advisors conducted due diligence on Millennium.

        On February 24, 2008, representatives from both companies met in Cambridge, Massachusetts to discuss TPC's initial proposed plans for integrating Millennium into the TPC family of companies and TPC's vision to build leadership in the oncology field with Millennium as the foundation.

        On February 25, 2008, representatives of TPC and Millennium held management sessions in Boston, Massachusetts, during which senior members of Millennium management and scientific teams presented a comprehensive overview of Millennium. Representatives from UBS and Millennium's financial advisor, Goldman Sachs & Co ("Goldman Sachs"), also attended.

        On March 11, 2008, based on the results of due diligence and TPC's further valuation work since the submission of its proposal to Millennium on February 1, 2008, the Steering Committee recommended to TPC's Executive Committee that TOC increase it proposed purchase price to $24 per share.

        On March 18, 2008, the Executive Committee approved the submission of a revised acquisition proposal to Millennium at a proposed purchase price of $24 per share in cash for 100% of the

17

outstanding equity of Millennium. Also on March 18, 2008, Mr. Hasegawa telephoned Dr. Dunsire to communicate this revised proposal, which was later memorialized in writing.

        Following a Millennium Board meeting, Dr. Dunsire telephoned Mr. Hasegawa to communicate that the Millennium Board was not prepared to accept the acquisition proposal of $24 per share in cash and that TPC would need to offer $25 per share in cash for the Millennium Board to consider acceptance of an acquisition proposal by TPC. On March 19, 2008, representatives of Goldman Sachs telephoned representatives of UBS to convey the same message.

        On March 20, 2008, Mr. Hasegawa telephoned Dr. Dunsire to communicate that TPC would be willing to offer $25 per share in cash if Millennium would agree to a reasonable exclusivity period in which the parties would negotiate a definitive merger agreement that would provide for customary no-shop and fiduciary termination provisions and a break-up fee of 3.5% of the equity value of Millennium implied by the terms offered. On the prior evening, in accordance with TPC's instructions, representatives of UBS had telephoned representatives of Goldman Sachs to convey this same message.

        In telephone discussions between Goldman Sachs and UBS on March 22 and 23, 2008, representatives of UBS, in accordance with TPC's instructions, informed representatives of Goldman Sachs that TPC only would consider increasing the purchase price to $25 per share in cash if Millennium accepted TPC's request for an exclusivity period and that such period be for 30 days. In telephone discussions between Ms. Protopapas and Mr. Araki on March 23, 2008, Mr. Araki communicated this same message.

        On March 23, 2008, Dr. Dunsire telephoned Mr. Hasegawa to communicate that Millennium would be willing to proceed with negotiations with respect to an acquisition at $25 per share in cash and would consider entering into an exclusivity agreement if TPC would agree to decrease the proposed amount of the break-up fee to be contained in the definitive merger agreement and to other specified terms, including shortening the proposed length of the exclusivity period.

        On March 24, 2008, Mr. Hasegawa sent a letter to Dr. Dunsire setting forth TPC's proposal of $25 per share in cash for 100% of Millennium's outstanding equity, subject to completion of limited confirmatory due diligence and the following additional conditions:

•

establishing an exclusivity period for approximately 20 days (through April 13, 2008),



•

negotiating a definitive agreement with customary no-shop and fiduciary termination provisions and a break-up fee of 2.8% of the equity value, payable in the event, among others, that Millennium were to breach its no-shop obligation or if any third party were to make a competing proposal and the transaction with TPC was not consummated, and



•

executing retention agreements with key executives and employees of Millennium.

        This increased purchase price of $25 per share represented a premium of approximately 76% to Millennium's closing price of $14.17 on March 20, 2008 and 81% to the 30-day average.

        On March 25, 2008, the parties entered into the exclusivity agreement described above.

        On March 25, 2008, Edwards Angell Palmer & Dodge LLP ("EAPD"), counsel to TPC, distributed a draft merger agreement to Wilmer Cutler Pickering Hale and Dorr LLP ("WilmerHale"), counsel to Millennium. On March 27, 2008, WilmerHale provided EAPD comments to the draft merger agreement. On March 28, 2008, TPC, together with its counsel, and Millennium, together with its counsel, participated in a telephone conference to discuss WilmerHale's comments on the draft merger agreement.

        On March 28, 2008, the TPC Board discussed the terms of the proposed merger agreement in its then current form and voted to approve the terms of merger in substantially the form described therein.

18

        On March 31, 2008, TPC, together with its counsel and financial advisor, and Millennium, together with its counsel and financial advisor, met at the offices of WilmerHale to discuss the key terms of the draft merger agreement. In the evening of March 31, 2008, EAPD provided a revised draft of the merger agreement that responded to WilmerHale's comments.

        On April 1, 2008, TPC, together with its counsel and financial advisor, and Millennium, together with its counsel and financial advisor, met at the offices of WilmerHale to continue finalizing the terms of the merger agreement. At this meeting, the parties reached preliminary agreement on major unresolved issues. Later on April 1, 2008, WilmerHale provided a revised draft of the merger agreement to TPC and its counsel reflecting these discussions and the preliminary agreements of the parties. In the evening of April 1, 2008, following the completion of negotiations by the parties, Dr. Dunsire met with Mr. Kitazawa to discuss TPC's proposed operating model for Millennium following the merger.

        On April 2, 2008, TPC, together with its counsel and financial advisor, and Millennium, together with its counsel and financial advisor, met at the offices of WilmerHale to discuss a small number of open issues in the merger agreement. After reaching preliminary agreement with respect to these issues, Dr. Dunsire met with representatives from TPC for an initial discussion regarding retention arrangements proposed by TPC for key employees of Millennium. In addition, Mr. Hasegawa telephoned Dr. Dunsire that evening regarding proposed terms of a retention arrangement for Dr. Dunsire with TPC.

        On April 3, 2008, WilmerHale distributed a revised draft of the merger agreement to TPC and its counsel reflecting the matters discussed at the April 2, 2008 meeting. Also on April 3, 2008, WilmerHale distributed a draft tender and support agreement to be entered into by TPC and directors and executive officers of Millennium. In addition, on April 3 and April 4, 2008, TPC met with members of Millennium's management to discuss the proposed terms of retention arrangements with these individuals.

        On April 4, 2008, counsel for TPC and Millennium had various communications regarding the merger agreement and related acquisition agreements addressing less significant issues and WilmerHale distributed a revised draft of the merger agreement.

        On April 6, 2008, Millennium held a Special Meeting of its Board of Directors to discuss the terms of the merger agreement with its legal and financial advisors.

        On April 9, 2008, Millennium held a Special Meeting of its Board of Directors and Compensation Committee, with its legal and financial advisors, to consider approval of the merger agreement.

        In the evening of April 9, 2008, TPC was informed that the Millennium Board had unanimously declared that the merger agreement and the transactions contemplated thereby, including the offer and the merger, are fair to and in the best interests of Millennium and its stockholders, unanimously approved and declared advisable the merger agreement and the transactions contemplated thereby, and unanimously recommended that Millennium's stockholders accept the offer, tender their shares of Millennium common stock pursuant to the Offer and adopt the merger agreement.

        During the evening of April 9, 2008, following the meeting of Millennium's Board, representatives of Millennium, TPC, WilmerHale and EAPD clarified several matters and finalized the terms of the merger agreement.

        On the morning of April 10, 2008, TPC and Millennium executed the merger agreement and publicly announced the merger.

19

11.   The Transaction Documents

The Merger Agreement.

        The following is a summary of the material provisions of the Merger Agreement. The following description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, a copy of which is filed as an exhibit to the Schedule TO and is incorporated herein by reference. For a complete understanding of the Merger Agreement, you are encouraged to read the full text of the Merger Agreement. The Merger Agreement is not intended to provide you with any other factual information about Takeda America, Purchaser or Millennium. Such information can be found elsewhere in this Offer to Purchase.

        The Offer.    The Merger Agreement provides for the commencement of the Offer as promptly as reasonably practicable, but in no event later than five business days after the date of the Merger Agreement, which was April 10, 2008. The obligations of Purchaser to (and the obligations of Takeda America to cause Purchaser to) to purchase, accept for payment, and pay for, Shares tendered pursuant to the Offer are subject only to the satisfaction or waiver of certain conditions (the "Offer Conditions") that are described in Section 15—"Certain Conditions of the Offer." Purchaser expressly reserves the right to increase the Offer Price and to waive any of the Offer Conditions and/or modify the terms of the Offer, except that without the consent of Millennium, Purchaser shall not (i) reduce the number of Shares subject to the Offer; (ii) reduce the Offer Price; (iii) change or waive the Minimum Tender Condition; (iv) extend the Offer, except (A) as required by applicable law, (B) in connection with an increase in the Offer Price of at least $0.25 per Share so as to comply with applicable SEC rules and regulations, or (C) as otherwise set forth in the next paragraph; (v) change the form of the consideration payable in the Offer; (vi) amend, modify or supplement the Offer Conditions or terms of the Offer in any manner adverse to the holders of Shares; or (vii) impose any condition to the Offer other than the Offer Conditions.

        The Merger Agreement provides that if at the scheduled Expiration Date any of the conditions to the obligation to purchase the Shares have not been satisfied or waived, Purchaser shall extend (and re-extend) the Offer for one or more periods of not more than 10 business days each until the earlier to occur of (i) a date as of which all of the Offer Conditions have been satisfied or waived and (ii) October 31, 2008. Purchaser shall also extend the Offer for any period required by any rule, regulation, interpretation or position of the SEC or the staff thereof applicable to the Offer or any period required by any other law. Purchaser is required to accept and pay for Shares validly tendered and not withdrawn as promptly as practicable following the later of: (i) the earliest date as of which Purchaser is legally permitted to accept such tendered Shares and (ii) the earliest date as of which each of the Offer Conditions is satisfied or waived.

        Subsequent Offering Period.    The Merger Agreement provides that following the Acceptance Time, Purchaser may, without the consent of Millennium, make available a subsequent offering period (a "Subsequent Offering Period") in accordance with Rule 14d-11 of the Exchange Act for up to 20 business days if at the commencement of the Subsequent Offering Period, the number of Shares owned by TPC, Takeda America, Purchaser and their respective subsidiaries represent less than 90% of the outstanding number of Shares. The Merger Agreement obligates Purchaser to provide for a Subsequent Offering Period of at least 10 business days, if requested by Millennium, in the event that, at the Acceptance Time, TPC, Takeda America, Purchaser and their respective subsidiaries own more than 80% but less than 90% (inclusive of shares issuable pursuant to the Top-Up Option described below) of the Shares outstanding at that time. Purchaser is required to accept and pay for Shares validly tendered during the Subsequent Offering Period as promptly as practicable after such Shares are so tendered.

        Top-Up Option.    Millennium granted Purchaser an option to purchase from Millennium shares of Millennium common stock (the "Top-Up Option Shares") equal to the number of Shares that when added to the number of Shares owned by Purchaser immediately prior to the exercise thereof,

20

constitutes one share more than 90% of the number of Shares then outstanding (after giving effect to the issuance of the Top-Up Option Shares) for a purchase price per Top-Up Option Share equal to the Offer Price. Notwithstanding the foregoing, Purchaser must exercise the "top-up option" if doing so would allow it to consummate the merger without approval of Millennium's stockholders pursuant to Section 253 of the DGCL. Purchaser may pay the exercise price for the "top-up option," at its election, either (i) in cash or (ii) by paying cash in an amount not less than the aggregate par value of the Top-Up Option Shares and by delivering to Millennium a promissory note having a principal amount equal to the remainder of the exercise price. Purchaser is required to consummate the Merger pursuant to Section 253 of the DGCL within two business days after Millennium issues the Top-Up Option Shares.

        Directors.    The Merger Agreement provides that after the Acceptance Time, Purchaser will be entitled to designate the number of directors, rounded up to the next whole number, to the Millennium Board of Directors that is in the same proportion as the percentage of Shares then owned by Purchaser or other subsidiaries of Takeda America, after giving effect to the election of such directors, to the total number of Shares outstanding. Millennium is required under the Merger Agreement to use reasonable best efforts to take all actions available to Millennium to cause Purchaser's designees to be elected or appointed to the Millennium Board, provided that the Millennium Board must always have at least two members of the Millennium Board who were members of the Millennium Board immediately prior to the Acceptance Time and who are not officers of Millennium (the "Continuing Directors"). Subject to applicable law and Nasdaq rules, Millennium will also cause the individuals designated by Purchaser to constitute the number of members, rounded up to the next whole number, on each committee of the Millennium Board and the board of directors of each subsidiary of Millennium (and each committee thereof) that represents the same percentage as such individuals represent on the Millennium Board.

        Following the election or appointment of Purchaser's designees and until the Effective Time, the approval of a majority of the Continuing Directors, (or if there should only be one or two Continuing Directors then in office, all of the Continuing Directors then in office) will be required to authorize (and such authorization will constitute the authorization of the Millennium Board):

•

any amendment, modification or termination of the Merger Agreement by Millennium;



•

any extension of time for performance of any of the obligations or other acts of Takeda America or Purchaser;



•

any waiver of any condition to any obligation of Millennium or any waiver or exercise of any right of Millennium under the Merger Agreement;



•

any amendment to Millennium's certificate of incorporation or by-laws;



•

any authorization of any agreement between Millennium, on the one hand, and Takeda America, Purchaser or any of their affiliates, on the other hand; or



•

any other action by Millennium with respect to the Merger Agreement, the Offer or the Merger, other than Millennium's performance of its obligations under the Merger Agreement, including the consummation of the Merger, and other actions that would not reasonably be expected to adversely affect the interests of Millennium's stockholders.

        The Merger.    The Merger Agreement provides that, at the effective time of the Merger (the "Effective Time"), Purchaser will be merged with and into Millennium with Millennium being the surviving corporation (the "Surviving Corporation"). Following the Merger, the separate existence of Purchaser will cease, and Millennium will continue as the Surviving Corporation, wholly-owned by Takeda America. The directors of Purchaser immediately prior to the Effective Time will be the directors of the Surviving Corporation. The officers of Millennium immediately prior to the Effective Time will be the initial officers of the Surviving Corporation.

21

        Pursuant to the Merger Agreement, at the Effective Time, each Share that is held by Millennium, Takeda America, Purchaser, TPC or by their wholly-owned subsidiaries, shall automatically be canceled and shall cease to exist, and no cash or other consideration shall be delivered in exchange therefor.

        Each Share issued and outstanding immediately prior to the Effective Time (other than Shares to be canceled in accordance with the foregoing sentence and Appraisal Shares (as defined below)) shall be canceled and converted into the right to receive the highest price per Share paid pursuant to the Offer, without interest thereon and less any required withholding taxes (the "Merger Consideration"). As of the Effective Time, all such Shares shall no longer be outstanding and shall automatically be cancelled and shall cease to exist, and each holder of a certificate formerly representing any such Shares shall cease to have any rights with respect thereto, except the right to receive the Merger Consideration, without interest.

        Shares outstanding immediately prior to the Effective Time held by a holder who is entitled to demand, and who properly demands, appraisal for such Shares in accordance with Section 262 of the DGCL ("Appraisal Shares") shall not be converted into a right to receive the Merger Consideration. Such stockholder shall be entitled to receive payment of the fair value of such Shares in accordance with the provisions of Section 262 of the DGCL. However, if such holder fails to perfect or shall have effectively withdrawn or otherwise lost such holder's right to appraisal, then the right of such holder to be paid the fair value of such holder's Appraisal Shares shall cease and such Appraisal Shares shall be deemed to have been converted as of the Effective Time into the right to receive the Merger Consideration.

        Millennium Options, Restricted Stock, RSUs and ESPP.    The Merger Agreement provides that each Option (as defined herein) to purchase Shares pursuant to the Stock Plans (as defined herein) outstanding immediately prior to the Effective Time (whether or not then vested or exercisable) will become fully vested and cancelled as of immediately following the Effective Time and converted into the right to receive at such time a lump sum cash amount equal to the Option Consideration (as defined herein) for each Share then subject to the Option (without interest and less applicable withholding taxes). If the Option Consideration is a negative number, no such cash payment will be due and owing. Option Consideration means, with respect to each Share issuable under a particular Option, an amount equal to (i) the Merger Consideration per Share, less (ii) the exercise price payable in respect of each Share issuable under such Option. Options means any option granted, and, immediately before the Effective Time not exercised, expired or terminated, to a current or former employee, director or independent contractor of Millennium or any of its subsidiaries or any former subsidiary or predecessor thereof to purchase Shares pursuant to the Stock Plans. Stock Plans means Millennium's 2000 Stock Incentive Plan, 1998 Non-Officer Equity Incentive Plan, assumed by Millennium as successor to COR Therapeutics, Inc., 1993 Incentive Stock Plan, Amended and Restated 1993 Stock Option Plan, assumed by Millennium as successor to LeukoSite, Inc., 1991 Equity Incentive Plan, assumed by Millennium as successor to COR Therapeutics, Inc., 1996 Equity Incentive Plan, as amended, 2007 Incentive Plan, 1997 Equity Incentive Plan, as amended, assumed by Millennium as successor to Millennium Biotherapeutics, Inc. and 1997 Equity Incentive Plan, as amended, assumed by Millennium as successor to Millennium Predictive Medicine, Inc.

        The Merger Agreement further provides that each share of restricted stock and each restricted stock unit granted pursuant to the Stock Plans outstanding immediately prior to the Effective Time, shall be converted immediately prior to the Effective Time into the right to a restricted cash payment equal to the Merger Consideration (net of applicable taxes). Such restrictions will lapse immediately following the Effective Time, at which time the payment shall be made.

        The current offering period under Millennium's 1996 Employee Stock Purchase Plan, or ESPP, will close in its ordinary course and ESPP options from the current period will be exercised as scheduled at

22

the end of April. Upon the closing of the Merger, any future contributions under new offering periods will be returned and the ESPP will be terminated.

        Representations and Warranties.    In the Merger Agreement, Millennium has made representations and warranties to Takeda America and Purchaser, including representations relating to: organization of Millennium and organization, existence and good standing of Millennium's subsidiaries; Millennium's capitalization; authorization of Millennium and no conflicts with or consents required in connection with the Merger Agreement; Millennium's subsidiaries; Millennium's public information; absence of material adverse changes; legal proceedings; information supplied; broker's and finder's fees; employee benefit plans; opinion of Millennium's financial advisor; taxes; environmental matters; compliance with laws; intellectual property; employment matters; insurance; material contracts; Millennium's rights agreement; real property; and the Delaware takeover statute.

        In the Merger Agreement, Takeda America and Purchaser have made representations and warranties to Millennium, including representations relating to: organization, existence and capitalization; authorization with respect to the Merger Agreement; no conflicts with or consents required in connection with the Merger Agreement; information supplied; availability of funds; broker's or finder's fees; ownership of Millennium's common stock; absence of litigation; other agreements or understandings with Millennium's directors or officers; and acknowledgement that Millennium makes no representations in addition to those described above.

        The representations and warranties contained in the Merger Agreement were made only for the purposes of the Merger Agreement and as of specified dates, were solely for the benefit of the parties to the Merger Agreement, and may be subject to limitations agreed upon by the contracting parties. The representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the agreement instead of establishing these matters as facts and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Stockholders are not third-party beneficiaries under the Merger Agreement for purposes of the representations and warranties and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of Millennium or Takeda America or any of their respective subsidiaries or affiliates. In addition, the assertions embodied in the representations and warranties contained in the Merger Agreement are qualified by information in a confidential disclosure letter that the parties have exchanged. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in Takeda America's or Millennium's public disclosures.

        Operating Covenants.    The Merger Agreement provides that, from the date of the Merger Agreement to the Acceptance Time, except as contemplated by the Merger Agreement (including in Millennium's disclosure schedule) and unless Takeda America otherwise consents in writing (which consent shall not be unreasonably withheld, conditioned or delayed), Millennium and its subsidiaries shall use reasonable best efforts to (i) conduct their business in the ordinary course of business and consistent in all material respects with past practice (ii) maintain and preserve intact the material aspects of their business organizations and to maintain their significant beneficial business relationships and (iii) retain the services of their present officers and key employees and to comply in all material respects with all applicable laws and the requirements of all of Millennium's material contracts.

        Between the date of the Merger Agreement and the Acceptance Time, Millennium is subject to specified operating covenants and restrictions, including restrictions relating to the purchase, sale or encumbrance of material property or material assets; acquisitions, mergers, consolidations and asset purchases; amendment of charter documents and bylaws; declaration, setting aside or payment of dividends; split, combination, subdivision, reclassification, redemption or purchase of outstanding stock and other securities; issuance, sale or pledge of stock; indebtedness; compensation of directors, officers

23

and employees; employee benefits plans; tax matters; changes in financial accounting methods; settlement or compromise of litigation; capital expenditures; arrangements limiting or restricting the business of Millennium or the Surviving Corporation; lease or sublease of real property; amendment, modification or termination of material contracts; engagement in new business activities; and insurance coverage.

        The Merger Agreement provides that, from the date of the Merger Agreement to the Effective Time of the Merger, except as contemplated by the Merger Agreement, or with Millennium's consent, TPC, Takeda America and Purchaser will not take any action that would reasonably be expected to materially delay, impair or prevent completion of the Offer or the Merger. Such undertaking by TPC, Takeda America and Purchaser does not, however, preclude them from exercising their rights under the Merger Agreement, including their right to terminate the Merger Agreement in the circumstances described under "Termination" below.

        Stockholders Meeting; Board Recommendation.    The Merger Agreement provides that, if the adoption of the Merger Agreement by Millennium's stockholders is required by applicable law, Millennium will, at Takeda America's request, as soon as practicable following the Acceptance Time, duly call and give notice of, convene and hold a meeting of its stockholders for the purpose of adopting the Merger Agreement. Takeda America agrees to cause all Shares then owned by TPC, Takeda America and Purchaser and their subsidiaries to be voted in favor of the adoption of the Merger Agreement. Notwithstanding the foregoing, under the Merger Agreement, if TPC, Takeda America, Purchaser and any other Takeda America subsidiary shall collectively acquire at least 90% of the then outstanding Shares, Takeda America and Purchaser shall take all necessary and appropriate action to cause the Merger to become effective as soon as practicable (and in any event within five business days) after the expiration of the Offer without a stockholders' meeting in accordance with Section 253 of the DGCL.

        Pursuant to the Merger Agreement, except as provided below, the Millennium Board shall not (i) withdraw or modify, or propose publicly to withdraw or modify, the recommendation by the Millennium Board that its stockholders accept the Offer, tender their Shares to Purchaser pursuant to the Offer and adopt the Merger Agreement (the "Board Recommendation") or (ii) approve or recommend, or propose publicly to approve or recommend, any Takeover Proposal (as defined below). Any action described in clause (i) or (ii) shall constitute a "Company Adverse Recommendation Change" and shall only be made in accordance with conditions set forth in Section 6.8 of the Merger Agreement.

        However, the Millennium Board may (i) withdraw or modify, or publicly propose to withdraw or modify, the Board Recommendation, (ii) approve or recommend, or publicly propose to approve or recommend, a Takeover Proposal that constitutes a Superior Proposal (as defined below) that did not result from a material breach of Millennium's no solicitation covenants set forth in Section 6.8 of the Merger Agreement, (iii) take any action in connection with Millennium's rights agreement or Section 203 of the DGCL to make either of them inapplicable to a Takeover Proposal that constitutes a Superior Proposal and that did not result from a material breach of Millennium's no solicitation covenants set forth in Section 6.8 of the Merger Agreement, or (iv) enter into a binding written agreement concerning a transaction that constitutes a Superior Proposal, if, in any such case, the Millennium Board determines in good faith, after consultation with outside counsel, that failure to do so would be inconsistent with its fiduciary obligations under applicable law.

        No Solicitation Provisions.    Section 6.8 of the Merger Agreement provides that, except as provided below, Millennium and its subsidiaries, as well as their respective officers, directors, agents and representatives, shall not directly or indirectly, (i) solicit, initiate, knowingly facilitate or knowingly encourage the submission of any Takeover Proposal, (ii) enter into any agreement, agreement-in- principle or letter of intent providing for or accept any Takeover Proposal, or (iii) participate or engage

24

in any discussions or negotiations regarding, or furnish to any person any non-public information for the purpose of encouraging or facilitating, any Takeover Proposal.

        However, the Merger Agreement also provides that Millennium may refer any third party to such no solicitation restrictions of the Merger Agreement and if, in response to a bona fide written Takeover Proposal made after the date of the Merger Agreement that did not result from a material breach of Millennium's no solicitation covenants under Section 6.8 thereof, the Millennium Board determines in good faith, after consultation with outside counsel and its financial advisor, that such takeover proposal constitutes or is reasonably likely to lead to a Superior Proposal, Millennium may (i) furnish information with respect to Millennium and its subsidiaries to the person making such Takeover Proposal (and its representatives) but only pursuant to a confidentiality agreement that is not materially less restrictive with respect to confidentiality of the other party than the confidentiality agreement with Takeda America (except that such confidentiality agreement shall contain additional provisions that expressly permit Millennium to comply with certain provisions of the Merger Agreement), provided that (A) it may not include any provision calling for an exclusive right to negotiate with Millennium, and (B) concurrently with its delivery of non-public information to such person Millennium delivers to Takeda America all such information not previously provided to Takeda America, (ii) participate or engage in discussions or negotiations with such person and its representatives and potential financing sources regarding such Takeover Proposal and (iii) amend, or grant a waiver or release under, any standstill agreement with respect to Millennium's common stock with any such person.

        The Merger Agreement contains a provision that Millennium shall provide Takeda America with oral and written notice, in no event later than the earliest to occur of (i) one business day after receipt, (ii) 48 hours after receipt and (iii) 24 hours after receipt by certain specified Millennium executive officers, of Millennium's receipt of any written Takeover Proposal, that indicates the identity of the person making such Takeover Proposal, and the material terms and conditions thereof (and shall include with such notice copies of any written materials received from or on behalf of such person relating thereto), and thereafter shall keep Takeda America reasonably informed of all material developments affecting the status and terms of such Takeover Proposal (and Millennium shall provide Takeda America with copies of any additional material documents received therewith).

        The Merger Agreement further contains a provision that the Millennium Board may (i) comply with Rule 14d-9 or 14e-2(a) of the Exchange Act or Item 1012(a) of Regulation M-A promulgated under the Exchange Act, or issue a "stop, look and listen" statement pending disclosure of its position thereunder, or (ii) make any disclosure to Millennium's stockholders if, in the case of a disclosure described in this clause (ii), the Millennium Board determines in good faith, after consultation with outside counsel, that failure to do so would be inconsistent with its fiduciary obligations under applicable law.

        As used in the Merger Agreement, a "Takeover Proposal" means any proposal or offer from any person (other than Takeda America, Purchaser or any of their affiliates) or "group" (as defined in Section 13(d) of the Exchange Act) for (i) the direct or indirect acquisition (whether in a single transaction or a series of related transactions) of assets of Millennium and Millennium's subsidiaries (including securities of Millennium's subsidiaries) equal to 20% or more of Millennium's consolidated assets, (ii) the acquisition from Millennium (whether in a single transaction or a series of related transactions) of 20% or more of the equity securities of Millennium, (iii) a tender offer or exchange offer that if consummated would result in any person or "group" (as defined in Section 13(d) of the Exchange Act) beneficially owning 20% or more of the equity securities of Millennium or (iv) a merger, consolidation, share exchange, business combination, recapitalization, liquidation, dissolution or similar transaction involving Millennium, in each case, other than the transactions contemplated by the Offer, the Merger and the other transactions contemplated by the Merger Agreement.

        As used in the Merger Agreement, a "Superior Proposal" means any bona fide written offer obtained after the date of the Merger Agreement to acquire more than 50% of the outstanding equity

25

securities or consolidated assets of Millennium and Millennium's subsidiaries on terms that the Millennium Board determines in its good faith judgment (after consultation with its financial advisor and outside counsel), taking into account all of the terms and conditions of such proposal and the Merger Agreement (including any offer by Takeda America to amend the terms of the Merger Agreement, which offer is not revocable for at least five business days), (i) would, if consummated, result in a transaction that is more favorable to the holders of Shares than the transactions contemplated by the Offer, the Merger and the other transactions contemplated by the Merger Agreement and (ii) is reasonably capable of being completed on the terms proposed, including with regard to any financing contemplated thereby.

        Employment and Employee Benefits.    Pursuant to the Merger Agreement, Takeda America has agreed that it will, until the first anniversary of the closing, provide to employees of Millennium (or its subsidiaries) (i) a base salary, annual bonus and commission opportunity no less favorable than provided to such employees immediately prior to the Effective Time, and (ii) employee benefits (excluding equity and equity based compensation) that are substantially comparable, in the aggregate, to the those benefits provided to them immediately prior to the closing. Takeda America further agreed in the Merger Agreement to honor and cause the Surviving Corporation to honor, in accordance with their terms as in effect immediately prior to the Acceptance Time, all of Millennium's employment and severance agreements.

        Pursuant to the Merger Agreement, for the purposes of all employee benefit plans of Takeda America and its subsidiaries (including, after the closing, the Surviving Corporation), each such plan shall treat the prior service with Millennium and its affiliates of each person who is an employee of Millennium or its subsidiaries immediately prior to the Effective Time as service rendered to Takeda America or its subsidiaries, to the extent permitted by law and applicable tax qualification requirements. However, none of the provisions contained in the Merger Agreement operate to duplicate any benefit.

        The Merger Agreement further provides that if any Millennium employee (who is not otherwise a party to an employment agreement) whose employment is terminated on or prior to the first anniversary of the Effective Time under circumstances under which such employee would have received severance benefits under Millennium's severance practices, Takeda America will cause the Surviving Corporation to provide that such employee shall be entitled to severance benefits from the Surviving Corporation that are equal to the severance benefits that would have been paid under Millennium's severance practices as in existence on the date of the Merger Agreement. Takeda America also agreed to pay to Millennium employees bonus payments under Millennium's 2008 Success Sharing Bonus Plan.

        Rule 14d-10(d).    Prior to the Acceptance Time, Millennium (acting through its Compensation and Talent Committee) agreed to take all such steps as may be required to cause each employment compensation, severance and employee benefit agreement, arrangement or understanding entered into by Millennium or Millennium subsidiaries on or after the date of the Merger Agreement with any of its officers, directors or employees pursuant to which consideration is paid to such officer, director or employee to satisfy the requirements of the non-exclusive safe-harbor set forth in Rule 14d-10(d)(2) of the Exchange Act.

        Indemnification and Insurance.    The Merger Agreement provides that for a period of not less than six years after the Effective Time, Takeda America and the Surviving Corporation will, to the full extent permitted by applicable law, indemnify, defend and hold harmless each director or officer who is now, or who has been at any time prior to the date of the Merger Agreement or who becomes prior to the Effective Time an officer or director of Millennium (and its subsidiaries) (the "Indemnified Parties") against all losses, claims, damages, liabilities, fees, expenses, judgments and fines arising in whole or in part out of actions or omissions in their capacities as such occurring at or prior to the Effective Time (including in respect of the Merger Agreement and the transactions contemplated thereby), whether

26

asserted or claimed prior to, at or after the Effective Time, and shall advance each Indemnified Party within 20 business days of receipt by Takeda America or the Surviving Corporation from the Indemnified Party of a request therefor for any reasonable legal or other expenses incurred by such Indemnified Party in connection with investigating or defending any such losses, claims, damages, liabilities, fees, expenses, judgments or fines as such expenses are incurred, but subject to an unsecured undertaking, to the extent required by the DGCL, by or on behalf of the Indemnified Party to repay such expenses if it is ultimately determined that such Indemnified Party is not entitled to indemnification hereunder, for a period of six years after the date of the Effective Time.

        Takeda America and the Surviving Corporation agree that all rights to advancement of expenses, indemnification and exculpation now existing in favor of the Indemnified Parties as provided in Millennium's charter and by-laws or pursuant to any other agreements in effect as of the date of the Merger Agreement shall survive the Merger and shall continue in full force and effect until for a period of not less than six years after the Effective Time.

        The Merger Agreement also provides that for a period of not less than six years after the Effective Time, Takeda America and the Surviving Corporation shall cause the individuals who served as the directors and officers of Millennium prior to the Effective Time who are covered by the current policies of directors' and officers' (D&O) liability insurance maintained by Millennium to be covered under a D&O liability insurance policy on terms and conditions no less advantageous to such individuals than Millennium's existing D&O liability insurance policy with respect to claims arising from facts or events that occurred at or prior to the Effective Time (including in respect of the Merger Agreement and the transactions contemplated thereby). However, Takeda America and the Surviving Corporation are not required to expend more than an amount per year equal to 250% of current annual premiums paid by Millennium for such insurance to maintain or procure insurance coverage. If the amount of the annual premiums (the "Maximum Amount") necessary to maintain or procure such insurance coverage exceeds such amount, Takeda America and the Surviving Corporation will procure and maintain for such six-year period as much coverage as is available for such amount. Takeda America has the right to cause coverage to be extended under Millennium's D&O insurance by obtaining a six-year "tail" policy on terms and conditions no less advantageous than Millennium's existing D&O insurance. Millennium has the right to purchase a reporting tail endorsement policy provided Millennium does not pay more than six times the Maximum Amount for such endorsement.

        Convertible Notes.    Millennium agreed to use reasonable best efforts to comply with certain provisions of the indenture governing its convertible notes, in respect of the transactions contemplated by the Merger Agreement.

        Reasonable Best Efforts to Cause the Merger to Occur.    Each of the parties to the Merger Agreement agrees to use its reasonable best efforts to take, or cause to be taken, all action, and to do, or cause to be done, all things necessary, proper or advisable to consummate and make effective the Offer, the Merger and all other transactions contemplated by the Merger Agreement in the most expeditious manner practicable, including obtaining all consents, approvals and authorizations required for the consummation by the parties of the transactions contemplated by the Merger Agreement, and the execution of any additional instruments necessary to consummate the transactions contemplated hereby.

        Hart-Scott-Rodino (HSR) and other Antitrust Approvals.    The Merger Agreement requires that each of Takeda America, Purchaser and Millennium, as promptly as practicable after the date of the Merger Agreement, make all filings required by each of them under the HSR Act, and applicable antitrust or competition laws of Germany and Austria with respect to the Offer, the Merger and the transactions contemplated hereby, and to cooperate with each other in connection with the making of all such filings. Takeda America and Millennium agree to use reasonable best efforts to obtain all permits, authorizations, consents, expiration or termination of waiting periods, and approvals from third parties

27

and any governmental entity necessary to consummate the Offer, the Merger and the transactions contemplated hereby.

        Directors and Officers.    The Merger Agreement provides that the directors of Purchaser immediately prior to the Effective Time will become the directors of the Surviving Corporation, each to hold office until the earlier of their resignation or removal or their respective successors are duly elected or appointed and qualified. The officers of Millennium immediately prior to the Effective Time shall be the officers of the Surviving Corporation, each to hold office until the earlier of their resignation or removal or their respective successors are duly elected or appointed and qualified. If requested by Takeda America prior to the Effective Time, Millennium will use reasonable best efforts to cause each director of each subsidiary of Millennium to tender their resignations as directors, effective upon the Effective Time.

        Conditions to the Merger.    The Merger Agreement provides that the respective obligations of each party to effect the Merger are subject to the satisfaction or waiver on or prior to the closing date of the Merger of the following conditions:

•

if required by law, the Merger Agreement shall have been adopted at a stockholder meeting by the requisite vote of the holders of Shares;



•

there shall not be any judgment, law or other legal restraint or prohibition in effect which would make the Merger illegal or otherwise prevent or prohibit the consummation thereof. Notwithstanding the foregoing, in no event shall this condition be satisfied, and the Merger shall not be consummated, if a Japanese court or other Japanese governmental authority shall have issued an order, stay, decree, judgment or injunction (preliminary or permanent) to TPC, the representative director of TPC, all or a part of the directors of TPC or the Chief Executive Officer of TPC, directing any of them to not consummate, or to not allow Takeda America or Purchaser to consummate, the Offer or the Merger, or making illegal, or restraining or preventing, any of such consummation. Prior to invoking this condition, each party shall use its reasonable best efforts to have such judgment, law or other legal restraint or prohibition lifted; and



•

Purchaser shall have purchased all Shares validly tendered and not withdrawn pursuant to the Offer; provided that neither Takeda America nor Purchaser shall be entitled to invoke this condition if, in breach of the Merger Agreement, Purchaser fails to purchase any Shares validly tendered and not withdrawn in the Offer.

        Termination.    The Merger Agreement may be terminated and the Offer, the Merger and the related transactions may be abandoned:

        (a)   by mutual written consent of the parties at any time prior to the Acceptance Time;

        (b)   by either Takeda America or Millennium if the Acceptance Time has not occurred on or before October 31, 2008, except that this right to terminate the Merger Agreement shall not be available to any party whose failure to fulfill any obligation under the Merger Agreement has been the cause of or resulted in the failure of the Acceptance Time to occur prior to October 31, 2008;

        (c)   by either Takeda America or Millennium, if any judgment, ruling, order, writ, injunction or decree of any governmental authority ("Judgment") issued by a court of competent jurisdiction or by a governmental entity, or law or other legal restraint or prohibition in each case making the Offer or the Merger illegal or permanently restraining, enjoining or otherwise preventing the consummation thereof shall be in effect and shall have become final and non-appealable; provided that the party seeking the right to terminate the Merger Agreement pursuant to the foregoing shall have used reasonable best efforts to resist, lift or resolve such Judgment, law or other legal restraint and the right to terminate pursuant to the foregoing shall not be available if the issuance

28

of such Judgment, legal restraint or prohibition was caused by or resulted from the failure of such party to perform in any material respect any of its obligations under the Merger Agreement;

        (d)   by Takeda America prior to the purchase of any Shares pursuant to the Offer, if:

          (i)  a Company Adverse Recommendation Change (as defined above) shall have occurred; provided that any such termination must occur within five business days of such Company Adverse Recommendation Change;

         (ii)  Millennium shall have materially breached its no solicitation covenants set forth in Section 6.8 of the Merger Agreement entitled "No Solicitation;" or

        (iii)  Millennium shall have breached or failed to perform any of its representations, warranties, covenants or agreements, which breach or failure to perform (A) would give rise to the failure of a condition set forth in paragraph (d) or (e) of Section 15—"Certain Conditions to the Offer," and (B) has not been cured within 20 days after receipt of written notice by Millennium of such breach or failure to perform; provided that neither Takeda America nor Purchaser is then in material breach of any representation, warranty or covenant under the Merger Agreement;

        (e)   by Millennium, if (i) Millennium has not materially breached its no solicitation covenants set forth in Section 6.8 of the Merger Agreement entitled "No Solicitation," (ii) Millennium has received a Takeover Proposal that the Millennium Board has determined in good faith, after consultation with outside counsel and its financial advisor, constitutes a Superior Proposal, (iii) Millennium has provided Takeda America with at least three business days' written notice that it intends to enter into a definitive agreement implementing such Superior Proposal, attaching the most current version of such agreement to such notice (a "Superior Proposal Notice"), (iv) Millennium prior to, or concurrently with, such termination pays to Takeda America the Termination Fee (as defined below) in accordance with the terms of the Merger Agreement, and (v) the Millennium Board concurrently approves, and Millennium concurrently enters into, a definitive agreement providing for the implementation of such Superior Proposal;

        (f)    by Millennium, if prior to the purchase of any Shares pursuant to the Offer, Takeda America or Purchaser shall have breached or failed to perform any of its representations, warranties, covenants or agreements in each case contained in the Merger Agreement, which breach or failure to perform (i) has had or is reasonably likely to have a Parent Material Adverse Effect (which is defined in the Merger Agreement to mean any change, event, occurrence or development that would reasonably be expected to prevent, or materially impair or delay, the ability of either Takeda America or Purchaser to perform its obligations under the Merger Agreement or to consummate the Offer, the Merger or related transactions), and (ii) has not been cured within 20 business days after receipt of written notice by Takeda America of such breach or failure to perform, provided that Millennium is not then in material breach of any representation, warranty or covenant in the Merger Agreement; or

        (g)   by Millennium (i) if, for any reason Purchaser shall have failed to commence the Offer by the date that is ten business days after the date of the Merger Agreement, or (ii) upon two business day's notice to Takeda America if, for any reason, Purchaser shall have breached its obligation under the Merger Agreement to purchase all Shares validly tendered (and not withdrawn) as of the expiration of the Offer.

        Termination Fee.    The Merger Agreement contemplates that a termination fee of $247,300,000 (the "Termination Fee") will be payable by Millennium to Takeda America under any of the following circumstances in accordance with the terms set forth therein:

•

the Merger Agreement is terminated by Takeda America pursuant to paragraph (d)(i) above;



•

the Merger Agreement is terminated by Millennium pursuant to paragraph (e) above;

29

•

(A) the Merger Agreement is terminated by Millennium or Takeda America pursuant to paragraph (b) above or by Takeda America pursuant to paragraph (d)(ii) above, (B) a written Takeover Proposal shall have been made to the Millennium Board that has not been withdrawn as of the termination of the Merger Agreement and (C) Millennium enters into a definitive agreement with respect to any Takeover Proposal (replacing "20%" in the definition thereof with "50%") within 12 months of such termination (so long as, such transaction is thereafter consummated); or



•

(A) the Merger Agreement is terminated by Takeda America pursuant to paragraph (d)(iii) above as a result of a knowing breach by Millennium, (B) a written Takeover Proposal shall have been made to the Millennium Board that has not been withdrawn as of the termination of the Merger Agreement and (C) Millennium enters into a definitive agreement with respect to any Takeover Proposal (replacing "20%" in the definition thereof with "50%") within 12 months of such termination (so long as such transaction is thereafter consummated).

        The Termination Fee, when paid, shall constitute the sole and exclusive remedy of Takeda America and Purchaser other than for a termination arising from Millennium's willful breach of the Merger Agreement (except that the Termination Fee will be Takeda America's and Purchaser's sole and exclusive remedy upon a termination described in paragraph (d)(iii) above, even if such breach is willful).

        Amendment.    The Merger Agreement may be amended by the parties to the agreement at any time before or after adoption of the Merger Agreement by the holders of the Shares; provided, however, that after adoption of the Merger Agreement by the stockholders of Millennium, there may not be made any amendment that pursuant to applicable law requires further approval by such stockholders without the further approval of such stockholders. The Merger Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties.

Tender and Support Agreement.

        In connection with the Merger Agreement, Millennium's directors and executive officers, including Deborah Dunsire, M.D., Millennium's Chief Executive Officer (collectively, the "Supporting Stockholders"), entered into a Tender and Support Agreement, dated as of April 10, 2008, with Takeda America. The Shares subject to the Tender and Support Agreement constitute approximately 1.51% of the outstanding Shares.

        The following summary of certain provisions of the Tender and Support Agreement is qualified in its entirety by reference to the Tender and Support Agreement itself, which is incorporated herein by reference. We have filed a copy of the Tender and Support Agreement as Exhibit (d)(2) to the Schedule TO. Stockholders and other interested parties should read the Tender and Support Agreement in its entirety for a more complete description of the provisions summarized below.

        Under the Tender and Support Agreement each of the Supporting Stockholders has agreed to tender all Shares such Supporting Stockholder holds or acquires after the commencement of the Offer promptly following the commencement of the Offer, and in any event no later than the second business day prior to the initial expiration date of the Offer. Each of the Supporting Stockholders has also agreed not to withdraw such Supporting Stockholder's Shares once tendered from the Offer at any time.

        Each Supporting Stockholder has agreed to vote all such Supporting Stockholder's Shares in connection with any meeting of Millennium's stockholders in favor of the Merger and/or against any alternative Takeover Proposal.

30

        During the term of the Tender and Support Agreement, except as otherwise provided therein, none of the Supporting Stockholders will do the following:

•

other than for estate planning or charitable purposes, assign or otherwise dispose of (whether by gift, merger, consolidation, reorganization or otherwise) any or all of such Supporting Stockholder's Shares;



•

enter into any contract, option or other agreement providing for the sale, transfer, pledge, encumbrance, assignment or other disposition of, or limitation on the voting rights of, any of the Supporting Stockholder's Shares with respect to any such transfer;



•

grant any proxy or power-of-attorney with respect to any of such Supporting Stockholder's Shares; or



•

deposit any of such Supporting Stockholder's Shares into a voting trust, or enter into a voting agreement or arrangement with respect to any of such Shares.

        The Tender and Support Agreement does not limit the rights or duties of any Supporting Stockholder from acting in his or her capacity as an officer or director, fulfilling the obligations of such office or performing any obligations required by such Supporting Stockholder's fiduciary duties.

        The Tender and Support Agreement, and all rights and obligations of Purchaser and the Supporting Stockholders thereunder, will terminate as to each Supporting Stockholder on the first to occur of: (i) the date the Merger Agreement is terminated in accordance with the terms of the Merger Agreement; (ii) the Merger Agreement or the Offer is amended without such Supporting Stockholder's consent so as to decrease the Offer Price or materially and adversely affect such Supporting Stockholder; and (iii) the Acceptance Time.

Confidentiality Agreement.

        On February 20, 2008, Millennium and TPC entered into a confidentiality agreement (the "Confidentiality Agreement") containing provisions, pursuant to which, among other matters, each party agreed to keep confidential all information furnished to it or its representatives by the other party, to use such material solely for purposes of evaluating and negotiating a possible transaction between the parties and not to disclose that discussions are taking place concerning a possible negotiated transaction between the parties or the status thereof. Under the Confidentiality Agreement, TPC agreed that, for a period of two years from the date of the Confidentiality Agreement, unless specifically invited in writing by Millennium, neither TPC nor any of its affiliates would directly or indirectly,

•

effect or seek: (i) the acquisition of any securities or assets of Millennium, (ii) any tender or exchange offer, merger or other business combination involving Millennium, (iii) any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect to Millennium, or (iv) any "solicitation" of "proxies" (as such terms are used in the proxy rules of the SEC) or consents to vote any voting securities of Millennium;



•

participate in a "group" (as defined under the Exchange Act) with respect to any securities of Millennium;



•

seek to control or influence Millennium's management, the Millennium Board or policies;



•

take any action which might force Millennium to make a public announcement with respect to the matters above; or



•

enter into any discussions or arrangements with any person with respect to any of the foregoing.

31

        These "standstill" obligations on the part of Takeda terminate, and Takeda is no longer bound thereby, if a third party enters into a letter of intent with Millennium, makes a tender offer for or solicits for purchase any Shares or publicly announces an offer for Shares or if Millennium executes a definitive agreement with a third party providing for an acquisition (by way of merger, tender offer or otherwise) of more than 50% of the outstanding Shares or all or substantially all of Millennium's assets.

        In addition, subject to specified exceptions, for a period of 18 months from the date of the Confidentiality Agreement, each party agreed not to solicit the employment of or hire any employee of the other party. The obligations set forth in the Confidentiality Agreement expire on the fourth anniversary of the date of the Confidentiality Agreement. Under the terms of the Merger Agreement, until the Effective Time, the provisions of the Confidentiality Agreement will remain in full force and effect in accordance with its terms. The summary of the Confidentiality Agreement contained herein is qualified by reference to the Confidentiality Agreement, which is filed herewith as Exhibit (d)(3) and is incorporated herein by reference.

Exclusivity Agreement.

        On March 24, 2008, Millennium and Takeda entered into an exclusivity agreement (the "Exclusivity Agreement"), pursuant to which, for the period through April 13, 2008, Millennium agreed, among other things, not to, directly or indirectly, solicit, initiate, knowingly encourage or knowingly facilitate any discussions with any third party regarding the acquisition of Millennium or a significant portion of Millennium's assets, or participate or engage in discussions or negotiations regarding, or disclose any non-public information relating to Millennium to any third party for the purpose of encouraging or facilitating, an acquisition of Millennium or a significant portion of Millennium's assets.

Retention Arrangements.

Amendments to employment agreements with executive officers

        On April 10, 2008, at the request of TPC, Millennium entered into amendments to existing employment agreements with certain of its executive officers, including Dr. Bianchi, Dr. Bolen, Dr. Dunsire, Ms. Fanucci, Mr. Gansler, Ms. Keating, Ms. Protopapas, Dr. Simonian and Dr. Smith (collectively, the "Employment Amendments"). The Employment Amendments will become effective only at the Effective Time and will be of no force or effect if the Merger Agreement is terminated.

        The Employment Amendments for Dr. Bianchi, Mr. Gansler and Ms. Keating amend provisions of each employee's existing employment agreement with Millennium that relate to termination for Good Reason (as defined in the existing employment agreements) to provide that if his or her employment with Millennium is terminated because of any material diminution in the employee's title, position, duties, responsibilities or authority, and in the case of Ms. Keating, if there is a change in control of Millennium that results in Ms. Keating ceasing to serve as chief legal officer of the surviving entity and any parent entity, he or she will be entitled to the payments and benefits specified in his or her employment agreement, only if such termination of employment occurs on or after the first anniversary of the Effective Time. The occurrence of any event described in the preceding sentence that occurs before the first anniversary of the Effective Time may be asserted by the employee as a reason to terminate employment on or after the first anniversary of the Effective Time. In addition, with respect to Dr. Bianchi, upon the Effective Time, Millennium will accelerate the vesting of Dr. Bianchi's $100,000 retirement benefit held in a tax-deferred account and will distribute that amount to him in a lump sum six months after a termination of his employment.

32

        The Employment Amendment for Dr. Dunsire amends provisions of her existing employment agreement with Millennium that relate to termination for Good Reason to provide that:

•

prior to the first anniversary of the Effective Time, she will not assert a termination of her employment other than due to:



•

any requirement by Millennium that she perform her principal duties outside a radius of 50 miles from Millennium's Cambridge location;



•

any breach by Millennium of any material provision of her employment agreement not cured within 30 days' of written notice; or



•

a reduction in her base salary (unless such reduction is effected in connection with a general and proportionate reduction of salaries for all members of the management team) or any reduction of her target bonus amount to less than 80% of her annual salary, and



•

after the first anniversary of the Effective Time, she will have the right to terminate her employment at any time and receive the severance payments and benefits specified in her existing employment agreement.

The Employment Amendment for Dr. Dunsire also provides that if a severance payment pursuant to her existing agreement with Millennium becomes payable, she will receive payment within 10 days following termination but not prior to January 1, 2009. In exceptional circumstances that are not expected to arise during the first eight months following the Effective Time, Dr. Dunsire and Millennium will explore the terms and conditions of a mutually agreeable solution to allow Dr. Dunsire to terminate her employment prior to the first anniversary of the Effective Time and receive the severance payments and benefits pursuant to her existing agreement. Upon the Effective Time, Millennium will accelerate the vesting of Dr. Dunsire's $500,000 retirement benefit held in a tax-deferred account and distribute that amount to her in a lump sum six months after a termination of her employment.

        The Employment Amendments provide for retention bonuses for each of the employees for their continued employment with Millennium following the Merger. The Employment Amendments provide that each employee is eligible for a lump sum cash payment, on the first and, in some cases, second anniversaries of the Effective Time, provided that he or she is employed by Millennium as of such date, in an amount equal to:

•

on the first anniversary of the Effective Time, other than in the case of Dr. Dunsire, the sum of (i) 100% of his or her annual base salary in effect as of the Effective Time plus (ii) 100% of his or her annual bonus for Millennium's fiscal year ending December 31, 2008 (the "First Year Retention Bonus"); and



•

on the second anniversary of the Effective Time, other than in the case of Dr. Dunsire, Ms. Fanucci and Ms. Keating, the sum of (i) 100% of his or her annual base salary in effect as of the Effective Time plus (ii) 100% of his or her annual bonus for Millennium's fiscal year ending December 31, 2008 (the "Second Year Retention Bonus").

        In the case of Dr. Dunsire:

•

the First Year Retention Bonus is the sum of (i) 200% of her annual base salary in effect as of the Effective Time plus (ii) 200% of her annual bonus for Millennium's fiscal year ending December 31, 2008, which will be based upon attainment by Millennium of performance and retention goals to be determined by mutual agreement between Dr. Dunsire and Millennium (with a minimum bonus of 100% of her 2008 target bonus and a maximum bonus of 200% of her 2008 target bonus); and

33

•

the Second Year Retention Bonus will be determined by mutual agreement between Dr. Dunsire and Millennium prior to the first anniversary of the Effective Time.

        Ms. Fanucci and Ms. Keating are not eligible for a Second Year Retention Bonus under the Employment Amendments.

        The Employment Amendments provide that in the event of an occurrence of Voluntary Termination for Good Reason (as defined in the Amended Agreements), or termination by Millennium other than for Justifiable Cause or in the event of an employee's death or permanent disability, as defined in Millennium's long-term disability policy:

•

during the first 12 month period following the Effective Time, the employee will be eligible for a pro rata portion of the First Year Retention Bonus, based on the employee's full months of employment with Millennium from the Effective Time through such termination, and



•

during the second 12 month period following the Effective Time, the employee will be eligible for a pro rata portion of the Second Year Retention Bonus (if the employee is eligible for a Second Year Retention Bonus), based on the employee's full months of employment with Millennium from the first anniversary of the Effective Time through such termination.

        With regard to the determination of the First Year Retention Bonus only, Voluntary Termination for Good Reason will not include any material diminution in an employee's title, position, duties, responsibilities or authority and, in the case of Dr. Dunsire, will not include a change in control of Millennium that results in her ceasing to serve as chief executive officer of the surviving entity or any parent entity.

        The Employment Amendments also provide that in 2009, Millennium, its successors and/or affiliates intend to grant to each of the employees long-term incentive compensation that is substantially similar in economic value to the equity awards granted to each employee by Millennium during 2008 prior to the Effective Time.

        The summary of the Employment Amendments contained in this Offer to Purchase is qualified by reference to the amendment to each executive's existing agreement, which are filed herewith as Exhibits (d)(4)(A) through (d)(4)(I) and are incorporated herein by reference.

Amendments to Severance Plan

        On April 10, 2008, at the request of TPC, pursuant to the Employment Amendments, Millennium and the applicable employee agreed to amend the Severance Plan as it applies to such employee to provide that, upon the Effective Time, the employee will automatically qualify for a voluntary termination for good reason due to a material diminution in his or her title, position, duties, responsibilities or authority, if the employee agrees not to make such assertion during the first 12 months following the Effective Time, and after the first anniversary of the Effective Time, the employee will have the right to receive the payments and benefits under the Severance Plan.

        In addition, the Severance Plan, as amended, provides that an employee will be paid a lump sum within 30 days following the date of the qualifying termination (but not prior to January 1, 2009) in an amount equal to the sum of:

•

a multiple, depending on employment level, of his or her base salary at the greater of his or her rate of pay in effect on the Effective Time or his or her rate of pay in effect on the date of termination;



•

a multiple, depending on employment level, of his or her target bonus for Millennium's fiscal year ending December 31, 2008 or his or her target bonus on the date of termination; and

34

•

a pro rata portion of the greater of his or her target bonus for Millennium's fiscal year ending December 31, 2008 or his or her target bonus on the date of termination.

        The Severance Plan, as amended, also provides that if an employee becomes entitled to payments described immediately above, then any unvested equity or long-term incentive compensation granted to an employee on or after the Effective Time will immediately become vested and exercisable on a pro-rata basis determined by reference to a ratio, the numerator of which shall be the number of his or her full months of employment with Millennium from the Effective Time and the denominator of which shall be the number of full months under the vesting schedule of the relevant equity compensation award.

Letter agreements with non-executive employees

        On April 10, 2008, Millennium entered into letter agreements with four vice presidents, who are not executive officers, that provide for lump sum cash payments to each employee on each of the first and second anniversaries of the Effective Time, provided that he or she is employed by Millennium as of such date, in an amount equal to the sum of a specified percentage of his or her annual base salary in effect as of the Effective Time plus a specified percentage of his or her annual bonus for Millennium's fiscal year ending December 31, 2008. In addition, in 2009 Millennium, its successors and/or affiliates intend to grant to each of these employees long-term incentive compensation that is substantially similar in economic value to the equity awards granted to each employee during 2008 prior to the Effective Time. On April 10, 2008, Millennium also entered into a letter agreement with a fifth vice president, who is not an executive officer, that provides the employee the same benefits as are being provided to Millennium's executive officers pursuant to the Employment Amendments, including a First Year Retention Bonus and a Second Year Retention Bonus in an amount equal to the sum of 100% of the employee's annual base salary in effect as of the Effective Time plus 100% of the employee's annual bonus for Millennium's fiscal year ending December 31, 2008, and severance benefits in connection with a termination for Good Reason.

Cash retention bonuses for other employees

        All Millennium employees who have not entered into separate letter agreements providing for the payments described above and who either, as of the date of the Merger Agreement, (i) have not given notice of resignation, (ii) are not currently subject to a performance improvement plan or (iii) have accepted a bona fide offer of employment from Millennium but have not begun employment with Millennium are eligible to receive cash retention bonus payments based on a specified percentage of the employee's salary in effect as of the Effective Time. These bonuses are payable over a period of 12 to 24 months. The bonus percentage and payment term is based on the employee's business area and employment level. An employee who is terminated without cause by Millennium will be eligible for a pro rata portion of the applicable retention bonus based on the number of full months worked following the Effective Time.

12.   Purpose of the Offer; Plans for Millennium

        Purpose of the Offer.    The purpose of the Offer is for Takeda America, through Purchaser, to acquire control of, and the entire equity interest in, Millennium. The Offer, as the first step in the acquisition of Millennium, is intended to facilitate the acquisition of all outstanding Shares. The purpose of the Merger is to acquire all outstanding Shares not tendered and purchased pursuant to the Offer. If the Offer is successful, Purchaser intends to consummate the Merger as promptly as practicable.

        If you sell your Shares in the Offer, you will cease to have any equity interest in Millennium or any right to participate in its earnings and future growth. If you do not tender your Shares, but the

35

Merger is consummated, you also will no longer have an equity interest in Millennium. Similarly, after selling your Shares in the Offer or the subsequent Merger, you will not bear the risk of any decrease in the value of Millennium.

        Short-form Merger.    The DGCL provides that if a parent company owns at least 90% of each class of stock of a subsidiary otherwise entitled to vote on a merger, the parent company can effect a short-form merger with that subsidiary without the vote or other action of the other stockholders of the subsidiary. Accordingly, if as a result of the Offer, the Top-Up Option or otherwise, Purchaser directly or indirectly owns at least 90% of the Shares, Takeda America and Purchaser anticipate effecting the Merger without prior notice to, or any vote or other action by, any other stockholder of Millennium.

        Plans for Millennium.    Except as otherwise provided in this Offer to Purchase, it is expected that, following the Merger, the business and operations of Millennium will be continued substantially as they are currently being conducted and Millennium will continue its operations in Cambridge, Massachusetts as a stand-alone business unit. TPC will continue to evaluate the business and operations of Millennium during the pendency of the Offer and after the consummation of the Offer and the Merger and will take such actions as it deems appropriate under the circumstances then existing. Thereafter, TPC intends to review such information as part of a comprehensive review of Millennium's business, operations, capitalization and management with a view to optimizing development of Millennium's potential in conjunction with TPC's existing business.

        The Merger Agreement provides that after the Acceptance Time, Purchaser will be entitled to designate the number of directors, rounded up to the next whole number, to the Millennium Board of Directors that is in the same proportion as the percentage of Shares then owned by Purchaser or other subsidiaries of Takeda America, after giving effect to the election of such directors, to the total number of Shares outstanding. Millennium is required under the Merger Agreement to use reasonable best efforts to take all actions available to Millennium to cause Purchaser's designees to be elected or appointed to the Millennium Board, provided that until the Effective Time, the Millennium Board must have at least two members who were members of the Millennium Board immediately prior to the Acceptance Time and who are not officers of Millennium (the "Continuing Directors"). Subject to applicable securities laws and Nasdaq rules, Millennium will also cause the individuals designated by Purchaser to constitute the number of members, rounded up to the next whole number, on each committee of the Millennium Board and the board of directors of each subsidiary of Millennium (and each committee thereof) that represents the same percentage as such individuals represented on the Millennium Board. If the number of Continuing Directors should be reduced below two for any reason, the Millennium Board will cause the person designated by the remaining Continuing Director to fill such vacancy, and such person shall be deemed to be a Continuing Director or, if no Continuing Directors then remain, the other directors of Millennium then in office will designate two persons to fill such vacancies who are not officers, stockholders or affiliates of Millennium, any Millennium subsidiary, Takeda America or Purchaser, and such persons shall be deemed Continuing Directors. Millennium has agreed to use its reasonable best efforts to either increase the size of the Millennium Board or obtain the resignation of such number of its current directors, or both, as is necessary to enable Purchaser's designees to be elected or appointed to Millennium's Board of Directors.

        Except as set forth in this Offer to Purchase, Purchaser and Takeda America have no present plans or proposals that would relate to or result in (i) any extraordinary corporate transaction involving Millennium or any of its subsidiaries (such as a merger, reorganization, liquidation, relocation of any operations or sale or other transfer of a material amount of assets), (ii) any sale or transfer of a material amount of assets of Millennium or any of its subsidiaries, (iii) any material change in Millennium's capitalization or dividend policy, or (iv) any other material change in Millennium's corporate structure or business.

36

13.   Certain Effects of the Offer

        Market for the Shares.    The purchase of Shares pursuant to the Offer will reduce the number of holders of Shares and the number of Shares that might otherwise trade publicly, which could adversely affect the liquidity and market value of the remaining Shares. We cannot predict whether the reduction in the number of Shares that might otherwise trade publicly would have an adverse or beneficial effect on the market price for, or marketability of, the Shares or whether such reduction would cause future market prices to be greater or less than the Offer Price.

        Stock Quotation.    Depending upon the number of Shares purchased pursuant to the Offer, the Shares may no longer meet the requirements for continued listing on Nasdaq. According to the published guidelines of Nasdaq, the Shares would not meet the criteria for continued listing on Nasdaq if, among other things, the number of publicly held Shares were less than 750,000, the aggregate market value of the publicly held Shares were less than $5,000,000, the number of total stockholders falls below 400, or there were fewer than two market makers for the Shares. If, as a result of the purchase of the Shares pursuant to the Offer, the Shares no longer meet these standards, the listing of Shares on Nasdaq could be discontinued and the market for the Shares could be adversely affected. In the event the Shares were no longer listed on Nasdaq, price quotations for the Shares might still be available from other sources. The extent of the public market for the Shares and availability of such quotations would, however, depend upon such factors as the number of holders and/or the aggregate market value of the publicly held Shares at such time, the interest in maintaining a market in the Shares on the part of securities firms, the possible termination of registration of the Shares under the Exchange Act and other factors.

        Margin Regulations.    The Shares are currently "margin securities" under the Regulations of the Board of Governors of the Federal Reserve System (the "Federal Reserve Board"), which has the effect, among other things, of allowing brokers to extend credit on the collateral of the Shares. Depending upon factors similar to those described above regarding the market for the Shares and stock quotations, it is possible that, following the Offer, the Shares would no longer constitute "margin securities" for the purposes of the margin regulations of the Federal Reserve Board and, therefore, could no longer be used as collateral for loans made by brokers.

        Exchange Act Registration.    The Shares are currently registered under the Exchange Act. Such registration may be terminated upon application of Millennium to the SEC if the Shares are neither listed on a national securities exchange nor held by 300 or more holders of record. Termination of registration of the Shares under the Exchange Act would substantially reduce the information required to be furnished by Millennium to its stockholders and to the SEC and would make certain provisions of the Exchange Act no longer applicable to Millennium, such as the short-swing profit recovery provisions of Section 16(b) of the Exchange Act, the requirement of furnishing a proxy statement pursuant to Section 14(a) of the Exchange Act in connection with stockholders' meetings and the related requirement of furnishing an annual report to stockholders and the requirements of Rule 13e-3 under the Exchange Act with respect to "going private" transactions. Furthermore, the ability of "affiliates" of Millennium and persons holding "restricted securities" of Millennium to dispose of such securities pursuant to Rule 144 promulgated under the Securities Act of 1933, as amended, may be impaired or eliminated. If registration of the Shares under the Exchange Act were terminated, the Shares would no longer be "margin securities" or be eligible for listing on Nasdaq. We intend and will cause Millennium to terminate the registration of the Shares under the Exchange Act as soon after consummation of the Offer as the requirements for termination of registration are met. If registration of the Shares is not terminated prior to the Merger, the registration of the Shares under the Exchange Act will be terminated following the consummation of the Merger.

37

14.   Dividends and Distributions

        The Merger Agreement provides that from the date of the Merger Agreement to the Effective Time, without the prior written consent of Takeda America, Millennium will not, and will not allow its subsidiaries to, declare, set aside, make or pay any dividends on or make any distribution payable in cash, capital stock, property or otherwise with respect to the Shares to any holder of the Shares.

15.   Certain Conditions of the Offer

        For the purposes of this Section 15, capitalized terms used but not defined herein will have the meanings set forth in the Merger Agreement. Notwithstanding any other term of the Offer or the Merger Agreement, Purchaser shall not be required to accept for payment or, subject to any applicable rules and regulations of the SEC, including Rule 14e-l(c) under the Exchange Act, to pay for any Shares tendered pursuant to the Offer, and may, subject to the provisions of the Merger Agreement, delay the acceptance for payment of or the payment for, any tendered Shares, and (subject to the provisions of the Merger Agreement) may terminate the Offer and not accept for payment any tendered Shares, unless each of the following conditions is satisfied:

        (a)   immediately prior to the expiration of the Offer (as extended in accordance with the Merger Agreement), the number of Shares validly tendered (including by guaranteed delivery) and not properly withdrawn, together with any Shares beneficially owned by TPC, Takeda America or any subsidiary of TPC or Takeda America, equals at least a majority of the Shares outstanding on a fully diluted basis on the date of purchase (where "on a fully diluted basis" means the number of Shares outstanding, plus (i) the number of Shares issuable upon the exercise of all then outstanding options (but only to the extent that they are then vested or exercisable) and (ii) the number of Shares into which the then outstanding convertible notes may be converted) (the "Minimum Tender Condition"); or

        (b)   immediately prior to the expiration of the Offer (as extended in accordance with the Merger Agreement), any waiting period (and any extensions thereof) under the HSR Act and any approvals or clearances applicable to the Offer or the consummation of the Merger under German and Austrian antitrust laws, shall have expired, or been terminated or obtained, as applicable.

Furthermore, Purchaser shall not be required to accept for payment or, subject to any applicable rules and regulations of the SEC, including Rule 14e-l(c) under the Exchange Act (relating to Purchaser's obligation to pay for or return tendered Shares promptly after the termination or withdrawal of the Offer), to pay for any Shares tendered pursuant to the Offer, and may, subject to the provisions of the Merger Agreement, delay the acceptance for payment of or the payment for, any tendered Shares, and (subject to the provisions of the Merger Agreement) may terminate the Offer and not accept for payment any tendered Shares, if at any time on or after the date of the Merger Agreement and before the expiration of the Offer, any of the following shall have occurred and be continuing unless, if any of the following have occurred and are continuing, they shall have resulted from the breach by Takeda America or Purchaser of any of their obligations under the Merger Agreement:

        (v)   any governmental authority of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any order, executive order, stay, decree, judgment or injunction (preliminary or permanent) or statute, rule or regulation which has the effect of prohibiting the consummation of the Offer or making the Merger illegal or otherwise prohibiting consummation of the Offer, the Merger or the other transactions contemplated by the Merger Agreement; provided, that in no event shall this condition be satisfied, and neither the Offer nor the Merger shall be consummated, if a Japanese court or other Japanese governmental authority of competent jurisdiction shall have issued an order, stay, decree, judgment or injunction (preliminary or permanent) to TPC, the representative director of TPC, all or a part of the directors of TPC, or the Chief Executive Officer of TPC, directing any of them to not consummate, or to not allow

38

Takeda America or Purchaser to consummate, the Offer or the Merger, or making illegal, or restraining or preventing, any of such consummation, and, provided, further, that Takeda America and Purchaser shall have used their reasonable best efforts to oppose any such order, executive order, stay, decree, judgment or injunction or to have such order, executive order, stay, decree, judgment or injunction vacated or made inapplicable to the Offer, the Merger or the other transactions contemplated by the Merger Agreement;

        (w)  (i) any of Millennium's representations or warranties set forth in Section 3.2(a), (c) and (f) (each relating to Millennium's capitalization), Section 3.3(a) (authorization), Section 3.3(b)(i) (no violation of charter documents), Section 3.19 (amendment to rights agreement) or Section 3.21 (inapplicability of state anti-takeover law) of the Merger Agreement shall not be true and correct in all material respects or (ii) any of Millennium's other representations and warranties set forth in the Merger Agreement that (A) are not made as of a specific date are not true and correct as of the Acceptance Time, or (B) are made as of a specific date are not true and correct as of such date, in each case, except where the failure of such representations or warranties to be true and correct (without giving effect to any limitation as to "materiality" or "Company Material Adverse Effect" set forth in such representations and warranties, other than the representation set forth in the first sentence of Section 3.6 regarding the absence of a material change), individually or in the aggregate, has not had and would not reasonably be likely to have a Company Material Adverse Effect (as defined in the Merger Agreement and set forth below);

        (x)   Millennium shall have failed to perform in any material respect any material covenant or material obligation required to be performed or complied with by it under the Merger Agreement at or prior to the Acceptance Time;

        (y)   Takeda America and Purchaser shall not have received a certificate executed by Millennium's Chief Executive Officer and Chief Financial Officer confirming on behalf of Millennium that the conditions set forth in clauses (w) and (x) of this Section 15 above are duly satisfied immediately prior to the Acceptance Time; or

        (z)   the Merger Agreement shall have been validly terminated in accordance with Article 8 of the Merger Agreement.

        The foregoing conditions are for the sole benefit of Takeda America and Purchaser and may be waived only by Takeda America or Purchaser, and then, in whole or in part, at any time and from time to time in the sole discretion of Takeda America or Purchaser (except for any condition that may only be waived with Millennium's consent, as described in Section 11—"The Transaction Documents—The Merger Agreement—The Offer"). The failure by Takeda America or Purchaser at any time to exercise any of the foregoing rights shall not be deemed a waiver of any such right, the waiver of any such right with respect to particular facts and circumstances shall not be deemed a waiver with respect to any other facts and circumstances and each such right shall be deemed an ongoing right that may be asserted at any time and from time to time in accordance with the terms of the Merger Agreement.

        A "Company Material Adverse Effect" means any change, event, occurrence or development that has a material adverse effect on the business, financial condition or results of operations of Millennium and Millennium's subsidiaries, taken as a whole; provided, however, that none of the following, or any change, event, occurrence or development resulting or arising from the following, shall constitute, or shall be considered in determining whether there has occurred, a Company Material Adverse Effect:

        a)    changes in conditions in the U.S. or global economy or capital or financial markets generally, including changes in interest or exchange rates (provided that such changes do not affect Millennium or any of its subsidiaries, taken as a whole, in a materially disproportionate manner as compared to other biotechnology or pharmaceutical companies);

39

        b)    changes in general legal, tax, regulatory, political or business conditions in the countries in which Millennium or any of its subsidiaries operates (provided that such changes do not affect Millennium or any of its subsidiaries, taken as a whole, in a materially disproportionate manner as compared to other biotechnology or pharmaceutical companies);

        c)     general market or economic conditions in the biotechnology or pharmaceutical industries (provided that such conditions do not affect Millennium or its subsidiaries, taken as a whole, in a materially disproportionate manner as compared to other biotechnology or pharmaceutical companies);

        d)    actions contemplated by the parties in connection with the Merger Agreement;

        e)    the negotiation, execution, announcement, pendency or performance of the Merger Agreement or the transactions contemplated hereby, the consummation of the transactions contemplated by this Agreement or any public communications by Takeda America or Purchaser regarding the Merger Agreement or the transactions contemplated thereby, including, in any such case, the impact thereof on relationships, contractual or otherwise, with customers, suppliers, vendors, lenders, investors, venture partners or employees;

        f)     changes after the date of the Merger Agreement in applicable United States or foreign, federal, state or local law, statutes, ordinances, decrees, rules, regulations or administrative policies, including rules, regulations and administrative policies of the United States Food and Drug Administration, or interpretations thereof;

        g)     changes in generally accepted accounting principles or the interpretation thereof;

        h)    any change, event, occurrence or development relating to the Company's Supplemental New Drug Application and the process relating to the expanded label for Velcade;

        i)     any filing of a paragraph IV certification relating to Velcade, any patent litigation initiated by Millennium or any of its subsidiaries against any such paragraph IV filer or any patent litigation initiated against Millennium or any of its subsidiaries with respect to Velcade;

        j)     any change, event, occurrence or development relating to the products or product candidates of any person (other than Millennium and its subsidiaries);

        k)    any action taken pursuant to or in accordance with the Merger Agreement (including Section 6.4 relating to public statements) or at the request or with the consent of Takeda America or Purchaser;

        l)     any regulatory, banking, legal, accounting and other professional fees or expenses incurred in connection with the transactions contemplated by the Merger Agreement;

        m)   any failure by Millennium to meet any projections, guidance, estimates, forecasts or milestones or published financial or operating predictions for or during any period ending (or for which results are released) on or after the date of the Merger Agreement (it being agreed that the facts and circumstances giving rise to such failure may be taken into account in determining whether a Company Material Adverse Effect has occurred);

        n)    any litigation arising from or relating to the Offer, the Merger or the transactions contemplated by the Merger Agreement;

        o)    a decline in the price of the Shares (it being agreed that the facts and circumstances giving rise to such decline may be taken into account in determining whether a Company Material Adverse Effect has occurred); and

        p)    any natural disaster or other acts of God, acts of war, armed hostilities, sabotage or terrorism, or any escalation or worsening of any such acts of war, armed hostilities, sabotage or

40

terrorism threatened or underway as of the date of this Agreement (provided that such conditions do not affect Millennium or its subsidiaries, taken as a whole, in a materially disproportionate manner as compared to other biotechnology or pharmaceutical companies).

16.   Certain Legal Matters; Regulatory Approvals

        General.    Based on our examination of publicly available information filed by Millennium with the SEC and other publicly available information concerning Millennium, we are not aware of any governmental license or regulatory permit that appears to be material to Millennium's business that might be adversely affected by our acquisition of Shares pursuant to the Offer or, except as set forth below, of any approval or other action by any government or governmental administrative or regulatory authority or agency, domestic or foreign, that would be required for our acquisition or ownership of Shares pursuant to the Offer. Should any such approval or other action be required or desirable, we currently contemplate that, except as described below under "State Takeover Statutes," such approval or other action will be sought. Except as described under "U.S. Antitrust" or "Foreign Approvals" there is no current intent to delay the purchase of Shares tendered pursuant to the Offer pending the outcome of any such matter. We are unable to predict whether we will determine that we are required to delay the acceptance for payment of or payment for Shares tendered pursuant to the Offer pending the outcome of any such matter. There can be no assurance that any such approval or other action, if needed, would be obtained (with or without substantial conditions) or that if such approvals were not obtained or such other actions were not taken adverse consequences might not result to Millennium's business or certain parts of Millennium's business might not have to be disposed of, any of which could cause us to elect to terminate the Offer without the purchase of Shares thereunder to the extent permitted pursuant to the terms of the Merger Agreement. Our obligation under the Offer to accept for payment and pay for Shares is subject only to the conditions set forth in Section 15—"Certain Conditions of the Offer."

        Delaware law.    As a Delaware corporation, Millennium is subject to Section 203 of the DGCL. In general, Section 203 of the DGCL would prevent an "interested stockholder" (generally defined in Section 203 of the DGCL as a person beneficially owning 15% or more of a corporation's voting stock) from engaging in a "business combination" (as defined in Section 203 of the DGCL) with a Delaware corporation for three years following the time such person became an interested stockholder unless: (i) before such person became an interested stockholder, the board of directors of the corporation approved the transaction in which the interested stockholder became an interested stockholder or approved the business combination; (ii) upon consummation of the transaction which resulted in the interested stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced (excluding for purposes of determining the number of shares of outstanding stock held by directors who are also officers and by employee stock plans that do not allow plan participants to determine confidentially whether to tender shares); or (iii) following the transaction in which such person became an interested stockholder, the business combination is (A) approved by the board of directors of the corporation and (B) authorized at a meeting of stockholders by the affirmative vote of the holders of at least 662/3% of the outstanding voting stock of the corporation not owned by the interested stockholder. In accordance with the provisions of Section 203, the Millennium Board has approved the Merger Agreement and the transactions contemplated thereby, and therefore the restrictions of Section 203 are inapplicable to the Merger and the transactions contemplated by the Merger Agreement.

        State Takeover Statutes.    A number of states have adopted laws which purport, to varying degrees, to apply to attempts to acquire corporations that are incorporated in, or that have substantial assets, stockholders, principal executive offices or principal places of business or whose business operations otherwise have substantial economic effects in, such states. Millennium, directly or through subsidiaries,

41

conducts business in a number of states throughout the United States, some of which may have enacted such laws. Except as described herein, we do not know whether any of these laws will, by their terms, apply to the Offer or the Merger, and we have not complied with any such laws. To the extent that certain provisions of these laws purport to apply to the Offer or any such merger or other business combination, we believe that there are reasonable bases for contesting such laws.

        For example, in 1982, in Edgar v. MITE Corp., the Supreme Court of the United States invalidated on constitutional grounds the Illinois Business Takeover Statute that, as a matter of state securities law, made takeovers of corporations meeting certain requirements more difficult. However, in 1987, in CTS Corp. v. Dynamics Corp. of America, the Supreme Court held that the State of Indiana could, as a matter of corporate law, constitutionally disqualify a potential acquiror from voting shares of a target corporation without the prior approval of the remaining stockholders where, among other things, the corporation is incorporated, and has a substantial number of stockholders, in the state. Subsequently, in TLX Acquisition Corp. v. Telex Corp., a U.S. federal district court in Oklahoma ruled that the Oklahoma statutes were unconstitutional as applied to corporations incorporated outside Oklahoma in that they would subject such corporations to inconsistent regulations. Similarly, in Tyson Foods, Inc. v. McReynolds, a U.S. federal district court in Tennessee ruled that four Tennessee takeover statutes were unconstitutional as applied to corporations incorporated outside Tennessee. This decision was affirmed by the United States Court of Appeals for the Sixth Circuit. In December 1988, a U.S. federal district court in Florida held in Grand Metropolitan PLC v. Butterworth, that the provisions of the Florida Affiliated Transactions Act and the Florida Control Share Acquisition Act were unconstitutional as applied to corporations incorporated outside of Florida.

        If any government official or third party seeks to apply any state takeover law to the Offer or the Merger, we will take such action as then appears desirable, which action may include challenging the applicability or validity of such statute in appropriate court proceedings. If it is asserted that one or more state takeover statutes is applicable to the Offer or the Merger and an appropriate court does not determine that it is inapplicable or invalid as applied to the Offer or the Merger, we may be required to file certain information with, or to receive approvals from, the relevant state authorities or holders of Shares, and we may be unable to accept for payment or pay for Shares tendered pursuant to the Offer, or be delayed in continuing or consummating the Offer or the Merger. In such case, we may not be obligated to accept for payment or pay for any tendered Shares. See Section 15—"Certain Conditions of the Offer."

        U.S. Antitrust.    Under the HSR Act and the rules that have been promulgated thereunder, certain acquisition transactions may not be consummated unless Premerger Notification and Report Forms have been filed with the Antitrust Division of the Department of Justice (the "Antitrust Division") and the Federal Trade Commission (the "FTC") and certain waiting period requirements have been satisfied. The purchase of Shares pursuant to the Offer is subject to such requirements.

        We expect to file a Premerger Notification and Report Form under the HSR Act with respect to the Offer with the Antitrust Division and the FTC on or about April 21, 2008. If filed on that date, the waiting period applicable to the purchase of Shares pursuant to the Offer will expire at 11:59 p.m., New York City time, May 6, 2008 unless earlier terminated by the FTC or the Antitrust Division. However, before such time, the Antitrust Division or the FTC may extend the waiting period by requesting additional information or documentary material relevant to the Offer from us. If such a request is made, the waiting period will be extended until 11:59 p.m., New York City time, 10 calendar days after our substantial compliance with such request. Thereafter, such waiting period can be extended only by court order or agreement of Millennium, Takeda America, Purchaser and the Antitrust Division or the FTC, as applicable.

        The Antitrust Division and the FTC frequently scrutinize the legality under the antitrust laws of transactions such as our acquisition of Shares pursuant to the Offer and Merger. At any time before or

42

after the consummation of any such transactions, the Antitrust Division or the FTC could take such action under the antitrust laws as it deems necessary or desirable in the public interest, including seeking to enjoin the purchase of Shares pursuant to the Offer or seeking divestiture of the Shares so acquired or divestiture of our or Millennium's substantial assets. Private parties (including individual states) may also bring legal actions under the antitrust laws. There can be no assurance that a challenge to the Offer on antitrust grounds will not be made, or if such a challenge is made, what the result will be. See Section 15—"Certain Conditions to the Offer" for certain conditions to the Offer, including conditions with respect to certain governmental actions.

        Foreign Approvals.    TPC, Takeda America and their subsidiaries conduct business in a number of countries outside of the United States in which Millennium's products are currently sold. Based on our review of the information currently available about the businesses in which Millennium and its subsidiaries are engaged, pre-merger notification filings are required to be made under the antitrust and competition laws of the Federal Republic of Germany and the Republic of Austria. Under the laws of Germany and Austria, the acquisition of Shares pursuant to the Offer may be consummated only if the acquisition is approved by the relevant governmental authorities of such countries, either by written approval or by the expiration of an applicable waiting period commenced by making the appropriate filings with such governmental authorities. Takeda America and Purchaser believe that the required pre-merger notification filings have been made, although we cannot be certain that the necessary approvals or exemption will be granted, and if such approvals or exemption are granted, we cannot be certain as to the date of those approvals or exemption. Transactions such as our acquisition of Shares pursuant to the Offer are frequently scrutinized by foreign antitrust authorities. Therefore, there can be no assurance that a challenge to the Offer under foreign antirust or competition grounds will not be made or, if such a challenge is made, the result thereof. If any applicable waiting period has not expired or been terminated or any approval or exemption required to consummate the Offer has not been obtained, we will not be obligated to accept for payment or pay for any tendered Shares unless and until such approval has been obtained or such applicable waiting period has expired or exemption been obtained. See Section 15—"Certain Conditions of the Offer" for certain conditions to the Offer, including with respect to foreign antitrust approvals.

        Antitrust in Germany.    Under the provisions of the German Act against Restraints on Competition ("ARC"), the acquisition of Shares pursuant to the Offer may be consummated only if the acquisition is approved by the German Federal Cartel Office ("FCO"), either by written approval or by expiration of a one month waiting period commenced by the filing by Takeda America of a complete notification (the "German Notification") with respect to the Offer, unless the FCO notifies Takeda America within the one-month waiting period of the initiation of an in-depth investigation. If the FCO initiates an in-depth investigation, the acquisition of Shares under the Offer may be consummated if the acquisition is approved by the FCO, either by written approval or by expiration of a four month waiting period commenced by the filing of the German Notification, unless the FCO notifies Takeda America within the four month waiting period that the acquisition satisfies the conditions for a prohibition and may not be consummated. The written approval by the FCO or the expiration of any applicable waiting period is a condition to Purchaser's obligation to accept for payment and pay for Shares tendered pursuant to the Offer.

        Antitrust in Austria.    Under the provisions of the Austrian Cartel Act 2005 (Kartellgesetz 2005—"KartG"), the acquisition of Shares pursuant to the Offer may be consummated if the Statutory Parties (Amtsparteien) within the meaning of the KartG have either waived their right to request an in-depth examination of the transaction, or they have not requested an in-depth examination of the transaction within the four-week waiting period from the filing of a complete notification and informed Purchaser accordingly. In case such an in-depth examination has been requested, the acquisition of Shares pursuant to the Offer may be consummated if the Cartel Court has either dismissed the request or

43

declared that the concentration will not be prohibited, or the Cartel Court has discontinued the examination proceedings.

17.   Appraisal Rights

        No appraisal rights are available with respect to Shares tendered and accepted for purchase in the Offer. However, if the Merger is consummated, stockholders who do not tender their Shares in the Offer will have certain rights under Section 262 of the DGCL to demand appraisal of, and to receive payment in cash of the fair value of, their Shares. Such appraisal rights, if the statutory procedures are met, could lead to a judicial determination of the fair value of the Shares, as of the Effective Time (excluding any element of value arising from the accomplishment or expectation of the Merger), required to be paid in cash to such dissenting holders for their Shares. In addition, such dissenting stockholders would be entitled to receive payment of interest from the date of consummation of the Merger through the date of the payment of the judgment on the amount determined to be the fair value of their Shares compounded quarterly and accruing at 5% over the Federal Reserve discount rates as established from time to time (unless the Court determines otherwise for good cause shown). Such determination could be based upon considerations other than, or in addition to, the market value of the Shares, including, among other things, asset values, investment value and earning capacity. Therefore, the value so determined in any appraisal proceeding could be the same as, or more or less than, the Offer Price or the Merger Consideration.

        If any holder of Shares who demands appraisal under Delaware law fails to perfect, or effectively withdraws or loses his rights to appraisal as provided under Delaware law, each Share of such stockholder will be converted into the right to receive the Offer Price. A stockholder may withdraw his demand for appraisal by delivering to Millennium a written withdrawal of his, her or its demand for appraisal and acceptance of the Merger.

The foregoing discussion is not a complete statement of law pertaining to appraisal rights under Delaware law and is qualified in its entirety by reference to Delaware law.

        You cannot exercise appraisal rights at this time. The information set forth above is for informational purposes only with respect to your alternatives if the Merger is consummated. If you are entitled to appraisal rights in connection with the Merger, you will receive additional information concerning appraisal rights and procedures to be followed in connection therewith, including the text of the relevant provisions of Delaware law, before you have to take any action relating thereto.

If you sell your Shares in the Offer, you will not be entitled to exercise appraisal rights with respect to your Shares but, rather, will receive the Offer Price therefor.

18.   Fees and Expenses

        UBS Securities LLC ("UBS") is acting as Dealer Manager in connection with the Offer and has acted as financial advisor to TPC in connection with the proposed acquisition of Millennium, for which services UBS will receive customary fees, a significant portion of which is contingent upon consummation of the Offer. TPC, Takeda America and Purchaser have agreed to reimburse UBS for its expenses, including the fees and disbursements of UBS' counsel, and to indemnify UBS, and related parties against liabilities, including liabilities under the federal securities laws relating to, or arising out of, its engagement. In the ordinary course of business, UBS and its affiliates may hold or trade, for their own accounts and the accounts of their customers, securities of TPC and Millennium and, accordingly, may at any time hold long or short positions in such securities.

        Takeda America and Purchaser have retained Altman Group to be the Information Agent and Computershare Trust Company, N.A. to be the Depositary in connection with the Offer. The Information Agent may contact holders of Shares by mail, telephone, telecopy, telegraph and personal

44

interview and may request banks, brokers, dealers and other nominees to forward materials relating to the Offer to beneficial owners of Shares.

        The Information Agent and the Depositary each will receive reasonable and customary compensation for their respective services in connection with the Offer, will be reimbursed for reasonable out-of-pocket expenses and will be indemnified against certain liabilities and expenses in connection therewith, including certain liabilities under federal securities laws.

        Neither Takeda America nor Purchaser will pay any fees or commissions to any broker or dealer or to any other person (other than to the Depositary and the Information Agent) in connection with the solicitation of tenders of Shares pursuant to the Offer. Brokers, dealers, commercial banks and trust companies will, upon request, be reimbursed by Purchaser for customary mailing and handling expenses incurred by them in forwarding offering materials to their customers.

19.   Miscellaneous

        The Offer is not being made to (nor will tenders be accepted from or on behalf of) holders of Shares in any jurisdiction in which the making of the Offer or the acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. In those jurisdictions where applicable laws require the Offer to be made by a licensed broker or dealer, the Offer shall be deemed to be made on behalf of Purchaser by one or more registered brokers or dealers licensed under the laws of such jurisdiction.

No person has been authorized to give any information or to make any representation on behalf of Takeda America or Purchaser not contained herein or in the Letter of Transmittal, and, if given or made, such information or representation must not be relied upon as having been authorized. No broker, dealer, commercial bank, trust company, fiduciary or other person shall be deemed to be the agent of Purchaser, the Depositary, the Dealer Manager or the Information Agent for the purpose of the Offer.

        Purchaser has filed with the SEC a Tender Offer Statement on Schedule TO pursuant to Rule 14d-3 of the General Rules and Regulations under the Exchange Act, together with exhibits furnishing certain additional information with respect to the Offer, and may file amendments thereto. In addition, Millennium has filed or will file with the SEC a Schedule 14D-9, together with exhibits, pursuant to Rule 14d-9 under the Exchange Act, setting forth the recommendation of the Millennium Board with respect to the Offer and the reasons for such recommendation and furnishing certain additional related information. A copy of such documents, and any amendments thereto, may be examined at, and copies may be obtained from, the SEC in the manner set forth under Section 7—"Certain Information Concerning Millennium" above.

Mahogany Acquisition Corp.
April 11, 2008

45

SCHEDULE I
DIRECTORS AND EXECUTIVE OFFICERS OF TPC, TAKEDA AMERICA AND PURCHASER

1.     DIRECTORS AND EXECUTIVE OFFICERS OF TPC

        The name, business address, present principal occupation or employment and material occupations, positions, offices or employment for the past five years of each of the directors and executive officers of Takeda Pharmaceutical Company Limited ("TPC") are set forth below. The business address and phone number of each such director and executive officer is c/o Takeda Pharmaceutical Company Limited, 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645 Japan, +81 6 6204-2111. All directors and executive officers listed below are citizens of Japan.

NAME AND POSITION	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND EMPLOYMENT HISTORY
Kunio Takeda Chairman of the Board	Chairman of the Board of TPC since June 2003. Mr. Takeda also served as President of TPC (June 1993–June 2003). Mr. Takeda has held a variety of positions with TPC since 1962.
Yasuchika Hasegawa President	President of TPC since June 2003. Mr. Hasegawa also served TPC as a member of the Board (June 1999–present), General Manager, Pharmaceutical Division (October 1998–June 2001) and General Manager, Corporate Strategy & Planning Department (June 2001–June 2003). Mr. Hasegawa has held a variety of positions with TPC since 1970.
Makoto Yamaoka Senior Managing Director	Senior Managing Director of TPC since June 2006. Mr. Yamaoka joined the Board of Directors of TPC June 2002, serving as Managing Director (June 2004–June 2006), and Senior Managing Director (June 2006–present). Mr. Yamaoka also previously served as an officer of TPC, as General Manager, Pharmaceutical Marketing Division (November 2000–April 2007) and General Manager Corporate Strategy & Planning Department (April 2007–April 2008). Mr. Yamaoka has held a variety of positions with TPC since 1969.
Hiroshi Akimoto, Ph.D. Managing Director	Managing Director of TPC since June 2003. Dr. Akimoto joined the Board of Directors of TPC June 2000, and served as General Manager, Intellectual Property Department (April 1995–June 2005). Dr. Akimoto has held a variety of positions with TPC since 1972.
Kiyoshi Kitazawa, Ph.D. Managing Director	Managing Director of TPC since June 2006. Dr. Kitazawa joined the Board of Directors of TPC June 2002, and served as General Manager Strategic Product Planning Department (April 2001–October 2002; June 2006–April 2008) and General Manager, Pharmaceutical Development Division (October 2002–June 2006). Dr. Kitazawa has held a variety of positions with TPC since 1971.

I-1

Hiroshi Shinha Director and General Manager, Legal Department	Director of TPC since June 2003 and General Manager, Legal Department since June 2002. Director and Secretary of Purchaser since April 2008. Mr. Shinha also served as Manager, Legal Department TPC (April 1991–June 2002). Mr. Shinha has held a variety of positions with TPC since 1971.
Yasuhiko Yamanaka Director and General Manager Pharmaceutical Marketing Division	Director of TPC since June 2007 and General Manager Pharmaceutical Marketing Division since April 2007. Mr. Yamanaka also previously served as an officer of TPC, as Senior Manager, Corporate Business Planning, Corporate Strategy & Planning Department (April 2002–June 2003) and General Manager Corporate Strategy & Planning Department (June 2003–April 2007). Mr. Yamanaka has held a variety of positions with TPC since 1979.
Masumitsu Inoue General Manager, Corporate Strategy and Planning Department	General Manager, Corporate Strategy and Planning Department of TPC since April 2008. Mr. Inoue also served TPC as Manager (Tax), Finance and Accounting Department (April 2002–June 2003), Senior Manager (Accounting), Finance and Accounting Department (June 2003–May 2006), Senior Manager (Corporate Business Planning), Corporate Strategy Planning Department (May 2006–April 2008).
Masato Iwasaki General Manager, Strategic Product Planning Department	General Manager, Strategic Product Planning Department of TPC since April 2008. Mr. Iwasaki also served TPC, as Group Manager, Marketing Department (Diabetes), Pharmaceutical Marketing Division (October 2002–November 2003), Manager Strategic Product Planning Department (November 2003–December 2003) and Category I Leader, Strategic Product Planning Department (December 2003–April 2008).
Youji Ishii General Manager, Human Resources Department	General Manager, Human Resources Department of TPC since April 2008. Mr. Ishii also served TPC, as Senior Manager (System Planning), Corporate Strategy and Planning Department (April 2002–May 2005), General Manager, Research Administration Department, Pharmaceutical Research Division (May 2005–April 2008).
Hiroshi Takahara General Manager Finance & Accounting Department	General Manager Finance & Accounting Department of TPC since June 2003. Director of Takeda America since June 2003. Mr. Takahara also served TPC as Senior Manager (Tax), Finance and Accounting Department (April 2002–June 2003).

I-2

Hirofumi Inoue General Manager, Corporate Communications Department	General Manager, Corporate Communications Department of TPC since June 2007. Mr. Inoue also served TPC as Manager (IR), Corporate Communications Department (April 2002–October 2002), Senior Manager (IR), Corporate Communications Department (October 2002–June 2007).
Yoichi Okumura General Manager, Intellectual Property Department	General Manager, Intellectual Property Department of TPC since October 2007. Mr. Okumura also served TPC as Senior Manager (License Affiliation), Intellectual Property Department (April 2002–November 2003) and Manager, Pharmaceutical Licensing Department (November 2003–November 2004). Mr. Okumura also served TPC's Global Licensing and Business Development Department as Manager (Pharmaceutical Licensing) (November 2004–July 2005), and Senior Manager (Business Development) (August 2006–October 2007). Mr. Okumura also served Takeda Pharmaceuticals North America, Inc. (One Takeda Parkway, Deerfield, IL 60015, USA) as Manager, Global Licensing and Business Development Department (July 2005–August 2006).
Naohisa Takeda General Manager, Overseas Business Planning Department	General Manager, Overseas Business Planning Department of TPC since June 2007. Mr. Takeda also served TPC as General Manager, Department of Europe, Pharmaceutical International Division (April 2000–June 2003), General Manager, Department of Europe (June 2003–November 2003), General Manager, Department of Europe and Asia (November 2003–June 2007).
Toshikazu Ban General Manager, Global Licensing and Business Development Department	General Manager, Global Licensing and Business Development Department of TPC since January 2008. Mr. Ban also served TPC as General Manager, SPU (December 2001–May 2004), Manager, Pharmaceutical Licensing Department (May 2004–November 2004) and Senior Manager, Pharmaceutical Licensing, Global Licensing and Business Development Department (November 2004–January 2008).
Shigenori Ohkawa, Ph.D. General Manager, Pharmaceutical Research Division	General Manager Pharmaceutical Research Division of TPC since October 2005. Mr. Ohkawa also served TPC as Research Manager and General Research Manager of Medical Chemistry Research Laboratories, Pharmaceutical Research Division (October 2002–October 2005).

I-3

Masaomi Miyamoto General Manager, Pharmaceutical Development Division	General Manager, Pharmaceutical Development Division of TPC since June 2006. Mr. Miyamoto also served TPC as General Manager, Pharmacology Research Laboratories I, II and III, Pharmaceutical Research Division (April 2002–December 2003; October 2005–June 2006) and Category III Leader, Strategic Product Planning Department (December 2003–October 2005).
Takashi Inkyo General Manager, Pharmaceutical Production Division	General Manager, Pharmaceutical Production Division of TPC since November 2006. Mr. Inkyo also served TPC as General Manager, Production Control Department, Pharmaceutical Production Division (April 2002–April 2004), General Manager, Shonan Plant (April 2004–April 2006) and General Manager, Auditing Department and Office of the Corporate Auditors (April 2006–November 2006).

2.     DIRECTORS AND EXECUTIVE OFFICERS OF TAKEDA AMERICA

        The name, business address, present principal occupation or employment and material occupations, positions, offices or employment for the past five years of each of the directors and executive officers of Takeda America Holdings, Inc. ("Takeda America") are set forth below. All directors and executive officers listed below are citizens of Japan.

NAME AND POSITION	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND EMPLOYMENT HISTORY
Hiroshi Takahara Director	Director of Takeda America since June 2003. General Manager Finance & Accounting Department of TPC since June 2003. Mr. Takahara also served TPC as Senior Manager (Tax), Finance and Accounting Department (April 2002–June 2003). Mr. Takahara's business address and telephone number is c/o Takeda Pharmaceutical Company Limited, 1-1 Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 540-8645 JAPAN, +81 6 6204-2111.
Iwaaki Taniguchi Director and President	Director and President of Takeda America since November 2004. Director and President of Purchaser since April 2008. Mr. Taniguchi also served Shinsei Bank Limited (399 Park Avenue, New York, NY 10022, USA) as Deputy Chief Representative, New York Representative Office (April 2001–December 2003). Mr. Taniguchi then served TPC as Manager, Finance and Accounting Department (Financing) (December 2003–November 2004) and Senior Manager, Finance and Accounting Department (Financing) (November 2004–September 2006). Mr. Taniguchi's business address and telephone number is c/o Takeda America Holdings, Inc., 767 Third Avenue, 8th Floor, New York, NY 10017, USA, 212-421-6950.

I-4

Takashi Mino
Executive Vice President, Treasurer
and Secretary
Executive Vice President, Treasurer and Secretary of Takeda America since July 2006. Mr. Mino has also served TPC's Finance and Accounting Department since (April 2002–July 2006), including as Assistant Manager (October 2005–July 2006). Mr. Mino's business address and telephone number is c/o Takeda America Holdings, Inc., 767 Third Avenue, 8^th Floor, New York, NY 10017, USA, 212-421-6950.

3.     DIRECTORS AND EXECUTIVE OFFICERS OF PURCHASER.

        The name, business address, present principal occupation or employment and material occupations, positions, offices or employment for the past five years of each of the directors and executive officers of Mahogany Acquisition Corp. (the "Purchaser") are set forth below. Unless otherwise noted, all directors and executive officers listed below are citizens of Japan.

NAME AND POSITION	PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND EMPLOYMENT HISTORY
Iwaaki Taniguchi Director and President	Director and President of Purchaser since April 2008. Director and President of Takeda America since November 2004. Mr. Taniguchi also served Shinsei Bank Limited (399 Park Avenue, New York, NY 10022, USA) as Deputy Chief Representative, New York Representative Office (April 2001–December 2003). Mr. Taniguchi then served TPC as Manager, Finance and Accounting Department (Financing) (December 2003–November 2004) and Senior Manager, Finance and Accounting Department (Financing) (November 2004–September 2006). Mr. Taniguchi's business address and telephone number is c/o Takeda America Holdings, Inc., 767 Third Avenue, 8th Floor, New York, NY 10017, USA, (212) 421-6954.
Hiroshi Shinha Director and Secretary	Director and Secretary of Purchaser since April 2008. Director of TPC since June 2003 and General Manager, Legal Department of TPC since June 2002. Mr. Shinha also served as Manager, Legal Department of TPC (April 1991–June 2002). Mr. Shinha has held a variety of positions with TPC since 1971. Mr. Shinha's business address and telephone number is c/o Takeda Pharmaceutical Company Limited, 1-1, Doshomachi 4-chome Chuo-ku, Osaka 540-8645, JAPAN, +81 6 6204-2111.

I-5

Ken Araki
Director
Director of Purchaser since April 2008. Senior Director (Business Development) of Global Licensing & Business Development Department of TPC since March 2008. Mr. Araki served Nomura Securities International, Inc. (a financial equity market entity; 2WFC, Building B, New York, NY, 10281-1198, USA) as Director, Global Equity Research (April 1997–September 2004). Mr. Araki then served Nomura Securities Co., Ltd. (a financial investment banking entity; Otemachi Urbannet Building, 2-2, Otemachi, 2-chome, Chiyoda-ku, Tokyo, 100-0004, JAPAN) as Managing Director, IB Research, Investment Banking Department (September 2004–May 2006). Mr. Araki also served TPC as Senior Director (Corporate Business Development) of Global Licensing & Business Development Department (May 2006–March 2008). Mr. Araki's business address and telephone number is c/o Takeda Pharmaceutical Company Limited, 12-10, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-8668, JAPAN, +81 3 3278-2111.

I-6

        Manually signed facsimiles of the Letter of Transmittal, properly completed, will be accepted. The Letter of Transmittal and certificates evidencing Shares and any other required documents should be sent or delivered by each stockholder or its, his or her broker, dealer, commercial bank, trust company or other nominees to the Depositary at one of its addresses set forth below:

The Depositary for the Offer is:

If delivering by mail:	By Facsimile Transmission:	If delivering by hand or courier:
Computershare Trust Company, N.A. c/o Computershare Shareholder Services, Inc. P.O. Box 43011 Providence, RI 02940-3014 Attn: Corporate Actions Voluntary Department	For Eligible Institution Only: (617) 360-6810 For Confirmation Only Telephone: (781) 575-2332	Computershare Trust Company, N.A. c/o Computershare Shareholder Services, Inc. 250 Royall Street Canton, MA 02021 Attn: Corporate Actions Voluntary Department

        Questions and requests for assistance may be directed to the Information Agent at the address and telephone numbers listed below. Additional copies of this Offer to Purchase, the Letter of Transmittal and the Notice of Guaranteed Delivery may also be obtained from the Information Agent. Stockholders may also contact brokers, dealers, commercial banks or trust companies for assistance concerning the Offer.

The Dealer Manager for the Offer is:

UBS Securities LLC
299 Park Avenue
New York, NY 10171
Telephone: (877) 211-0850

The Information Agent for the Offer is:

1200 Wall Street West, 3^rd Floor
Lyndhurst, New Jersey 07071
Holders call toll-free: (866) 751-6316
Banks and Brokers call: (201) 806-7300
Fax: (201) 460-0050

EX-99.(A)(1)(B)

Exhibit (a)(1)(B)

LETTER OF TRANSMITTAL

To Tender Shares of Common Stock
of
MILLENNIUM PHARMACEUTICALS, INC.
Pursuant to the Offer to Purchase
dated April 11, 2008
by
MAHOGANY ACQUISITION CORP.
a wholly-owned subsidiary of
TAKEDA AMERICA HOLDINGS, INC.
a wholly-owned subsidiary of
TAKEDA PHARMACEUTICAL COMPANY LIMITED

THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THURSDAY, MAY 8, 2008, UNLESS THE OFFER IS EXTENDED.

The Depositary for the Offer is:

By Mail:	By Facsimile Transmission:	By Overnight Courier:
Computershare Trust Company, N.A. c/o Voluntary Corporate Actions P.O. Box 43011 Providence, RI 02940-3011	For Eligible Institutions Only: (617) 360-6810    For Confirmation Only Telephone: (781) 575-2332	Computershare Trust Company, N.A. c/o Voluntary Corporate Actions 250 Royall Street Canton, MA 02021

ALL QUESTIONS REGARDING THE OFFER SHOULD BE DIRECTED TO THE INFORMATION AGENT, THE ALTMAN GROUP, INC., AT THE ADDRESS AND TELEPHONE NUMBERS AS SET FORTH ON THE BACK OF THIS LETTER OF TRANSMITTAL AND ON THE BACK COVER PAGE OF THE OFFER TO PURCHASE.

DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE, OR TRANSMISSION OF INSTRUCTIONS VIA A FACSIMILE NUMBER OTHER THAN AS SET FORTH ABOVE, FOR THE DEPOSITARY WILL NOT CONSTITUTE A VALID DELIVERY.

THIS LETTER OF TRANSMITTAL AND THE INSTRUCTIONS ACCOMPANYING THIS LETTER OF TRANSMITTAL SHOULD BE READ CAREFULLY BEFORE THIS LETTER OF TRANSMITTAL IS COMPLETED.

DESCRIPTION OF SHARES TENDERED

Name(s) and Address(es) of Registered Holder(s) (Please fill in, if blank, exactly as name(s) appear(s) on Share Certificate(s))	Shares Tendered (Attach additional signed list if necessary) See Instruction 3.
	Share Certificate Number(s)*	Total Number of Shares Represented by Share Certificate(s)*	Number of Shares Tendered**
	Total

*	Need not be completed by stockholders tendering by book-entry transfer.
**	Unless otherwise indicated, it will be assumed that all shares of common stock, par value $0.001, of Millennium Pharmaceuticals, Inc., represented by any certificates described above are being tendered. See Instruction 4.

This Letter of Transmittal is to be used if certificates are to be forwarded herewith or, unless an Agent's Message (as defined in the Offer to Purchase) is utilized, if delivery of Shares (as defined below) is to be made by book-entry transfer to the account of The Computershare Trust Company, N.A. (the "Depositary") at The Depository Trust Company (the "Book-Entry Transfer Facility"), pursuant to the procedures set forth in Section 3 of the Offer to Purchase.

Holders of outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Millennium Pharmaceuticals, Inc., a Delaware corporation, whose certificates for such shares are not immediately available or who cannot deliver such certificates and all other required documents to the Depositary on or prior to the expiration of the Offer (as defined below), or who cannot comply with the procedures for book-entry transfer on a timely basis, may tender their Shares according to the guaranteed delivery procedure set forth in Section 3 of the Offer to Purchase. See Instruction 2. Delivery of documents to the Book-Entry Transfer Facility does not constitute delivery to the Depositary.

o    CHECK HERE IF TENDER IS BEING MADE OF SHARES REPRESENTED BY LOST, DESTROYED OR STOLEN SHARE CERTIFICATE(S). SEE INSTRUCTION 9.

Number of Shares represented by lost, destroyed or stolen Share Certificate(s):

o    CHECK HERE IF SHARES ARE BEING DELIVERED BY BOOK-ENTRY TRANSFER TO THE DEPOSITARY'S ACCOUNT AT THE BOOK-ENTRY TRANSFER FACILITY AND COMPLETE THE FOLLOWING:

Name of Tendering Institution:

Account Number:

Transaction Code Number:

o    CHECK HERE IF SHARES ARE BEING TENDERED PURSUANT TO A NOTICE OF GUARANTEED DELIVERY PREVIOUSLY SENT TO THE DEPOSITARY AND COMPLETE THE FOLLOWING:

Name(s) of Tendering Stockholder(s):

Date of Execution of Notice of Guaranteed Delivery:

Name of Institution that Guaranteed Delivery:

If delivery is by book-entry transfer check box: o

Name of Tendering Institution:

Account Number:

Transaction Code Number:

Ladies and Gentlemen:

The undersigned hereby tenders to Mahogany Acquisition Corp. ("Purchaser"), a Delaware corporation and wholly-owned subsidiary of Takeda America Holdings, Inc. ("Takeda America"), which is a New York corporation and wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan, the above-described shares of common stock, par value $0.001 per share, of Millennium Pharmaceuticals, Inc. ("Millennium"), pursuant to Purchaser's offer to purchase all outstanding Shares at $25.00 per Share, net to the seller in cash, without interest and subject to any required withholding of taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated April 11, 2008, receipt of which is hereby acknowledged, and in this Letter of Transmittal (which, together as amended or supplemented from time to time, collectively constitute the "Offer"). The Offer expires at 12:00 midnight, New York City time, at the end of Thursday, May 8, 2008, unless extended as described in the Offer to Purchase (as extended, the "Expiration Date").

Upon the terms and subject to the conditions of the Offer and effective upon acceptance for payment of and payment for the Shares tendered herewith, the undersigned hereby sells, assigns and transfers to, or upon the order of, Purchaser all right, title and interest in and to all the Shares that are being tendered hereby (and any and all other Shares or other securities issued or issuable in respect thereof on or after April 11, 2008) and appoints the Depositary the true and lawful agent and attorney-in-fact of the undersigned with respect to such Shares (and all such other Shares or securities), with full power of substitution (such power of attorney being deemed to be an irrevocable power coupled with an interest in the Shares) to the fullest extent of the undersigned's rights with respect to such Shares (and all such other Shares or securities), to (i) deliver certificates for such Shares (and all such other Shares or securities), or transfer ownership of such Shares (and all such other Shares or securities) on the account books maintained by The Depository Trust Company (the "Book-Entry Transfer Facility"), together, in any such case, with all accompanying evidences of transfer and authenticity, to or upon the order of Purchaser, (ii) present such Shares (and all such other Shares or securities) for transfer on the books of Millennium and (iii) receive all benefits and otherwise exercise all rights of beneficial ownership of such Shares (and all such other Shares or securities), all in accordance with the terms of the Offer.

The undersigned hereby irrevocably appoints Purchaser and designees of Purchaser as attorneys-in-fact and proxies of the undersigned, each with full power of substitution, to exercise all voting and other rights of the undersigned in such manner as each such attorney-in-fact and proxy or his or her substitute shall in his or her sole discretion deem proper, with respect to all of the Shares tendered hereby that have been accepted for payment and paid for by Purchaser prior to the time of any vote or other action (and any and all other Shares or other securities issued or issuable in respect thereof on or after April 11, 2008), at any meeting of stockholders of Millennium (whether annual or special and whether or not an adjourned meeting), or otherwise. This proxy is irrevocable and is granted in consideration of, and is effective upon, the acceptance for payment of and payment for such Shares by Purchaser in accordance with the terms of the Offer. Such acceptance for payment and payment shall, without further action, revoke all prior powers of attorney, proxies and consents given by such stockholder with respect to such Shares, and no subsequent powers of attorney, proxies, consents or revocations may be given by such stockholder (and, if given, will not be deemed effective).

The undersigned hereby represents and warrants that the undersigned has full power and authority to tender, sell, assign and transfer the Shares tendered herein (and any and all other Shares or other securities issued or issuable in respect thereof on or after April 11, 2008) and that when the same are accepted for payment and paid for by Purchaser, Purchaser will acquire good and unencumbered title thereto, free and clear of all liens, restrictions, charges and encumbrances and not subject to any adverse claims. The undersigned will, upon request, execute and deliver any additional documents deemed by the Depositary, Purchaser or Takeda America to be necessary or desirable to complete the sale, assignment and transfer of the Shares tendered hereby (and all such other Shares or securities).

All authority herein conferred or agreed to be conferred shall survive the death or incapacity of the undersigned, and any obligation of the undersigned hereunder shall be binding upon the heirs, personal

representatives, successors and assigns of the undersigned. Except as stated in the Offer, this tender is irrevocable.

The undersigned understands that the tender of Shares pursuant to any one of the procedures described in Section 3 of the Offer to Purchase will constitute the tendering stockholder's acceptance of the Offer, as well as the tendering stockholder's representation and warranty that such stockholder has the full power and authority to tender and assign the Shares tendered, as specified in the Letter of Transmittal. The undersigned's acceptance for payment of Shares tendered pursuant to the Offer will constitute a binding agreement between the tendering stockholder and Purchaser upon the terms and subject to the conditions of the Offer.

Unless otherwise indicated under "Special Payment Instructions", please issue the check for the purchase price of any Shares purchased, and return any Shares not tendered or not purchased, in the name(s) of the undersigned (and, in the case of Shares tendered by book-entry transfer, by credit to the account at the Book-Entry Transfer Facility). Similarly, unless otherwise indicated under "Special Delivery Instructions", please mail the check for the purchase price of any Shares purchased and any certificates for Shares not tendered or not purchased (and accompanying documents, as appropriate) to the undersigned at the address shown below the undersigned's signature(s). In the event that both "Special Payment Instructions" and "Special Delivery Instructions" are completed, please issue the check for the purchase price of any Shares purchased and return any Shares not tendered or not purchased in the name(s) of, and mail said check and any certificates to, the person(s) so indicated. The undersigned recognizes that Purchaser has no obligation, pursuant to the "Special Payment Instructions", to transfer any Shares from the name of the registered holder(s) thereof if Purchaser does not accept for payment any of the Shares so tendered.

SPECIAL PAYMENT INSTRUCTIONS
(See Instructions 1, 6, 7 and 8)

To be completed ONLY if (i) the check for the purchase price of Shares purchased (less the amount of any federal income and backup withholding tax required to be withheld) or (ii) certificates for Shares not tendered or not purchased are in either case to be issued in the name of someone other than the undersigned.

Issue

o

Check

o

Certificate(s) to:

Name:
	(Please Print)

Address:
	(Include Zip Code)
	(Tax ID or Social Security Number(s)) (See Substitute Form W-9)

o

Credit unpurchased Shares delivered by book-entry transfer to DTC account set forth below.

Account Number:

SPECIAL DELIVERY INSTRUCTIONS
(See Instructions 1, 6, 7 and 8)

To be completed ONLY if (i) the check for the purchase price of Shares purchased (less the amount of any federal income and backup withholding tax required to be withheld) or (ii) certificates for Shares not tendered or not purchased are in either case to be mailed to someone other than the undersigned or to the undersigned at an address other than that shown below the undersigned's signature(s).

Mail

o

Check

o

Certificate(s) to:

Name:
	(Please Print)

Address:
	(Include Zip Code)
	(Tax ID or Social Security Number(s)) (See Substitute Form W-9)

PLEASE SIGN ON THIS PAGE
(To be completed by all stockholders tendering Shares regardless of whether
Shares are being physically delivered herewith)

X
X
	(Signature(s) of Registered Holder(s) or Authorized Signatory)

Dated:                              , 2008

(Must be signed by registered holder(s) exactly as name(s) appear(s) on the Share Certificate(s) or on a security position listing or by person(s) authorized to become registered holder(s) by certificates and documents transmitted with this Letter of Transmittal. If signature is by trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation or other person acting in a fiduciary or representative capacity, please provide the following information and see Instruction 5.)

Name(s):
	(Please Print)

Name of Firm:

Capacity (full title):

Address:
	(Include Zip Code)

Area Code and Telephone Number:

Taxpayer Identification or Social Security Number:

(Complete Substitute Form W-9 at the End of this Letter of Transmittal)

GUARANTEE OF SIGNATURE(S)
(If required; see Instructions 1 and 5)

FOR USE BY ELIGIBLE INSTITUTIONS ONLY
PLACE MEDALLION GUARANTEE IN SPACE BELOW

Name(s):
	(Please Print)

Name of Firm:

Capacity (full title):

Address:
	(Include Zip Code)

Area Code and Telephone Number:

Dated:                              , 2008

Substitute Form W-9 Request for Taxpayer Identification Number and Certification
PAYOR'S NAME: Computershare Trust Company, N.A.
(See Instruction 8 and "Important Tax Information")

Name as shown on account (if joint, list first and circle name of the person or entity whose number you enter below)

Name:

Address:
	City, State and Zip Code:

Check appropriate box:	o    Individual/ Sole Proprietor	o    Partnership	o    Exempt from backup withholding
	o    Corporation	o    Other:

SUBSTITUTE
Form W-9
Department of the Treasury
Internal Revenue Service

  

Payer's Request for
Taxpayer Identification Number (TIN) PART 1—TAXPAYER IDENTIFICATION NUMBER
Enter your taxpayer identification number in the
appropriate space at right and certify by signing and
dating below.



For most individuals your taxpayer identification
number is your social security number. If you do not
have a number, see "How to Obtain a TIN" in the
enclosed Guidelines.



Note: If the account is in more than one name, see the chart in the enclosed Guidelines on which number to give the payor. Social Security Number or Employer Identification Number

PART 2—FOR PAYEES EXEMPT FROM BACKUP WITHHOLDING (See Page 2 of enclosed Guidelines) If you are exempt from backup
withholding, write "EXEMPT" here

PART 3—CERTIFICATION

Under penalties of perjury, I certify that:

(1)

the number shown on this form is my correct Taxpayer Identification Number (or I am waiting for a number to be issued to me),

(2)

I am not subject to backup withholding either because: (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service ("IRS") that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding, and

(3)

I am a U.S. person (including a U.S. resident alien).

Certification Instructions—You must cross out Item (2) above if you have been notified by the IRS that you are subject to backup withholding because of underreporting interest or dividends on your tax returns. However, if after being notified by the IRS that you were subject to backup withholding you received another notification from the IRS that you are no longer subject to backup withholding, do not cross out Item (2).

Signature: Date:

NOTE:

FAILURE TO COMPLETE AND RETURN THIS FORM MAY RESULT IN BACKUP WITHHOLDING OF 28% OF ANY CASH PAYMENT MADE TO YOU WITH RESPECT TO SHARES SURRENDERED IN CONNECTION WITH THE TENDER OFFER OR THE MERGER AND MAY RESULT IN CERTAIN PENALTIES IMPOSED BY THE IRS. PLEASE REVIEW THE ENCLOSED GUIDELINES FOR CERTIFICATION OF TAXPAYER IDENTIFICATION NUMBER ON SUBSTITUTE FORM W-9 FOR ADDITIONAL DETAILS.

YOU MUST COMPLETE THE FOLLOWING CERTIFICATE IF YOU WROTE "APPLIED FOR" IN THE SPACE FOR THE "TIN" ON THE SUBSTITUTE FORM W-9.

CERTIFICATE OF AWAITING TAXPAYER IDENTIFICATION NUMBER

I certify under the penalty of perjury that a taxpayer identification number has not been issued to me and either (a) I have mailed or delivered an application to receive a taxpayer identification number to the appropriate Internal Revenue Service Center or Social Security Administration Office or (b) I intend to mail or deliver an application in the near future. I understand that if I do not provide a taxpayer identification number by the time of payment, 28% of all reportable payments made to me thereafter will be withheld until I provide a number, and if a taxpayer identification number is not provided within 60 days, such retained amounts shall be remitted to the IRS as backup withholding.

Signature Date

INSTRUCTIONS
Forming Part of the Terms and Conditions of the Offer

1.    Guarantee of Signatures.    Except as otherwise provided below, all signatures on this Letter of Transmittal must be guaranteed by a financial institution (including most commercial banks, savings and loan associations and brokerage houses) that is a member of a recognized Medallion Program approved by The Securities Transfer Association, Inc., including the Securities Transfer Agents Medallion Program (STAMP), the Stock Exchange Medallion Program (SEMP) and the New York Stock Exchange, Inc. Medallion Signature Program (MSP) or any other "eligible guarantor institution" (as such term is defined in Rule 17Ad-15 under the Securities Exchange Act of 1934, as amended) (each an "Eligible Institution"). Signatures on this Letter of Transmittal need not be guaranteed (i) if this Letter of Transmittal is signed by the registered holder(s) of the Shares (which term, for purposes of this document, shall include any participant in the Book-Entry Transfer Facility whose name appears on a security position listing as the owner of Shares) tendered herewith and such holder(s) has not completed the box entitled "Special Delivery Instructions" or the box entitled "Special Payment Instructions" on this Letter of Transmittal or (ii) if such Shares are tendered for the account of an Eligible Institution. See Instruction 5.

2.    Delivery of Letter of Transmittal and Shares.    This Letter of Transmittal is to be used either if certificates are to be forwarded herewith or, unless an Agent's Message is utilized, if delivery of Shares is to be made by book-entry transfer pursuant to the procedures set forth in Section 3 of the Offer to Purchase. Certificates for all physically delivered Shares, or a confirmation of a book-entry transfer into the Depositary's account at the Book-Entry Transfer Facility of all Shares delivered electronically, as well as a properly completed and duly executed Letter of Transmittal (or facsimile thereof or, in the case of a book-entry transfer, an Agent's Message) and any other documents required by this Letter of Transmittal, must be received by the Depositary at one of its addresses set forth on the front page of this Letter of Transmittal by the Expiration Date. Stockholders who cannot deliver their Shares and all other required documents to the Depositary by the Expiration Date may tender their Shares pursuant to the guaranteed delivery procedure set forth in Section 3 of the Offer to Purchase. Pursuant to such procedure: (i) such tender must be made by or through an Eligible Institution, (ii) a properly completed and duly executed Notice of Guaranteed Delivery substantially in the form provided by Purchaser must be received by the Depositary by the Expiration Date and (iii) the certificates for all physically delivered Shares, or a confirmation of a book-entry transfer into the Depositary's account at the Book-Entry Transfer Facility of all Shares delivered electronically, as well as a properly completed and duly executed Letter of Transmittal (or facsimile thereof or, in the case of a book-entry delivery, an Agent's Message) and any other documents required by this Letter of Transmittal, must be received by the Depositary within three trading days after the date of execution of such Notice of Guaranteed Delivery, all as provided in Section 3 of the Offer to Purchase. A "trading day" is any day on which quotations are available for shares listed on The Nasdaq Stock Market LLC.

The method of delivery of Shares and all other required documents, including through the Book-Entry Transfer Facility, is at the option and risk of the tendering stockholder. If certificates for Shares are sent by mail, registered mail with return receipt requested, properly insured, is recommended. In all cases, sufficient time shall be allowed to ensure timely delivery.

No alternative, conditional or contingent tenders will be accepted, and no fractional Shares will be purchased. By executing this Letter of Transmittal (or facsimile thereof), the tendering stockholder waives any right to receive any notice of the acceptance for payment of the Shares.

3.    Inadequate Space.    If the space provided herein is inadequate, the certificate numbers and/or the number of Shares should be listed on a separate schedule attached hereto.

4.    Partial Tenders (not applicable to stockholders who tender by book-entry transfer).    If fewer than all the Shares represented by any certificate delivered to the Depositary are to be tendered, fill in the number of Shares which are to be tendered in the box entitled "Number of Shares Tendered". In such case, a new certificate for the remainder of the Shares represented by the old certificate will be issued

and sent to the person(s) signing this Letter of Transmittal, unless otherwise provided in the boxes entitled "Special Payment Instructions" or "Special Delivery Instructions", as the case may be, on this Letter of Transmittal, as promptly as practicable following the expiration or termination of the Offer. All Shares represented by certificates delivered to the Depositary will be deemed to have been tendered unless otherwise indicated.

5.    Signatures on Letter of Transmittal; Stock Powers and Endorsements.    If this Letter of Transmittal is signed by the registered holder(s) of the Shares tendered hereby, the signature(s) must correspond with the name(s) as written on the face of the certificates without alteration, enlargement or any change whatsoever.

If any of the Shares tendered hereby is held of record by two or more persons, all such persons must sign this Letter of Transmittal.

If any of the Shares tendered hereby are registered in different names on different certificates, it will be necessary to complete, sign and submit as many separate Letters of Transmittal as there are different registrations of certificates.

If this Letter of Transmittal is signed by the registered holder(s) of the Shares tendered hereby, no endorsements of certificates or separate stock powers are required unless payment of the purchase price is to be made, or Shares not tendered or not purchased are to be returned, in the name of any person other than the registered holder(s). Signatures on any such certificates or stock powers must be guaranteed by an Eligible Institution.

If this Letter of Transmittal is signed by a person other than the registered holder(s) of the Shares tendered hereby, certificates must be endorsed or accompanied by appropriate stock powers, in either case, signed exactly as the name(s) of the registered holder(s) appear(s) on the certificates for such Shares. Signature(s) on any such certificates or stock powers must be guaranteed by an Eligible Institution.

If this Letter of Transmittal or any certificate or stock power is signed by a trustee, executor, administrator, guardian, attorney-in-fact, officer of a corporation or other person acting in a fiduciary or representative capacity, such person should so indicate when signing, and proper evidence satisfactory to Purchaser of the authority of such person so to act must be submitted.

6.    Stock Transfer Taxes.    Purchaser will pay any stock transfer taxes with respect to the sale and transfer of any Shares to it or its order pursuant to the Offer. If, however, payment of the purchase price is to be made to, or Shares not tendered or not purchased are to be returned in the name of, any person other than the registered holder(s), or if a transfer tax is imposed for any reason other than the sale or transfer of Shares to Purchaser pursuant to the Offer, then the amount of any stock transfer taxes (whether imposed on the registered holder(s), such other person or otherwise) will be deducted from the purchase price unless satisfactory evidence of the payment of such taxes, or exemption therefrom, is submitted herewith.

7.    Special Payment and Delivery Instructions.    If the check for the purchase price of any Shares purchased is to be issued, or any Shares not tendered or not purchased are to be returned, in the name of a person other than the person(s) signing this Letter of Transmittal or if the check or any certificates for Shares not tendered or not purchased are to be mailed to someone other than the person(s) signing this Letter of Transmittal or to the person(s) signing this Letter of Transmittal at an address other than that shown above, the appropriate boxes on this Letter of Transmittal should be completed. Stockholders tendering Shares by book-entry transfer may request that Shares not purchased be credited to such account at the Book-Entry Transfer Facility as such stockholder may designate under "Special Payment Instructions". If no such instructions are given, any such Shares not purchased will be returned by crediting the account at the Book-Entry Transfer Facility designated above.

8.    Substitute Form W-9.    Under the U.S. federal income tax laws, the Depositary will be required to withhold 28% of the amount of any payments made to certain stockholders pursuant to the Offer. In order to avoid such backup withholding, each tendering stockholder, and, if applicable, each other

payee, must provide the Depositary with such stockholder's or payee's correct taxpayer identification number and certify that such stockholder or payee is not subject to such backup withholding by completing the Substitute Form W-9 set forth above. In general, if a stockholder or payee is an individual, the taxpayer identification number is the social security number of such individual. If the Depositary is not provided with the correct taxpayer identification number, the stockholder or payee may be subject to a $50 penalty imposed by the Internal Revenue Service. In addition, payments that are made to such stockholder with respect to Shares purchased pursuant to the Offer may be subject to backup withholding. If a stockholder makes a false statement that results in no imposition of backup withholding, and there was no reasonable basis for such statement, a $500 penalty may also be imposed by the Internal Revenue Service, in addition to any criminal penalty provided by law. Certain stockholders or payees (including, among others, corporations and certain foreign individuals) are not subject to these backup withholding and reporting requirements. Exempt stockholders, other than foreign individual stockholders, should furnish their taxpayer identification number, write "exempt" in Part 2 of the Substitute Form W-9 above, sign and date the form, and return it to the Depositary. In order to satisfy the Depositary that a foreign individual qualifies as an exempt recipient, such stockholder or payee must submit a Form W-8BEN Certificate of Foreign Status (or other applicable Form W-8) to the Depositary. Such certificates can be obtained from the Depositary. For further information concerning backup withholding and instructions for completing the Substitute Form W-9 (including how to obtain a taxpayer identification number if you do not have one), consult the enclosed Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9.

Failure to complete the Substitute Form W-9 will not, by itself, cause Shares to be deemed invalidly tendered, but may require the Depositary to withhold 28% of the amount of any payments made pursuant to the Offer. Backup withholding is not an additional federal income tax. Rather, the federal income tax liability of a person subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund may be obtained provided that the required information is furnished to the Internal Revenue Service. Failure to complete and return the Substitute Form W-9 may result in backup withholding of 28% of any payments made to you pursuant to the Offer. Please review the enclosed Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9 for additional details.

9.    Mutilated, Lost, Stolen or Destroyed Certificates.    If the certificate(s) representing Shares to be tendered have been mutilated, lost, stolen or destroyed, stockholders should (i) complete this Letter of Transmittal and check the appropriate box above and (ii) contact the Depositary immediately by calling Computershare Trust Company, N.A. at (781) 575-2879. The Depositary will provide such holder with all necessary forms and instructions to replace any such mutilated, lost, stolen or destroyed certificates. The stockholder may be required to give the Depository, Purchaser or Takeda America a bond as indemnity against any claim that may be made against it with respect to the certificate(s) alleged to have been mutilated, lost, stolen or destroyed.

10.    Waiver of Conditions.    Purchaser reserves the right to waive any of the specified conditions in the Offer in the case of any Shares tendered.

11.    Determination of Validity.    All questions as to the validity, form, eligibility (including time of receipt) and acceptance for payment of any tender of Shares will be determined by Purchaser, in its sole discretion, which determination shall be final and binding on all parties. Purchaser reserves the absolute right to reject any and all tenders determined by it not to be in proper form or the acceptance for payment of which may, in the opinion of its counsel, be unlawful. It also reserves the absolute right to waive any defect or irregularity in the tender of any Shares of any particular stockholder, whether or not similar defects or irregularities are waived in the case of other stockholders.

12.    Requests for Assistance or Additional Copies.    Requests for assistance or additional copies of the Offer to Purchase and this Letter of Transmittal may be obtained from the Information Agent at the address or telephone numbers set forth on the back of this letter.

Important: This Letter of Transmittal (or a facsimile hereof), together with share certificates or confirmation of book-entry transfer or the notice of guaranteed delivery, and all other required documents, must be received by the Depositary on or prior to the Expiration Date.

Questions or requests for assistance or for additional copies of the Offer to Purchase, this Letter of Transmittal or other materials related to the Offer may be directed to The Altman Group, Inc., the Information Agent for the Offer at its respective address and telephone numbers set forth below. Stockholders may also contact their brokers, dealers, banks, trust companies or other nominees for assistance concerning the Offer.

The Dealer Manager for the Offer is:

UBS Securities LLC
299 Park Avenue
New York, NY 10171
Telephone: (877) 211-0850

The Information Agent for the Offer is:

1200 Wall Street West, 3rd Floor
Lyndhurst, New Jersey 07071
Holders call toll-free: (866) 751-6316
Banks and Brokers call: (201) 806-7300
Fax: (201) 460-0050

EX-99.(A)(1)(C)

Exhibit (a)(1)(C)

NOTICE OF GUARANTEED DELIVERY

To Tender Shares of Common Stock
of
MILLENNIUM PHARMACEUTICALS, INC.
Pursuant to the Offer to Purchase
dated April 11, 2008
by
MAHOGANY ACQUISITION CORP.
a wholly-owned subsidiary of
TAKEDA AMERICA HOLDINGS, INC.
a wholly-owned subsidiary of
TAKEDA PHARMACEUTICAL COMPANY LIMITED

        This form, or a substantially equivalent form, must be used to accept the Offer (as defined below) if (i) the certificates representing shares of common stock, par value $0.001 per share (the "Shares"), of Millennium Pharmaceuticals, Inc., a Delaware corporation, are not immediately available, (ii) the procedure for book-entry transfer cannot be completed on a timely basis or (iii) time will not permit all required documents to reach the Depositary prior to the expiration of the Offer. Such form may be delivered by hand or transmitted by facsimile transmission or mail to the Depositary. See Section 3 of the Offer to Purchase.

The Depositary for the Offer is:

By Mail:	By Facsimile Transmission:	By Hand or Overnight Courier:
Computershare Trust Company, N.A.	For Eligible Institutions Only:	Computershare Trust Company, N.A.
c/o Voluntary Corporate Actions	(617) 360-6810	c/o Voluntary Corporate Actions
P.O. Box 43011		250 Royall Street
Providence, RI 02940-3011	For Confirmation Only Telephone:	Canton, MA 02021
	(781) 575-2332

DELIVERY OF THIS NOTICE OF GUARANTEED DELIVERY TO AN ADDRESS OTHER THAN AS SET FORTH ABOVE, OR TRANSMISSION OF INSTRUCTIONS VIA A FACSIMILE NUMBER OTHER THAN AS SET FORTH ABOVE, WILL NOT CONSTITUTE A VALID DELIVERY.

This Notice of Guaranteed Delivery is not to be used to guarantee signatures. If a signature on a Letter of Transmittal is required to be guaranteed by an Eligible Institution under the instructions thereto, such signature guarantee must appear in the applicable space provided in the signature box on the Letter of Transmittal.

o    CHECK HERE IF SHARE CERTIFICATES HAVE BEEN MUTILATED, LOST, STOLEN OR DESTROYED. SEE INSTRUCTION 9 OF THE LETTER OF TRANSMITTAL.

Ladies and Gentlemen:

The undersigned hereby tenders to Mahogany Acquisition Corp. ("Purchaser"), a Delaware corporation and wholly-owned subsidiary of Takeda America Holdings, Inc. ("Takeda America"), which is a New York corporation and wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan, upon the terms and subject to the conditions set forth

in the Offer to Purchase dated April 11, 2008 and the related Letter of Transmittal (which, together with any amendments and supplements thereto, collectively constitute the "Offer"), receipt of which is hereby acknowledged, the shares of common stock, par value $0.001 per share (the "Shares") of Millennium Pharmaceuticals, Inc., a Delaware corporation ("Millennium"), as set forth below pursuant to the guaranteed delivery procedure set forth in Section 3 of the Offer to Purchase.

Number of Shares:
	(Please Type or Print)

Share Certificate Number(s) (if available):

Please check this box is Shares will be tendered by book-entry transfer: o

Account Number:

Date:

Name of Record Holder(s):

Address:

Telephone Number:

Signature(s):

Dated:

GUARANTEE
(Not to be Used for Signature Guarantees)

The undersigned, a firm which is a bank, broker, dealer, credit union, savings association or other entity which is a member in good standing of a recognized Medallion Program approved by the Securities Transfer Association Inc., including the Securities Transfer Agents Medallion Program (STAMP), the Stock Exchange Medallion Program (SEMP) and the New York Stock Exchange, Inc. Medallion Signature Program (MSP) or any other "eligible guarantor institution" (as such term is defined in Rule 17Ad-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), guarantees to deliver to the Depositary the Shares tendered hereby, together with properly completed and duly executed Letter(s) of Transmittal (or facsimile(s) thereof) and certificates for the Shares to be tendered or an Agent's Message (as defined in the Offer to Purchase) in the case of a book-entry delivery, and any other required documents, all within three Nasdaq Global Select Market ("Nasdaq") trading days of the date hereof. Failure to do so could result in a financial loss to the undersigned.

Name of Firm:

Authorized Signature:

Name:
	(Please Type or Print)

Title:

Address:

Telephone Number:

Dated:                         , 2008

NOTE: DO NOT SEND SHARES WITH THIS FORM; SHARES SHOULD BE SENT WITH YOUR LETTER OF TRANSMITTAL SO THAT THEY ARE RECEIVED BY THE DEPOSITARY WITHIN THREE NASDAQ TRADING DAYS AFTER THE DATE OF EXECUTION OF THE NOTICE OF GUARANTEED DELIVERY.

EX-99.(A)(1)(D)

Exhibit (a)(1)(D)

Offer to Purchase for Cash
All Outstanding Shares of Common Stock
of
MILLENNIUM PHARMACEUTICALS, INC.
at
$25.00 Net Per Share
by
MAHOGANY ACQUISITION CORP.
a wholly-owned subsidiary of
TAKEDA AMERICA HOLDINGS, INC.
a wholly-owned subsidiary of
TAKEDA PHARMACEUTICAL COMPANY LIMITED

THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THURSDAY, MAY 8, 2008, UNLESS THE OFFER IS EXTENDED.

April 11, 2008

To Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees:

Mahogany Acquisition Corp. ("Purchaser"), a Delaware corporation and a wholly-owned subsidiary of Takeda America Holdings, Inc. ("Takeda America"), which is a New York corporation and wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan, is making an offer to purchase all outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Millennium Pharmaceuticals, Inc., a Delaware corporation ("Millennium"), at $25.00 per Share, net to the seller in cash, without interest, upon the terms and subject to the conditions set forth in Purchaser's Offer to Purchase dated April 11, 2008, and the related Letter of Transmittal (which, together with any amendments or supplements thereto, collectively constitute the "Offer"). UBS Securities LLC has been appointed to act as the Dealer Manager in connection with the Offer.

For your information and for forwarding to your clients for whom you hold Shares registered in your name or in the name of your nominee, we are enclosing the following documents:

1. Offer to Purchase, dated April 11, 2008;

2. Letter of Transmittal, including a Substitute Form W-9, for your use and for the information of your clients;

3. Notice of Guaranteed Delivery to be used to accept the Offer if the Shares and all other required documents cannot be delivered to Computershare Trust Company, N.A. (the "Depositary") by the expiration of the Offer or if the procedure for book-entry transfer cannot be completed by the expiration of the Offer;

4. A form of letter that may be sent to your clients for whose accounts you hold Shares registered in your name or in the name of your nominee, with space provided for obtaining such clients' instructions with regard to the Offer;

5. Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9 providing information relating to backup federal income tax withholding; and

6. A return envelope addressed to the Depositary, for your use only.

WE REQUEST THAT YOU CONTACT YOUR CLIENTS AS PROMPTLY AS POSSIBLE.

THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THURSDAY, MAY 8, 2008, UNLESS THE OFFER IS EXTENDED.

Purchaser will not pay any fees or commissions to any broker, dealer or other person (other than the Dealer Manager, the Information Agent and the Depositary as described in the Offer to Purchase) for soliciting tenders of Shares pursuant to the Offer. Purchaser will, however, upon request, reimburse brokers, dealers, banks and trust companies for reasonable and necessary costs and expenses incurred by them in forwarding materials to their customers. Purchaser will pay all stock transfer taxes applicable to its purchase of Shares pursuant to the Offer, subject to Instruction 6 of the Letter of Transmittal.

In order to accept the Offer a duly executed and properly completed Letter of Transmittal and any required signature guarantees, or an Agent's Message (as defined in the Offer to Purchase) in connection with a book-entry delivery of Shares, and any other required documents, should be sent to the Depositary by 12:00 midnight, New York City time, at the end of Thursday, May 8, 2008.

Any inquiries you may have with respect to the Offer should be addressed to, and additional copies of the enclosed materials may be obtained from, the Information Agent at the address and telephone numbers set forth on the back cover of the Offer to Purchase.

Very truly yours,

UBS Securities LLC

NOTHING CONTAINED HEREIN OR IN THE ENCLOSED DOCUMENTS SHALL CONSTITUTE YOU THE AGENT OF MAHOGANY ACQUISITION CORP. OR ANY OF ITS AFFILIATES, THE DEALER MANAGER, THE INFORMATION AGENT OR THE DEPOSITARY, OR AUTHORIZE YOU OR ANY OTHER PERSON TO USE ANY DOCUMENT OR MAKE ANY STATEMENT ON BEHALF OF ANY OF THEM IN CONNECTION WITH THE OFFER OTHER THAN THE DOCUMENTS ENCLOSED HEREWITH AND THE STATEMENTS CONTAINED THEREIN.

EX-99.(A)(1)(E)

Exhibit (a)(1)(E)

Offer to Purchase for Cash
All Outstanding Shares of Common Stock
of
MILLENNIUM PHARMACEUTICALS, INC.
at
$25.00 Net Per Share
by
MAHOGANY ACQUISITION CORP.
a wholly-owned subsidiary of
TAKEDA AMERICA HOLDINGS, INC.
a wholly-owned subsidiary of
TAKEDA PHARMACEUTICAL COMPANY LIMITED

THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THURSDAY, MAY 8, 2008, UNLESS THE OFFER IS EXTENDED.

April 11, 2008

To Our Clients:

Enclosed for your consideration are the Offer to Purchase dated April 11, 2008 and the related Letter of Transmittal (which, together with any amendments or supplements thereto, collectively constitute the "Offer") in connection with the offer by Mahogany Acquisition Corp. ("Purchaser"), a Delaware corporation and a wholly-owned subsidiary of Takeda America Holdings, Inc. ("Takeda America"), which is a New York corporation and wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan, to purchase for cash all outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Millennium Pharmaceuticals, Inc., a Delaware corporation ("Millennium"). We are the holder of record of Shares held for your account. A tender of such Shares can be made only by us as the holder of record and pursuant to your instructions. The Letter of Transmittal is furnished to you for your information only and cannot be used by you to tender Shares held by us for your account.

We request instructions as to whether you wish us to tender any or all of the Shares held by us for your account, upon the terms and subject to the conditions set forth in the Offer to Purchase and the Letter of Transmittal.

Your attention is directed to the following:

1.

The tender price is $25.00 per Share, net to you in cash without interest, less any required withholding tax.

2.

The Offer and withdrawal rights expire at 12:00 midnight, New York City time, at the end of Thursday, May 8, 2008, unless extended (as extended, the "Expiration Date").

3.

The Offer is conditioned upon, among other things, the condition that, prior to the Expiration Date, the number of Shares validly tendered in accordance with the terms of the Offer and not properly withdrawn, together with all other Shares beneficially owned by Purchaser and its affiliates, shall equal at least a majority of the Shares then outstanding on the date of purchase (as determined on a fully-diluted basis).

4.

Any stock transfer taxes applicable to the sale of Shares to Purchaser pursuant to the Offer will be paid by Purchaser, except as otherwise provided in Instruction 6 of the Letter of Transmittal.

If you wish to have us tender any or all of your Shares, please so instruct us by completing, executing, detaching and returning to us the instruction form below. An envelope to return your instructions to us is enclosed. If you authorize tender of your Shares, all such Shares will be tendered unless otherwise specified on the instruction form. Your instructions should be forwarded to us in ample time to permit us to submit a tender on your behalf by the Expiration Date.

The Offer is not being made to, nor will tenders be accepted from or on behalf of, holders of Shares in any jurisdiction in which the making of the Offer or acceptance thereof would not be in compliance with the laws of such jurisdiction.

Payment for Shares purchased pursuant to the Offer will in all cases be made only after timely receipt by Computershare Trust Company, N.A. (the "Depositary") of (i) certificates representing the Shares tendered or timely confirmation of the book-entry transfer of such Shares into the account maintained by the Depositary at The Depository Trust Company (the "Book-Entry Transfer Facility"), pursuant to the procedures set forth in Section 3 of the Offer to Purchase, (ii) the Letter of Transmittal (or a facsimile thereof), properly completed and duly executed, with any required signature guarantees or an Agent's Message (as defined in the Offer to Purchase), in connection with a book-entry delivery, and (iii) any other documents required by the Letter of Transmittal. Accordingly, payment may not be made to all tendering stockholders at the same time depending upon when certificates for or confirmations of book-entry transfer of such Shares into the Depositary's account at the Book-Entry Transfer Facility are actually received by the Depositary.

Instruction Form with Respect to
Offer to Purchase for Cash
All Outstanding Shares of Common Stock
of
Millennium Pharmaceuticals, Inc.
by
Mahogany Acquisition Corp.
a wholly-owned subsidiary of
Takeda America Holdings, Inc.
a wholly-owned subsidiary of
Takeda Pharmaceutical Company Limited

The undersigned acknowledge(s) receipt of your letter and the enclosed Offer to Purchase dated April 11, 2008, and the related Letter of Transmittal, in connection with the offer by Mahogany Acquisition Corp. to purchase all outstanding shares of common stock, par value $0.001 per share (the "Shares") of Millennium Pharmaceuticals, Inc.

This will instruct you to tender the number of Shares indicated below held by you for the account of the undersigned, upon the terms and subject to the conditions set forth in the Offer to Purchase and the related Letter of Transmittal.

Number of Shares to be Tendered:

Account Number:

Dated:

* Unless otherwise indicated, we are authorized to tender all Shares held by us for your account.

PLEASE SIGN HERE

Signature(s):

Name(s) (Please Print):

Address:

Zip Code:

Area Code and Telephone No.:

Tax Identification or Social Security No.:

My Account Number With You:

Date:

EX-99.(A)(1)(F)

Exhibit (a)(1)(F)

GUIDELINES FOR CERTIFICATION OF TAXPAYER
IDENTIFICATION NUMBER ON SUBSTITUTE FORM W-9

Guidelines for Determining the Proper Identification Number to Give the Payer—Social Security numbers have nine digits separated by two hyphens: i.e., 000-00-0000. Employer identification numbers have nine digits separated by only one hyphen: i.e., 00-0000000. The table below will help determine the number to give the payer.

For this type of account			Give the SOCIAL SECURITY number of:
1.	An individual's account		The individual
2.	Two or more individuals (joint account)		The actual owner of the account or, if combined funds, the first individual on the account(1)
3.	Custodian account of a minor (Uniform Gift to Minors Act)		The minor(2)
4.	a.	The usual revocable savings trust account (grantor is also trustee)	The grantor-trustee(1)
	b.	So-called trust account that is not a legal or valid trust under State law	The actual owner(1)
5.	Sole proprietorship or single-owner LLC account		The owner(3)

For this type of account		Give the EMPLOYER IDENTIFICATION number of:
6.	Sole proprietorship or single-owner LLC account	The owner(3)
7.	A valid trust, estate, or pension trust	Legal entity(4)
8.	Corporate account or LLC electing corporate status	The corporation
9.	Association, club, religious, charitable, educational or other tax-exempt organization	The organization
10.	Partnership or multi-member LLC	The partnership
11.	A broker or registered nominee	The broker or nominee
12.	Account with the Department of Agriculture in the name of a public entity (such as a State or local government, school district or prison) that receives agricultural program payments	The public entity

1

List first and circle the name of the person whose number you furnish. If only one person on a joint account has a social security number, that person's number must be furnished.

2

Circle the minor's name and furnish the minor's social security number.

3

You must show your individual name, but you may also enter your business or "doing business as" name. You may use either your social security number or employer identification number (if you have one).

4

List first and circle the name of the legal trust, estate, or pension trust. (Do not furnish the identifying number of the personal representative or trustee unless the legal entity itself is not designated in the account title.)

Note: If no name is circled when more than one name is listed, the number will be considered to be that of the first name listed.

How to Obtain a TIN

If you don't have a taxpayer identification number or you don't know your number, obtain Form SS-5, Application for a Social Security Number Card, or Form SS-4, Application for Employer Identification Number, at the local office of the Social Security Administration or the Internal Revenue Service ("IRS") and apply for a number. If you have applied for a taxpayer identification number or you intend to apply for one soon, write "Applied For" in the space for the taxpayer identification number, sign and date the Substitute Form W-9, and return it to the Depositary.

Payees Exempt from Backup Withholding

Payees exempt from backup withholding on all payments include the following:

1.

An organization exempt from tax under section 501(a), any IRA, or a custodial account under section 403(b)(7) if the account satisfies the requirements of Section 401(f)(2).

2.

The United States or any of its agencies or instrumentalities.

3.

A state, the District of Columbia, a possession of the United States, or any of their political subdivisions or instrumentalities.

4.

A foreign government or any of its political subdivisions, agencies, or instrumentalities.

5.

An international organization or any of its agencies or instrumentalities.

Other payees that may be exempt from backup withholding include:

6.

A corporation.

7.

A foreign central bank of issue.

8.

A dealer in securities or commodities required to register in the United States, the District of Columbia, or a possession of the United States.

9.

A futures commission merchant registered with the Commodity Futures Trading Commission.

10.

A real estate investment trust.

11.

An entity registered at all times during the tax year under the Investment Company Act of 1940.

12.

A common trust fund operated by a bank under section 584(a).

13.

A financial institution.

14.

A middleman known in the investment community as a nominee or custodian.

15.

A trust exempt from tax under section 664 or described in section 4947.

The chart below shows two of the types of payments that may be exempt from backup withholding. The chart applies to the exempt recipients listed above, 1 through 15.

IF the payment is for . . .	THEN the payment is exempt for . . .
Interest and dividend payments	All exempt recipients except for 9
Broker transactions	Exempt recipients 1 through 13; also, a person who regularly acts as a broker and who is registered under the Investment Advisers Act of 1940

Exempt payees should file the Substitute Form W-9 to avoid possible erroneous backup withholding. FURNISH YOUR TAXPAYER IDENTIFICATION NUMBER, WRITE "EXEMPT" IN PART 2 OF THE SUBSTITUTE FORM W-9, SIGN AND DATE THE FORM, AND RETURN IT TO THE DEPOSITARY. Foreign payees who are not subject to backup withholding should complete the appropriate IRS Form W-8 and return it to the Depositary.

Privacy Act Notice

Section 6109 requires most recipients of dividend, interest or other payments to give their correct taxpayer identification numbers to payers who must report the payments to the IRS. The IRS uses the numbers for identification purposes and to help verify the accuracy of tax returns. It may also provide this information to the Department of Justice for civil and criminal litigation, and to cities, states, the District of Columbia, and U.S. possessions to carry out their tax laws. It may also disclose this information to other countries under a tax treaty, to federal and state agencies to enforce federal nontax criminal laws, and to federal law enforcement and intelligence agencies to combat terrorism.

Payees must provide payers with their taxpayer identification numbers whether or not they are required to file tax returns. Payers must generally withhold 28% of taxable interest, dividend and certain other payments to a payee who does not furnish a taxpayer identification number to a payer. Certain penalties may also apply.

Penalties

(1)

Penalty for Failure to Furnish Taxpayer Identification Number—If you fail to furnish your correct taxpayer identification number to a payer, you are subject to a penalty of $50 for each such failure unless your failure is due to reasonable cause and not to willful neglect.

(2)

Civil Penalty for False Information With Respect to Withholding—If you make a false statement with no reasonable basis which results in no imposition of backup withholding, you are subject to a penalty of $500.

(3)

Criminal Penalty for Falsifying Information—Willfully falsifying certifications or affirmations may subject you to criminal penalties including fines and/or imprisonment.

FOR ADDITIONAL INFORMATION CONTACT YOUR TAX CONSULTANT OR THE INTERNAL REVENUE SERVICE.

EX-99.(A)(1)(G)

Exhibit (a)(1)(G)

This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase dated April 11, 2008, and the related Letter of Transmittal, and any amendments or supplements thereto, and is being made to all holders of Shares. Purchaser (as defined below) is not aware of any jurisdiction where the making of the Offer or the tender of Shares in connection therewith would not be in compliance with the laws of such jurisdiction. If Purchaser becomes aware of any jurisdiction in which the making of the Offer or the tender of Shares in connection therewith would not be in compliance with applicable law of such jurisdiction, Purchaser will make a good faith effort to comply with any such law. If, after such good faith effort, Purchaser cannot comply with any such law, the Offer will not be made to, nor will tenders be accepted from or on behalf of, holders of Shares in such jurisdiction. In any jurisdiction where the securities, blue sky, or other laws require that the Offer be made by a licensed broker or dealer, the Offer shall be deemed to be made on behalf of Purchaser by one or more registered brokers or dealers licensed under the laws of that jurisdiction.

Notice of Offer to Purchase for Cash
All Outstanding Shares of Common Stock
of
MILLENNIUM PHARMACEUTICALS, INC.
at $25.00 Net Per Share
by
MAHOGANY ACQUISITION CORP.
a wholly-owned subsidiary of
TAKEDA AMERICA HOLDINGS, INC.
a wholly-owned subsidiary of
TAKEDA PHARMACEUTICAL COMPANY LIMITED

        Mahogany Acquisition Corp. ("Purchaser"), a Delaware corporation and wholly-owned subsidiary of Takeda America Holdings, Inc. ("Takeda America"), which is a New York corporation and wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan ("TPC"), is offering to purchase all outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Millennium Pharmaceuticals, Inc., a Delaware corporation ("Millennium"), at a purchase price of $25.00 per Share, net to the seller in cash, without interest thereon and subject to any required withholding of taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase dated April 11, 2008 (the "Offer to Purchase") and in the related Letter of Transmittal (which, together with any amendments or supplements thereto, collectively constitute the "Offer"). Following the Offer, Purchaser intends to effect the Merger (as defined below).

THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME,
AT THE END OF THURSDAY, MAY 8, 2008, UNLESS THE OFFER IS EXTENDED.

        The Offer is conditioned upon, among other things, (i) there being validly tendered and not properly withdrawn a number of Shares that, when considered together with all other Shares beneficially owned by TPC, Takeda America and their respective subsidiaries, equals at least a majority of the Shares outstanding on the date of purchase (on a fully diluted basis) (the "Minimum Tender Condition") and (ii) expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, and the regulations promulgated thereunder and any approvals or clearances applicable to the Offer or the consummation of the Merger under certain applicable foreign anti-trust laws. The Offer is also subject to the other conditions described in the Offer to Purchase. The Offer is not conditioned upon TPC, Takeda America or Purchaser obtaining financing. The Offer is being made pursuant to an Agreement and Plan of Merger, dated as of April 10, 2008 (the "Merger Agreement"), by and among Millennium, Purchaser, Takeda America and TPC, under which, after completion of the Offer and the satisfaction or waiver of certain conditions, Purchaser will be merged with and into Millennium, with Millennium surviving as a wholly-owned subsidiary of Takeda America (the "Merger"). At the Effective Time (as defined in the Merger Agreement) of the Merger, each Share (other than Shares held by Millennium, Purchaser, Takeda America or TPC or by stockholders who properly exercise their appraisal rights available under

Delaware law in connection with the Merger) will be canceled and converted into the right to receive $25.00 per Share (or any higher price paid in the Offer), in cash, without interest and subject to any required withholding of taxes.

        The Millennium Board of Directors, among other things, has unanimously (i) approved and declared advisable, the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, (ii) determined that the terms of the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are fair to and in the best interests of Millennium and the stockholders of Millennium and (iii) recommended that the holders of the Shares accept the Offer and tender their Shares pursuant to the Offer and, if necessary, adopt the Merger Agreement.

        If at the scheduled expiration date any condition to the Offer (including the Minimum Tender Condition) is not satisfied or waived, then Purchaser must extend the Offer and the expiration date (in intervals of not more than ten business days) until the earlier of (i) the date on which all conditions, including the Minimum Tender Condition, are satisfied, and (ii) October 31, 2008, at which time either Purchaser or Millennium may terminate the Offer.

        Pursuant to the Merger Agreement, following Purchaser's acceptance of Shares tendered in the Offer, Purchaser may, without the consent of Millennium, initiate a subsequent offering period in accordance with Rule 14d-11 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") for up to 20 business days if at the commencement of such subsequent offering period, the number of Shares owned by TPC, Takeda America, Purchaser and their subsidiaries represent less than 90% of the outstanding number of Shares. The Merger Agreement obligates Purchaser to provide for a subsequent offering period of at least ten business days, if requested by Millennium, in the event that, at the Acceptance Time (as defined in the Merger Agreement) TPC, Takeda America, Purchaser and their subsidiaries own more than 80% but less than 90% of the Shares outstanding at the time (inclusive of shares issuable pursuant to the Top-Up Option (as defined in the Merger Agreement)). Purchaser is required pursuant to the Merger Agreement as promptly as practicable to accept and pay for Shares validly tendered during the subsequent offering period.

        If Purchaser extends the Offer, Purchaser will inform Computershare Trust Company, N.A. (the "Depositary") of the extension, and will make a related public announcement, not later than 9:00 a.m., New York City time, on the next business day after the day on which the Offer was scheduled to expire. For purposes of the Offer (including during a subsequent offering period), Purchaser will be deemed to have accepted for payment Shares validly tendered and not withdrawn, if and when Purchaser gives oral or written notice to the Depositary of Purchaser's acceptance of or payment for Shares pursuant to the Offer. Payment for Shares accepted for payment pursuant to the Offer will be made by deposit of the Offer Price with the Depositary, which will act as the agent for holders of tendered Shares for the purpose of receiving payments from Purchaser and transmitting those payments to such holders. If Purchaser extends the Offer, is delayed in its acceptance of or payment for Shares or is unable to accept for payment or pay for Shares pursuant to the Offer for any reason, then, without prejudice to Purchaser's rights under the Offer, the Depositary may, nevertheless, on Purchaser's behalf, retain the tendered Shares, and such Shares may not be withdrawn except to the extent that stockholders are entitled to withdrawal rights in accordance with the Merger Agreement or as otherwise required by Rule 14e-1(c) promulgated under the Exchange Act. Under no circumstances will interest on the purchase price for Shares be paid, regardless of any delay in making such payment.

        In all cases, payment for Shares tendered and accepted for payment pursuant to the Offer will be made only after timely receipt by the Depositary of (i) certificates representing such Shares (or a confirmation of a book-entry transfer of such Shares into the Depositary's account or an affidavit of loss relating to such certificates), (ii) a properly completed and duly executed Letter of Transmittal (or a manually signed facsimile thereof), with all required signature guarantees (or, in the case of a book-entry transfer, an Agent's Message (as defined in the Offer to Purchase) in lieu of a Letter of Transmittal) and (iii) any other documents required by the Letter of Transmittal.

        Tenders of Shares made pursuant to the Offer may be withdrawn at any time prior to the expiration of the Offer. Thereafter, such tenders are irrevocable, except that they may be withdrawn after Monday, June 9, 2008, unless such Shares have been accepted for payment as provided in the Offer to Purchase. To withdraw tendered Shares, a written or facsimile transmission notice of withdrawal with respect to such Shares must be timely received by the Depositary at one of its addresses set forth on the back cover of the Offer to Purchase, and the notice of withdrawal must specify the name of the person who tendered the Shares to be withdrawn, the number of Shares to be withdrawn and the name of the registered holder of Shares, if different from that of the person who tendered such Shares. If the Shares to be withdrawn have been delivered to the Depositary, a signed notice of withdrawal with (except in the case of Shares tendered by an Eligible Institution (as defined in the Offer to Purchase)) signatures guaranteed by an Eligible Institution must be submitted prior to the release of such Shares. In addition, such notice must specify, in the case of Shares tendered by delivery of certificates, the name of the registered holder (if different from that of the tendering stockholder) and the serial numbers shown on the particular certificates evidencing the Shares to be withdrawn or, in the case of Shares tendered by book-entry transfer, the name and number of the account at the Book-Entry Transfer Facility to be credited with the withdrawn Shares.

        The information required to be disclosed by paragraph (d)(1) of Rule 14d-6 of the General Rules and Regulations under the Exchange Act is contained in the Offer to Purchase and the related Letter of Transmittal and is incorporated herein by reference.

        Millennium has provided Purchaser with its stockholder list and security position listings for the purpose of disseminating the Offer to holders of Shares. The Offer to Purchase and the related Letter of Transmittal will be mailed to record holders of Shares and will be furnished to brokers, banks and similar persons whose names, or the names of whose nominees, appear on the stockholder list or, if applicable, who are listed as participants in a clearing agency's security position listing for subsequent transmittal to beneficial owners of Shares.

The Offer to Purchase and the related Letter of Transmittal contain important information. Stockholders should carefully read both in their entirety before any decision is made with respect to the Offer.

        Any questions or requests for assistance may be directed to the Information Agent at the telephone numbers and address set forth below. Requests for copies of the Offer to Purchase and the related Letter of Transmittal and other tender offer materials may be directed to the Information Agent as set forth below, and copies will be furnished promptly at Purchaser's expense. Stockholders may also contact their broker, dealer, commercial bank, trust company or nominee for assistance concerning the Offer. To confirm delivery of Shares, stockholders are directed to contact the Depositary, Computershare Trust Company, N.A.

The Dealer Manager for the Offer is:

UBS Securities LLC
299 Park Avenue
New York, NY 10171
Telephone: (877) 211-0850

The Information Agent for the Offer is:

1200 Wall Street West, 3rd Floor
Lyndhurst, New Jersey 07071
Holders call toll-free: (866) 751-6316
Banks and Brokers call: (201) 806-7300
Fax: (201) 460-0050

April 11, 2008

EX-99.(A)(5)

Exhibit A(5)

FOR RELEASE FRIDAY, APRIL 11, 2008

Investor Contact:	Media Contact:
Tomoyuki Ooue (011-81) 3-3278-2301 ooue_tomoyuki@takeda.com	Matt Kuhn (224) 554-5609 mkuhn@tpna.com

TAKEDA COMMENCES CASH TENDER OFFER FOR ALL OUTSTANDING
SHARES OF MILLENNIUM

OSAKA, Japan, and NEW YORK, New York., USA, April 11, 2008—Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) today announced the commencement of its cash tender offer for all outstanding shares of the common stock of Millennium Pharmaceuticals, Inc. ("Millennium", NASDAQ: MLNM) for US$25.00 per share. The tender offer is being made by Mahogany Acquisition Corp., a wholly owned subsidiary of Takeda America Holdings, Inc., which is a wholly owned subsidiary of Takeda, pursuant to an Offer to Purchase, dated April 11, 2008, and the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 10, 2008, by and among Takeda America Holdings, Inc., Mahogany Acquisition Corp., and Millennium. Takeda is also a party to the Merger Agreement for certain purposes.

The tender offer is scheduled to expire at 12:00 midnight (New York City Time) at the end of Thursday, May 8, 2008, unless the tender offer is extended. Following the completion of the tender offer and, if required, receipt of approval by Millennium's stockholders, Takeda expects to consummate a merger of Mahogany Acquisition Corp. and Millennium in which shares of Millennium that have not been purchased in the tender offer will be converted into the right to receive the same cash price per share as paid in the tender offer. The tender offer and the merger are subject to customary closing conditions, including the acquisition by Mahogany Acquisition Corp. in the tender offer of a majority of Millennium's outstanding shares on a fully-diluted basis and the expiration or early termination of the waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and certain specified foreign antitrust laws.

The Depositary for the tender offer is Computershare Trust Company, N.A., the Dealer Manager for the tender offer is UBS Investment Bank, and the Information Agent for the tender offer is The Altman Group.

About Takeda

Founded in 1781 and located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

Forward-Looking Statements

This press release contains "forward-looking statements" that involve significant risks and uncertainties. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including statements regarding the ability to complete the transaction considering the various closing conditions; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause results to differ from expectations include: uncertainties as to the timing of the tender offer and

Page 1

merger; uncertainties as to how many of the Millennium stockholders will tender their stock in the offer; the risk that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, licensees, other business partners or governmental entities; other business effects, including the effects of industry, economic or political conditions outside of Takeda's control; transaction costs; actual or contingent liabilities; and other risks and uncertainties discussed in the tender offer documents filed by Mahogany Acquisition Corp. with the Securities and Exchange Commission and the Solicitation/Recommendation Statement to be filed by Millennium. Takeda undertakes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise.

Important Additional Information Has Been Filed with the Securities and Exchange Commission ("SEC")

The tender offer described in this news release has commenced, but this news release is neither an offer to purchase nor a solicitation of an offer to sell shares of Millennium's common stock. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT AND THE SOLICITATION/RECOMMENDATION STATEMENT REGARDING THE TENDER OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION. The tender offer statement has been or promptly will be filed by Mahogany Acquisition Corp. with the SEC, and the solicitation/recommendation statement has been or promptly will be filed by Millennium with the SEC. Investors and security holders may obtain a free copy of these statements and other documents filed by Mahogany Acquisition Corp. or Millennium with the SEC at the website maintained by the SEC at www.sec.gov. The tender offer statement and related materials, solicitation/recommendation statement, and such other documents may be obtained for free by directing such requests to The Altman Group, the information agent for the tender offer, at 1-201-806-7300 for banks and brokers or 1-866-751-6316 for shareholders and all others.

###

Page 2

EX-99.(D)(2)

Exhibit (d)(2)

TENDER AND SUPPORT AGREEMENT

This TENDER AND SUPPORT AGREEMENT (this “Agreement”), is dated as of April 10, 2008, by and between TAKEDA AMERICA HOLDINGS, INC., a New York corporation (the “Parent”), and the stockholders listed on the signature pages hereto (each a “Stockholder” and collectively, the “Stockholders”).

W I T N E S S E T H:

WHEREAS, Parent, Mahogany Acquisition Corp., a Delaware corporation and indirectly wholly-owned subsidiary of Parent (the “Purchaser”), and Millennium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), are entering into an Agreement and Plan of Merger, dated as of the date hereof (as it may be amended from time to time in accordance with its terms, the “Merger Agreement”), providing for, among other things, Purchaser to commence a cash tender offer (the “Offer”) to acquire all of the outstanding shares of common stock, par value $0.001 per share, of the Company (the “Company Common Stock”) followed by the subsequent merger of Purchaser with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent, in each case, on the terms and subject to the conditions set forth therein (capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Merger Agreement); and

WHEREAS, as of the date hereof, each Stockholder is the beneficial owner of the number of issued shares of Company Common Stock set forth on Attachment A hereto (the “Owned Shares”); and

WHEREAS, as a condition to Parent and Purchaser’s willingness to enter into and perform its obligations under the Merger Agreement, Parent and Purchaser have required that each Stockholder agree, and each Stockholder has agreed, to tender in the Offer (and not withdraw) all of such Stockholder’s Owned Shares as well as any shares of Company Common Stock acquired by such Stockholder after the execution of this Agreement (all of which, after so acquired, shall constitute “Owned Shares”); and

WHEREAS, each Stockholder desires to express its support for the Merger Agreement and the transactions contemplated thereby, including the Offer, by executing this Agreement;

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration given to each party hereto, the receipt of which is hereby acknowledged, the parties agree as follows:

1.      Agreement to Tender and Vote; Irrevocable Proxy.

1.1     Agreement to Tender.  Each Stockholder hereby agrees that promptly after the commencement of the Offer, but in any event no later than 5:00 p.m. New York time on the second Business Day before the initially scheduled expiration of the Offer, such Stockholder shall tender into the Offer all of such Stockholder’s Owned Shares.  No Stockholder shall withdraw any of such Stockholder’s Owned Shares previously tendered.

1.2     Agreement to Vote. Each Stockholder hereby agrees that, during the time this Agreement is in effect, at any meeting of the stockholders of the Company, however called, or any adjournment or postponement thereof, such Stockholder shall be present (in person or by proxy) and vote (or cause to be voted) all of its Owned Shares (a) in favor of the adoption of the Merger Agreement and (b) against any alternative Takeover Proposal.

1.3     Irrevocable Proxy. Solely with respect to the matters described in Section 1.2, for so long as this Agreement has not terminated in accordance with Section 4.1, each Stockholder hereby irrevocably appoints Parent (or any nominee of Parent) as its attorney and proxy with full power of substitution and resubstitution, to the full extent of such Stockholder’s voting rights with respect to such Stockholder’s Owned Shares (which proxy is irrevocable and which appointment is coupled with an interest, including for purposes of Section 212 of the Delaware General Corporation Law) to vote all such Stockholder’s Owned Shares solely on the matters described in Section 1.2, and in accordance therewith. Each Stockholder hereby revokes any proxies previously granted that would otherwise conflict with the proxy contemplated pursuant to this Section 1.3 and agrees to execute any further agreement or form reasonably necessary or appropriate to confirm and effectuate the grant of the proxy contained herein. Such proxy shall automatically terminate upon the valid termination of this Agreement in accordance with Section 4.1.

2.      Representations and Warranties of Stockholders.  Each Stockholder hereby represents and warrants to Parent, on a several and not joint basis, as follows:

2.1     Due Organization.  Such Stockholder, if a corporation or other entity, has been duly organized, is validly existing and is in good standing under the laws of the state of its formation or organization.

2.2     Power; Due Authorization; Binding Agreement.  Such Stockholder has full legal capacity, power and authority to execute and deliver this Agreement, to perform his, her or its obligations hereunder and to consummate the transactions contemplated hereby.  This Agreement has been duly and validly executed and delivered by such Stockholder and constitutes a valid and binding agreement of such Stockholder, enforceable against such Stockholder in accordance with its terms, except to the extent that enforceability may be subject to the effect of any applicable bankruptcy, reorganization, insolvency, moratorium or other similar laws affecting or relating to the enforcement of creditors rights generally and to general principles of equity.

2.3     Ownership of Shares.  On the date hereof, the Owned Shares set forth opposite such Stockholder’s name on Attachment A hereto are owned of record or beneficially by such Stockholder in the manner reflected thereon and include all of the Owned Shares owned of record or beneficially by such Stockholder.

2.4     No Conflicts.  The execution and delivery of this Agreement by such Stockholder does not, and the performance of the terms of this Agreement by such Stockholder will not, (a) require such Stockholder to obtain the consent or approval of, or make any filing with or notification to, any Governmental Authority, (b) require the consent or approval of any other Person pursuant to any agreement, obligation or instrument binding on such Stockholder or

2

his, her or its properties and assets or (c) conflict with or violate any organizational document or law, rule, regulation, order, judgment or decree applicable to such Stockholder or pursuant to which any of his, her or its properties or assets are bound.  The Owned Shares are not, with respect to the voting or transfer thereof, subject to any other agreement, including any voting agreement, stockholders agreement, irrevocable proxy or voting trust.

3.      Certain Covenants of the Stockholders.  Each Stockholder hereby covenants and agrees with Parent as follows:

3.1     Restriction on Transfer.  Each Stockholder hereby agrees, while this Agreement is in effect, at any time prior to the Acceptance Time, and otherwise as is contemplated by the Merger Agreement or the Offer, not to, other than as may be specifically required by a court order, (a) assign or otherwise dispose of (including, without limitation, by gift, merger, consolidation or reorganization), or enter into any contract, option or other agreement providing for the sale, transfer, pledge, encumbrance, assignment or other disposition of, or limitation on the voting rights of, any of the Owned Shares (any such action, a “Transfer”) or (b) grant any proxies or powers of attorney, deposit any Owned Shares into a voting trust or enter into a voting agreement with respect to any Owned Shares.  The foregoing restrictions on Transfer shall not prohibit the exercise by such Stockholder of any options to purchase Owned Shares and shall not prohibit any Transfers for estate planning or charitable purposes provided the transferee and such Stockholder expressly agree to be bound by the provisions of this Agreement with respect to such transferred Owned Shares in a written instrument reasonably satisfactory to Parent.  If any involuntary Transfer of any of the Owned Shares shall occur (including, but not limited to, a sale by a Stockholder’s trustee in any bankruptcy, or a sale to a purchaser at any creditor’s or court sale or any sale or transfer by operation of law, including, without limitation, by will or intestacy), the transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial transferee) shall take and hold such Owned Shares subject to all of the restrictions, liabilities and rights under this Agreement, which shall continue in full force and effect until valid termination of this Agreement.

3.2     Additional Shares.  Each Stockholder hereby agrees, while this Agreement is in effect, that any shares of Company Common Stock acquired by such Stockholder after the date hereof shall be subject to the terms of this Agreement as though owned by such Stockholder on the date hereof.

3.3     No Limitations on Actions.  Each Stockholder signs this Agreement solely in his, her or its capacity as the owner of the Owned Shares; any trustee who signs this Agreement on behalf of a Stockholder that is a trust is signing only in his, her or its fiduciary capacity and not as an individual; this Agreement shall not limit or otherwise affect the actions of such Stockholder or any affiliate, employee or designee of such Stockholder or any of his, her or its affiliates in any other capacity, including such person’s capacity, if any, as an officer of the Company or a member of the board of directors of the Company; and nothing herein shall limit or affect the Company’s rights in connection with the Merger Agreement.

3

4.      Miscellaneous.

4.1     Termination of this Agreement.  This Agreement shall terminate upon the first to occur of (i) the termination of the Merger Agreement in accordance with its terms, (ii) any amendment to the Merger Agreement or the Offer effected without such Stockholder’s consent that decreases the Offer Price or materially and adversely affects such Stockholder and (iii) the Acceptance Time.

4.2     Effect of Termination.  In the event of a termination of this Agreement pursuant to Section 4.1, this Agreement shall become void and of no effect with no liability on the part of any party hereto; provided, however, no such termination shall relieve any party hereto from any liability for any breach of this Agreement occurring prior to such termination; and provided, further, that upon payment of the Termination Fee no Stockholder shall have further liability with respect to this Agreement or the transactions contemplated hereby.

4.3     Entire Agreement; Assignment.  This Agreement constitutes the entire agreement among the parties with respect to the subject matter hereof and supersedes all other prior agreements and understandings, both written and oral, among the parties with respect to the subject matter hereof.  Nothing in this Agreement, express or implied, is intended to or shall confer upon any other person or entity any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.  This Agreement shall not be assigned by operation of law or otherwise and shall be binding upon and inure solely to the benefit of each party hereto.

4.4     Amendments.  This Agreement may not be modified, amended, altered or supplemented, except upon the execution and delivery of a written agreement executed by each of the parties hereto.

4.5     Notices.  Any notice required to be given hereunder shall be sufficient if in writing, and sent by facsimile transmission (provided that any notice received by facsimile transmission or otherwise at the addressee’s location on any Business Day after 5:00 p.m. (addressee’s local time) shall be deemed to have been received at 9:00 a.m. (addressee’s local time) on the next Business Day), by reliable overnight delivery service (with proof of service), hand delivery or certified or registered mail (return receipt requested and first-class postage prepaid), addressed as follows:

If to the Stockholders:

To the respective addresses and fax numbers shown on the signature pages for each Stockholder

If to Parent:

Takeda Pharmaceutical Company Limited

Tokyo Head Office

12-10 Nihonbashi 2 – Chome
Chuo-Ku
Tokyo 103-8668
Japan
Facsimile:  81-3-3278 – 2323
Telephone:  81-3-3278-2287

Attention:  Ken Araki, Senior Director (Business Development) of Global Licensing & Business Development Department

4

and

Takeda Pharmaceutical Company Limited

Tokyo Head Office
12-10 Nihonbashi 2 – Chome
Chuo-Ku
Tokyo 103-8668
Japan
Facsimile: 81-3-3728-2077
Telephone:  81-3-3278-2924
Attention: Hiroshi Shinha, General Manager of Legal Department

with copies to:

Edwards Angell Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA  02199
Attention:    Bruce W. Raphael, Esq.
and Leonard Q. Slap, Esq.
Facsimile: 617-227-4420

or to such other address as any party shall specify by written notice so given, and such notice shall be deemed to have been delivered as of the date so telecommunicated, personally delivered or received.  Any party to this Agreement may notify any other party of any changes to the address or any of the other details specified in this paragraph; provided, however, that such notification shall only be effective on the date specified in such notice or two Business Days after the notice is given, whichever is later.  Rejection or other refusal to accept or the inability to deliver because of changed address of which no notice was given shall be deemed to be receipt of the notice as of the date of such rejection, refusal or inability to deliver.

4.6     Governing Law.  This Agreement shall be governed by, and construed in accordance with, the Laws of the State of Delaware, without giving effect to conflicts of laws principles that would result in the application of the Law of any other state.

4.7     Specific Performance.  The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with its specific terms or were otherwise breached.  Each Stockholder agrees that, in the event of any breach or threatened breach by such Stockholder of any covenant or obligation contained in this Agreement, Parent shall be entitled (in addition to any other remedy that may be available to it, including monetary damages) to seek (a) a decree or order of specific performance to enforce the observance and performance of such covenant or obligation, and (b) an injunction restraining such breach or threatened breach.  Each Stockholder further agrees that neither Parent nor any other person or entity shall be required to obtain, furnish or post any bond or similar instrument

5

in connection with or as a condition to obtaining any remedy referred to in this Section 4.7, and each Stockholder irrevocably waives any right it may have to require the obtaining, furnishing or posting of any such bond or similar instrument.

4.8     Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the parties hereto and delivered to the other parties, it being understood that all parties need not sign the same counterpart.  This Agreement may be executed and delivered by facsimile transmission.

4.9     Descriptive Headings.  The descriptive headings used herein are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Agreement.

4.10    Severability.  Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction.  If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified.  In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term.

4.11    No Obligation to Exercise Options.  Notwithstanding any provision in this Agreement to the contrary, nothing in this Agreement shall obligate any Stockholder to exercise any Option or other right to acquire shares of Company Common Stock.

[REMAINDER OF PAGE INTENTIONALLY BLANK]

6

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

TAKEDA AMERICA HOLDINGS, INC.
By:	/s/ Iwaaki Taniguchi
	Name:	Iwaaki Taniguchi
	Title:	President

7

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Deborah Dunsire, M.D.

Deborah Dunsire, M.D.

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Robert F. Friel

Robert F. Friel

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ A. Grant Heidrich, III

A. Grant Heidrich, III

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Charles J. Homcy, M.D.

Charles J. Homcy, M.D.

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Raju S. Kucherlapati, Ph. D.

Raju S. Kucherlapati, Ph.D.

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Jeffery M. Leiden, M.D., Ph.D.

Jeffrey M. Leiden, M.D., Ph.D.

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Mark J. Levin

Mark J. Levin

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Norman C. Selby

Norman C. Selby

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Kenneth E. Weg

Kenneth E. Weg

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Anthony H. Wild, Ph.D.

Anthony H. Wild, Ph.D.

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Christophe Bianchi, M.D.

Christophe Bianchi, M.D.

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Joseph B. Bolen, Ph.D.

Joseph B. Bolen, Ph.D.

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Marsha H. Fanucci

Marsha H. Fanucci

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Stephen M. Gansler

Stephen M. Gansler

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Laurie B. Keating

Laurie B. Keating

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Anna Protopapas

Anna Protopapas

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Nancy Simonian, M.D.

Nancy Simonian, M.D.

Address:

Fax:

IN WITNESS WHEREOF, the parties hereto have caused this Stockholders’ Agreement to be duly executed as of the day and year first above written.

/s/ Peter F. Smith, Ph.D.

Peter F. Smith, Ph.D.

Address:

Fax:

ATTACHMENT A

Details of Ownership

Shares		Entity or Individual Name
806,074		Deborah Dunsire, M.D.
12,408		Robert F. Friel
103,000		A. Grant Heidrich, III
64,514		Charles J. Homcy, M.D.
709,981		Raju S. Kucherlapati, Ph.D.
0		Jeffrey M. Leiden, M.D., Ph.D.
2,264,224	(1)	Mark J. Levin
7,000		Norman C. Selby
10,000		Kenneth E. Weg
12,914		Anthony H. Wild, Ph.D.
201,400		Christophe Bianchi, M.D.
90,929		Joseph B. Bolen, Ph.D.
112,784		Marsha H. Fanucci
120,411		Stephen M. Gansler
103,240		Laurie B. Keating
170,073		Anna Protopapas
75,234		Nancy Simonian, M.D.
84,899		Peter F. Smith, Ph.D.

(1) Excludes 400,000 shares of Company Common Stock to be Transferred by Mr. Levin to a charitable foundation to be established, which shares shall not be subject to the provisions of this Agreement.

EX-99.(D)(3)

Exhibit (d)(3)

CONFIDENTIALITY AGREEMENT

This Confidentiality Agreement (the “Agreement”) dated and effective as of February 20, 2008 (the “Effective Date”), between Millennium Pharmaceuticals, Inc., a Delaware corporation with its principal office at 40 Landsdowne Street, Cambridge, Massachusetts 02139 (“MPI”), and Takeda Pharmaceutical Company Limited, with its principal office at 12-10 Nihonbashi 2-Chome, Chuo-Ku, Tokyo 10-8668, Japan (“Takeda”).

Background

1.Takeda has requested MPI to provide certain information, which is either confidential or proprietary in nature, in connection with its consideration of a possible negotiated transaction between the two companies (the “Contemplated Transaction”).

2.MPI desires to protect the confidentiality of the information it provides and to have Takeda take or abstain from taking certain actions in accordance with the terms of this Agreement.

3.Takeda may provide MPI with certain information, which is either confidential or proprietary in nature, relating to the Contemplated Transaction, and Takeda desires to protect the confidentiality of the information it provides and to have MPI take or abstain from taking certain actions in accordance with the terms of this Agreement.

4.MPI and Takeda (hereinafter, individually, a “Party” and, collectively, the “Parties”) desire to hold the Transaction Information (as hereinafter defined) in strict confidence.

NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

Section 1.  Definitions.

(a)“Confidential Information” means, singly and collectively as the context requires, the MPI Evaluation Material and the Takeda Evaluation Material, provided, however, that “Confidential Information” does not include information which:

(i)is or becomes generally available to the public other than as a result of a disclosure directly or indirectly by the receiving Party or its Representatives;

(ii)was within the receiving Party’s possession prior to it being furnished to the receiving Party or it Representatives by or on behalf of the disclosing Party pursuant to this Agreement or otherwise in connection with the Contemplated Transaction, provided that such information is not subject to another confidentiality agreement with or other contractual, legal or fiduciary obligation of confidentiality to the disclosing Party or any other party with respect to such information;

(iii)becomes available to the receiving Party on a non-confidential basis from a source other than the disclosing Party or any of its Representatives, provided that such source is not bound by a confidentiality agreement with or other contractual, legal or fiduciary obligation of confidentiality to the disclosing Party or any other party with respect to such information; or

(iv)            is independently developed by the receiving Party or others on its behalf without reference to or reliance upon any information furnished to the receiving Party or any of its Representatives by or on behalf of the disclosing Party, which the receiving Party shall have the burden of demonstrating by clear and convincing evidence.

(b)“MPI Evaluation Material” means any information concerning MPI (whether prepared by MPI, its Representatives or otherwise and irrespective of the form of communication) that is furnished to Takeda or any of its Representatives by or on behalf of MPI, and all notes, analyses, compilations, studies, interpretations, memoranda, reports or other documents (regardless of the form thereof) prepared by Takeda or its Representatives which contain, reflect or are based upon, in whole or in part, any information furnished to Takeda or its Representatives pursuant to this Agreement.

(c)“Representatives” means, with respect to a Party, its parents and subsidiaries, and its and their respective directors, officers, affiliates, employees, partners, agents, commercial banks or other similar lenders providing debt (but not equity) financing, or advisors (including, without limitation, attorneys, accountants, consultants, bankers and financial advisors).

(d)“Takeda Evaluation Material” means any information concerning Takeda (whether prepared by Takeda, its Representatives or otherwise and irrespective of the form of communication) that is furnished to MPI or any of its Representatives by or on behalf of Takeda, and all notes, analyses, compilations, studies, interpretations, memoranda, reports or other documents (regardless of the form thereof) prepared by MPI or its Representatives which contain, reflect or are based upon, in whole or in part, any information furnished to MPI or its Representatives pursuant to this Agreement.

(e)The term “person” shall be broadly interpreted to include the media and any corporation, company, partnership, joint venture, group, limited liability company other entity or individual and the term “affiliate” has the meaning set forth in Rule 12b-2 under the Securities Exchange Act of 1934 (the “Exchange Act”).

Section 2.  Use and Disclosure of Confidential Information.

(a)Except as otherwise provided in this Agreement, Takeda hereby agrees that it and its Representatives shall:

(i)use the MPI Evaluation Material solely for the purpose of evaluating and negotiating a possible transaction between the Parties;

(ii)keep the MPI Evaluation Material confidential in accordance with the terms of this Agreement; and

2

(iii)not disclose any MPI Evaluation Material except in accordance with the terms of this Agreement;

provided, however, that Takeda may disclose any MPI Evaluation Material to Takeda’s Representatives who need to know such information for the sole purpose of evaluating and negotiating a possible transaction between the Parties, provided that Takeda’s Representatives are informed of the confidential nature of such Evaluation Material and are bound to use such information solely for the purpose of evaluating and negotiating a possible transaction between the Parties and likewise bound to maintain the confidentiality of such MPI Evaluation Material.

(b)Except as otherwise provided in this Agreement, MPI hereby agrees that it and its Representatives shall:

(i)use the Takeda Evaluation Material solely for the purpose of evaluating and negotiating a possible transaction between the Parties;

(ii)keep the Takeda Evaluation Material confidential in accordance with the terms of this Agreement; and

(iii)not disclose any Takeda Evaluation Material except in accordance with the terms of this Agreement;

provided, however, that MPI may disclose any Takeda Evaluation Material to MPI’s Representatives who need to know such information for the sole purpose of evaluating and negotiating a possible transaction between the Parties, provided that MPI’s Representatives are informed of the confidential nature of such Takeda Evaluation Material and are bound to use such information solely for the purpose of evaluating and negotiating a possible transaction between the Parties and likewise bound to maintain the confidentiality of such Takeda Evaluation Material.

(c)Except as otherwise provided in this Agreement, neither MPI nor Takeda nor any of its respective Representatives shall disclose to any other person (i) the existence of this Agreement, (ii) the fact that Confidential Information has been made available to the receiving Party, (iii) that discussions are taking place concerning a possible negotiated transaction between the Parties, (iv) any of the proposed terms, conditions or other facts with respect thereto, or (v) the status of such discussions (collectively, the “Transaction Information”).

(d)The receiving Party shall be liable to the disclosing Party for any use or disclosure by any of the receiving Party’s Representatives of the other Party’s Confidential Information or of the Transaction Information.  Each Party shall be liable to the other Party for any use or disclosure by such Party’s Representatives of Confidential Information or Transaction Information which if done by either Party itself would be a breach of this Agreement.  Each Party agrees, at its sole expense, to take reasonable measures to restrain its Representatives from prohibited or unauthorized disclosure or use of the other Party’s Confidential Information and the Transaction Information.

(e)To the extent that any Confidential Information or Transaction Information may

3

include materials subject to the attorney-client privilege, work product doctrine or any other applicable privilege concerning pending or threatened legal proceedings or governmental investigations, the Parties understand and agree that they have a commonality of interest with respect to such matters and it is their mutual desire, intention and understanding that the sharing of such material is not intended to, and shall not, waive or diminish in any way the confidentiality of such material or its continued protection under the attorney-client privilege, work product doctrine or other applicable privilege.  All Confidential Information or Transaction Information that is entitled to protection under the attorney-client privilege, work product doctrine and other applicable privilege shall remain entitled to such protection under these privileges, this agreement, and under the joint defense doctrine.

Section 3.  Legally Required Disclosure.

If either Party (the “Requested Party”) or any of its Representatives is requested or required (by oral questions, interrogatories, requests for information or documents in legal proceedings, subpoena, civil investigative demand or other similar process, or by the rules or regulations of any regulatory authority having jurisdiction over the requested Party or a stock exchange on which such Requested Party’s securities are traded) to disclose any of the Confidential Information or the Transaction Information, as the case may be, the Requested Party shall, except as prohibited by law, provide the other Party with prompt written notice of any such request or requirement so that the other Party may seek, at such other Party’s expense, a protective order or other remedy and/or waive compliance with the provisions of this Agreement.  If the other Party seeks a protective order or other remedy, the Requested Party shall provide such cooperation as the other Party shall reasonably request.  If, in the absence of a protective order or other remedy or the receipt by the Requested Party of a waiver from the other Party, the Requested Party or any of its Representatives is nonetheless, in the written opinion of its outside legal counsel, legally compelled to disclose Confidential Information and/or Transaction Information to any tribunal or other entity or else stand liable for contempt or suffer other censure or penalty, the Requested Party or its Representatives may, without liability hereunder, disclose to such tribunal or other entity only that portion of the Confidential Information or Transaction Information which such counsel advises the Requested Party or such Representatives is legally required to be disclosed, provided that the Requested Party and its Representatives shall exercise reasonable best efforts to minimize the disclosure of the Confidential Information and/or Transaction Information and to preserve the confidentiality thereof.

Section 4.  Return of Confidential Information.

(a)At any time upon the written request of MPI for any reason:

(i)Takeda shall promptly (and in no event later than five business days after such request) return to MPI all MPI Evaluation Material (and all copies thereof) furnished to Takeda or its Representatives by or on behalf of MPI and shall not retain any copies, extracts or other reproductions (including MPI Evaluation Material stored in any computer or other electronic storage device) in whole or in part of such material except for one archival copy to be maintained under the control of Takeda’s Legal Division for the sole purposes of (a) satisfying any legally mandated disclosure obligations and (b) reviewing the contents of the MPI

4

Evaluation Material in order to confirm Takeda’s compliance with this Agreement; and provided that such material shall continue to be subject to the restrictions set forth in this Agreement; and

(ii)Takeda and its Representatives shall destroy all MPI Evaluation Material prepared by Takeda or its Representatives and shall not retain any copies, extracts or other reproductions (including MPI Evaluation Material stored in any computer or other electronic storage device) in whole or in part of such material except for one archival copy to be maintained under the control of Takeda’s Legal Division for the sole purposes of (a) satisfying any legally mandated disclosure obligations and (b) reviewing the contents of the MPI Evaluation Material in order to confirm Takeda’s compliance with this Agreement; and provided that such material shall continue to be subject to the restrictions set forth in this Agreement, and such destruction shall be certified in writing to MPI by an authorized officer of Takeda upon request of MPI.

Notwithstanding the return or destruction of MPI Evaluation Material, Takeda and its Representatives shall continue to be bound by their obligations hereunder.

(b)At any time upon the written request of Takeda for any reason:

(i)MPI shall promptly (and in no event later than five business days after such request) return to Takeda all Takeda Evaluation Material (and all copies thereof) furnished to MPI or its Representatives by or on behalf of Takeda and shall not retain any copies, extracts or other reproductions (including Takeda Evaluation Material stored in any computer or other electronic storage device) in whole or in part of such material except for one archival copy to be maintained under the control of MPI’s Legal Division for the sole purposes of (a) satisfying any legally mandated disclosure obligations and (b) reviewing the contents of the Takeda Evaluation Material in order to con firm MPI’s compliance with this Agreement; and provided that such material shall continue to be subject to the restrictions set forth in this Agreement; and

(ii)MPI and its Representatives shall destroy all Takeda Evaluation Material prepared by MPI or its Representatives and shall not retain any copies, extracts or other reproductions (including Takeda Evaluation Material stored in any computer or other electronic storage device) in whole or in part of such material except for one archival copy to be maintained under the control of MPI’s Legal Division for the sole purposes of (a) satisfying any legally mandated disclosure obligations and (b) reviewing the contents of the Takeda Evaluation Material in order to confirm MPI’s compliance with this Agreement; and provided that such material shall continue to be subject to the restrictions set forth in this Agreement, and such destruction shall be certified in writing to Takeda by an authorized officer of MPI upon request of Takeda.

Notwithstanding the return or destruction of Takeda Evaluation Material, MPI and its Representatives shall continue to be bound by their obligations hereunder.

Section 5.  Term.

This Agreement shall apply to all Confidential Information disclosed prior to the date that is 12 months after the Effective Date.  Unless otherwise expressly stated herein, the obligations set forth in this Agreement shall continue until the fourth anniversary of the Effective Date (the “Term”); provided, however, that as to Confidential Information that is subject to a

5

confidentiality obligation on the part of MPI that extends beyond the fourth anniversary of the Effective Date, MPI shall so notify Takeda of such extended confidentiality obligation and shall not disclose such Confidential Information to Takeda until Takeda agrees to abide by the obligations set forth in th is Agreement with respect to such Confidential Information for the term of MPI’s confidentiality obligation applicable to such Confidential Information, in which event the term of this Agreement shall be deemed to be so extended as to such Confidential Information.

Section 6.  Non-solicitation.

For a period of eighteen months from the Effective Date, neither Party shall solicit to employ any person who (i) is an officer of the other Party or any of its subsidiaries or (ii) who is employed in any capacity by the other Party or any of its subsidiaries and with whom Representatives of the Party came in contact or first identified during the process of considering a transaction contemplated by this Agreement; provided, however, that this paragraph shall not prevent either Party or it respective subsidiaries from hiring a person identified in clause (i) or (ii) (a “Covered Person”) if: (1) such Covered Person contacts such Party or its Representatives on the Covered Person’s own initiative without any direct or indirect solicitation by or encouragement from such Party or its Representatives; (2) the personnel of the Party who solicited the Covered Person have no knowledge of any of the other Parties’ Confidential Information and none of the personnel of such Party who have knowledge of any of the other Parties’ Confidential Information have actual advance knowledge of such solicitation; or (3) such Covered Person responds to a general solicitation of employment not specifically directed towards the other Party or any of its subsidiaries or particular employees of the other Party or any of its subsidiaries.

Section 7.  Standstill.

Takeda agrees that, for a period of two years from the Effective Date, unless Takeda shall have been specifically invited in writing by MPI, neither Takeda nor any of its affiliates shall in any manner, directly or indirectly, except in connection with the Contemplated Transaction:

(a)effect or seek, offer or propose (whether publicly or otherwise) to effect, or cause or participate in or in any way advise, assist or encourage any other person to effect or seek, offer or propose (whether publicly or otherwise) to effect or participate in, (i) any acquisition of any securities (or beneficial ownership thereof) or assets of MPI; (ii) any tender or exchange offer, merger or other business combination involving MPI; (iii) any recapitalization, restructuring, liquidation, dissolution or other extraordinary transaction with respect to MPI; or (iv) any “solicitation” of “proxies” (as such terms are used in the proxy rules of the Securities and Exchange Commission) or consents to vote any voting securities of MPI; provided, however, that, notwithstanding the provisions of the foregoing subsection (a)(i), Takeda and its subsidiaries and affiliates may invest in third party mutual funds, and other similar passive investment vehicles that own equity interests in MPI;

(b)form, join or in any way participate in a “group” (as defined under the Exchange Act) with respect to any securities of MPI;

6

(c)otherwise act, alone or in concert with others, to seek to control or influence the management, Board of Directors or policies of MPI; provided, however, that this provision shall not preclude Takeda from proposing to MPI a research, development or similar commercial collaboration with respect to one or more of MPI’s development molecules;

(d)take any action which might force MPI to make a public announcement regarding any of the types of matters set forth in paragraph (a) above; or

(e)enter into any discussions or arrangements with any person with respect to any of the foregoing.

Takeda also agrees during such period not to request MPI (or its Representatives), directly or indirectly, to amend or waive any provision of this section (including this sentence). For purposes of clarity, executives of Takeda shall not be prohibited from engaging in customary business and social communications with executives of MPI that do not violate this Section 7.  Takeda represents and warrants that, as of the date of this Agreement, neither Takeda nor any of its affiliates owns, of record or beneficially, any voting securities of MPI, or any securities convertible into or exercisable for any voting securities of MPI.  Notwithstanding the foregoing, MPI acknowledges and agrees that Takeda and its subsidiaries and affiliates may invest in third party mutual funds and other similar passive investment vehicles that own equity interests in MPI.

Notwithstanding the foregoing provisions of this Section 7 (the “Standstill Provisions”), if a third party enters into a letter of intent with MPI, makes a tender offer for or solicits for purchase any shares of capital stock of MPI or publicly announces an offer for shares of MPI or if MPI executes a definitive agreement with a third party providing for an acquisition (by way of merger, tender offer or otherwise) of more than 50% of MPI’s outstanding capital stock or all or substantially all of MPI’ assets, then (in any of such cases) Takeda shall immediately, and without any other action by MPI, be released from its obligations under the Standstill Provisions.

Section 8.  Trading in Securities.

Each Party acknowledges that it is aware (and that its Representatives who are apprised of a possible transaction between the Parties have been or will be advised) that applicable securities laws prohibit my person who is aware of material, non-public information about a company obtained directly or indirectly from that company from purchasing or selling securities of such company or front communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities.

Section 9.  No Representations and Warranties; Relationship to Definitive Agreement.

(a)Each Party understands and acknowledges that neither the other Party nor any of its Representatives has made or is making any representation or warranty, express or implied, as to the accuracy or completeness of the Confidential Information.  Each Party agrees that neither the other Party nor any of its Representatives shall have any liability relating to or resulting from the receiving Party’s reliance on or use of Confidential Information or any errors therein or omissions therefrom. Only those representations and warranties which are made in a definitive

7

agreement between the Parties, when, and if executed, and subject to such limitations and restrictions as may be specified there, will have any legal effect.

(b)Each Party understands and agrees that no contract or agreement providing for any transaction involving the Parties shall be deemed to exist unless and until a definitive agreement has been executed and delivered and each Party hereby waives in advance any claims, including without limitation claims for breach of contract, in connection with any transaction between the Parties unless and until the Parties shall have entered into a definitive agreement. Each Party also agrees that unless and until a definitive agreement regarding a transaction between the Parties has been executed and delivered, neither Party will be under any legal obligation of any kind whatsoever with respect to such a transaction by virtue of this Agreement or any other written or oral communication with respect to such transaction, except for the matters specifically agreed to herein.  For purposes of this Agreement, the term “definitive agreement” does not include any executed letter of intent or any other preliminary written agreement, nor does it include any written or verbal acceptance of any offer or bid made by one Party.

(c)Each Party reserves the right, in its sole discretion, to reject any and all proposals made by the other Party with regard to a transaction between the Parties and to terminate discussions and negotiations with the other Party at any time and for any reason or no reason.  Each Party understands that each Party and its Representatives shall be free to conduct any process for any transaction in such manner as they, in their sole discretion, shall determine (including, without limitation, negotiating with other interested persons and entering into a preliminary or definitive agreement without prior notice to the other Party or any other person) and that any procedures relating to such process or transaction may be changed at any time without notice to the other Party or any other person.

(d)If during the Term of this Agreement, MPI enters into in a confidentiality agreement with any person other than Takeda or one or more of its subsidiaries, which confidentiality agreement applies to a transaction that is similar in nature to the Contemplated Transaction, MPI agrees to use commercially reasonable efforts to negotiate terms and conditions in such agreement that are no less restrictive, on the whole, than those that are provided in this Agreement.  Notwithstanding any provision of this Agreement to the contrary, if, during the Term of this Agreement, MPI enters into in a confidentiality agreement with any person other than Takeda or one or more of its subsidiaries, which confidentiality agreement applies to a transaction that is similar in nature to the Contemplated Transaction and which confidentiality agreement contains terms and conditions that are less restrictive than the provisions of Sections 6 and 7 of this Agreement, then Sections 6 and 7 of this Agreement shall be construed so as to afford Takeda the benefit of any such less restrictive provisions.  In such event, Takeda’s obligations shall be the same as those provided in such confidentiality agreement between MPI and a third party, but only to the extent that such provisions would be less burdensome to Takeda than the provisions set forth herein.

Section 10.  Contacts and Communications.

Each Party agrees that all contacts or communications by it or its Representatives with the other Party regarding a possible transaction between the Parties or the Confidential

8

Information, all requests for additional information, or management meetings and all discussions or questions regarding procedures with respect to a possible transaction, will be submitted or directed only to the following persons:

(a)to MPI:  to: (i) the chief executive officer; (ii) the SVP, Corporate Development; (iii) executives of the Healthcare Investment Banking Group in the New York offices of Goldman Sachs designated by MPI; or (iii) other persons whom MPI in writing advises Takeda to contact; and

(b)to Takeda:  to: (i) Yasuchika Hasegawa, President; (ii) Ken Araki or Catherine Sazdanoff, the Senior Directors of Takeda Global Licensing and Business Development; (iii) executives of Takeda’s investment banking advisors who are designated by Takeda; or (iv) other persons whom Takeda in writing advises MPI to contact.

(c)Without the express prior consent of the other Party, each Party agrees that it will not, directly or indirectly, contact or communicate with any officer, employee, director, stockholder, agent, customer or business partner of such other Party regarding Confidential Information or a possible transaction between the Parties.

Section 11.  Miscellaneous.

(a)This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without giving effect to the conflicts of law principles thereof.

(b)Each Party recognizes and acknowledges the competitive value and confidential nature of the other Party’s Confidential Information and that irreparable damage may result to the other Party if information contained therein or derived therefrom is disclosed to any person except as herein provided or is used for any purpose other than the evaluation of a possible negotiated transaction between the Parties. Each Party further understands and agrees that money damages may nm be a sufficient remedy for any breach of this Agreement by it or any of its Representatives and that the non-breaching Party may be entitled to equitable relief, including injunction and specific performance, as a remedy for any such breach.  Such remedies shall not be deemed to be the exclusive remedies for a breach by the non-breaching Party of this Agreement, but shall be in addition to all of such non-breaching Party’s other remedies available at law or equity.  In the event of litigation relating to this Agreement, if a court of competent jurisdiction determines in a final, nonappealable order that a Party has breached this Agreement, then such breaching Party shall be liable for and pay to the non-breaching Party the reasonable legal fees and disbursements that the non-breaching Party has incurred in connection with such litigation, including any appeal therefrom.

(c)This Agreement may not be assigned in whole or in part by either Party without the prior written consent of the other Party; provided that no such consent shall be required and this Agreement may be assigned by a Party in the case of a sale by such Party of all or substantially all of its business or assets, whether by merger, sale of assets or otherwise; provided, however, that the assignee agrees in writing to assume such Party’s obligations under this Agreement. Subject to the foregoing, this Agreement shall be binding upon and inure to the

9

benefit of the Parties and their respective successors and assigns.

(d)This Agreement contains the entire agreement between the Parties concerning the subject matter hereof.  No provision of this Agreement may be waived or amended except by the express written consent of the Parties.  No failure or delay by either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or future exercise thereof or the exercise of any other right, power or privilege hereunder.

(e)All notices and other communications hereunder shall be in writing.  Any notice or other communication hereunder shall be deemed duly delivered one business day after it is sent for next business day delivery via a reputable nationwide overnight courier service, in each case to the intended recipient as set forth below:

If to MPI: Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, Massachusetts 02139 Attention: General Counsel	Copy to: Wilmer Hale 60 State Street Boston, Massachusetts 02109 Attention: David E. Redlick, Esq.
If to Takeda: Takeda Pharmaceutical Company Ltd. 17-85, Jusohonmachi 2-chome Yodogawa-ku, Osaka 532-8686 Japan Attention: Mr. Hiroshi Shinha	Copy to: Edwards Angell Palmer & Dodge LLP 111 Huntington Avenue Boston, MA 02199 Attention: Bruce W. Raphael, Esq.

Either Party may give any notice or other communication hereunder using any other means (including personal delivery, expedited courier, messenger service, telecopy, telex, ordinary mail, or electronic mail), but no such notice or other communication shall be deemed duly given unless and until the Party for whom it is intended actually receives it.  Any Party may change the address to which notices and other communications hereunder are to be delivered by giving the other Party notice in the manner herein set forth.

(f)For the convenience of the Parties, this Agreement may be executed by facsimile and in counterparts, each of which shall be deemed to be an original, and both of which, taken together, shall constitute one agreement binding on both Parties.

(g)The section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement.

[Remainder of page intentionally left blank.]

10

EXECUTED as of the date first above written.

Millennium Pharmaceuticals, Inc.
By:	/s/ Laurie B. Keating
Name: Laurie B. Keating
Title: Senior Vice President and General Counsel
Takeda Pharmaceutical Company Ltd.
By:	/s/ Hiroshi Shinha
Name: Hiroshi Shinha
Title: Member of the Board, General Manager of the Legal Department

[Signature page to Confidentiality Agreement.]

11